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 2 
Abstract 
 
Introduction 
The term “congestion” is used to describe a broad range of clinical 
presentations. Congestion is a variably understood and assessed entity. Patients 
develop a mixture of central (pulmonary) and/or peripheral (non-pulmonary) 
symptoms of congestion. These are likely to have different pathophysiological 
mechanisms.  The presence of subclinical congestion is an independent risk 
factor for early re-hospitalisation and morbidity. Novel techniques to assess 
congestion have been developed, but their clinical role is not yet established. 
 
Methods 
I performed two systematic reviews of acute heart failure (AHF) trials and 
registries from Jan 1, 2001 to Dec 31, 2018 on EMBASE and MEDLINE to 
determine the methods and techniques used to assess and grade congestion. The 
search terms utilised were “acute heart failure”, “decompensated heart failure” 
and “hospitalized heart failure”. The minimum enrolment numbers were 180 
patients for randomised trials and 2,000 patients for registries. 
 
Results 
18 major acute heart failure registries and 21 major trials were analysed. 
There are no standardised methods for assessing central or peripheral 
congestion.  Acute heart failure trials preferentially recruited patients with 
pulmonary congestion (manifesting as dyspnoea at rest). In 6 of 8 trials with 
available data, this was mandatory for 100% of patients. By contrast, for large 
registry trials this rate ranged from 34 to 73%. Dyspnoea on exertion was a more 
predominant presentation (61 to 95%). With the exception of a chest X-ray, no 
trial or registry routinely utilised non-invasive (e.g. lung ultrasound) or invasive 
(e.g. right heart catheterisation) techniques to objectively and systematically 
quantify either congestion on recruitment or congestion on discharge.   
 
Conclusion 
Congestion is variably assessed and defined.  Internationally agreed definitions 
of the presence and severity of congestion are required.  These definitions 
should include conventional symptoms and signs as well as newer methods of 
assessing congestion.  Trials of treatments for central or peripheral congestion 
may have different inclusion criteria.   
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1 Introduction to heart failure 
 
1.1 Definition of heart failure 
 
 
Heart failure (HF) can be defined as complex syndrome comprised of typical 
symptoms and clinical signs which are the result of structural and/or functional 
cardiac abnormalities, resulting in reduced cardiac output and elevated 
intracardiac pressures.1,2 As a result of failure to produce an adequate cardiac 
output to meet the metabolic demands of the body, neurohormonal responses 
are activated to try to restore perfusion.3 These secondary maladaptive changes 
produce salt and water retention and eventually recognised features of 
congestion are manifested clinically. The terms “left ventricular (LV) 
dysfunction” and “cardiomyopathy” may often be incorrectly used when 
describing HF, as these are not entirely interchangeable. HF can occur as a 
result of a wide range of cardiovascular conditions (arrhythmia, coronary artery 
disease, hypertension etc) which produce the characteristic HF syndrome. 
 
The modes of presentation of HF can vary markedly depending on the underlying 
aetiology, precipitant trigger and general functional state of the patient. 
Demonstration of a cardiac abnormality in the setting of classic clinical 
symptoms are key to concluding a diagnosis of HF.  
 
 
1.2 Clinical evaluation 
 
As HF becomes symptomatic, a wide constellation of clinical signs and symptoms 
may appear. These can be classified into features arising from central pulmonary 
or peripheral (non-pulmonary) congestion, but the distinctions are arbitrary and 
no formal universal definitions exist.4,5 In reality, usually a mix of both tend to 
predominate. The ESC Scientific Statement on Assessing and Grading Congestion 
(2010) provides a general outline of major symptoms which should be assessed 
(dyspnoea, orthopnoea, dyspnoea on exertion, pulmonary rales, jugular venous 
pressure, oedema and body weight) but without mandating any specific 
 16 
classification system or grading mechanism.6 Older classifications have 
historically partitioned features into left and/or right sided congestion.  
 
 
 
1.2.1 Central (pulmonary) congestion 
 
Symptoms of central congestion include dyspnoea, orthopnoea and paroxysmal 
nocturnal dyspnoea (PND). Clinical signs include hypoxia, tachypnoea, and 
pulmonary rales (on lung auscultation).7 These can also be regarded as more left 
sided signs which arise from left heart dysfunction leading to elevated 
pulmonary pressures and subsequent fluid transudation into the alveolar space.6  
 
 
1.2.2 Peripheral (non-pulmonary) congestion 
 
Symptoms of peripheral (non-pulmonary) congestion include ankle and leg 
swelling, abdominal discomfort and swelling, nausea, anorexia and weight gain.8 
Clinical signs include elevated jugular venous pressure (JVP), ankle oedema, 
ascites and hepatomegaly. 9 These signs could be regarded as more right sided 
which can often arise where there is isolated right ventricular (RV) dysfunction. 
RV failure can produce elevated peripheral systemic venous pressures which 
causes fluid to transudate into interstitial space in the lower legs, peritoneal 
cavity and intestinal capillary bed.10  
 
 
1.2.3 Mixed congestive signs 
 
The distinction between central and peripheral is not absolute.5 Both central 
and peripheral congestion can cause breathlessness on exertion – either due to 
pulmonary oedema or the increased workload of having to move more congested 
limbs.11 Fatigue and cachexia are common complaints in both congestive 
subtypes. Isolated central or peripheral features are rare. Right heart failure 
(RHF) – secondary to RV infarction or RV cardiomyopathy - can produce a set of 
exclusively right sided peripheral features. Where left heart disease exists, right 
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heart dysfunction also eventually arises and mixed central and peripheral 
congestive signs will normally become apparent.5  
 
 
1.3 Terminology 
 
In 2016, HF was separated into 3 distinct categories based on left ventricular 
ejection fraction (LVEF): 2,12 
- heart failure with preserved ejection fraction (HFpEF) where the LVEF is 
≥50%  
- heart failure with reduced ejection fraction (HFrEF) where the LVEF is 
<40% 
- a third “grey zone” in the evidence base for patients with an LVEF 
between 40 and 49% has also been defined and termed heart failure with 
mid-range ejection fraction (HFmREF).1 
 
Patients with HFrEF had been thought of as having LV systolic (contractile) 
dysfunction and those with HFpEF as having LV diastolic (relaxational) 
dysfunction. In reality an overlap of contractile and relaxant abnormalities are 
found in both cohorts. Though both may also share similar aetiologies and 
present with similar features of congestion, they have distinct demographic 
profiles, pathophysiology and prognoses13. Medical therapies which have been 
successful in patients with HFrEF have not produced similar results in HFpEF, 
therefore being cognisant of a patient’s ejection fraction is key to direct 
evidence based care.1,2  
 
 
1.3.1 HFpEF 
 
Patients with HFpEF tend to exhibit abnormalities of diastolic function; and the 
term “diastolic heart failure” has previously been used for this syndrome.14 
However, this is not always prevalent and the true mechanism of how congestion 
manifests is incompletely understood. Instead the term “preserved EF” has been 
employed (rather than “normal EF”) as systolic function in these patients still 
may have various pathological subtleties which affect contractile function (but 
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are not significant enough to alter the EF parameter). At present, no gold 
standard for diagnosing HFpEF exists. The syndrome often been under-
recognised so its true incidence, prevalence and prognosis remain more difficult 
to define.  
 
HFpEF patients characteristically tend to be older, female and with concomitant 
arterial hypertension, diabetes mellitus, atrial fibrillation and/or obesity.2 
Echocardiographically, LV hypertrophy (and subsequently left atrial 
enlargement) are frequently noted. Thickening of the myocardial wall causes the 
heart to “stiffen” and become unable to relax and “suck in” blood from the 
venous circulation during the diastolic phase of the cardiac cycle.15 Increased 
filling pressures subsequently develop and the classical features of congestion 
then become evident.  
 
 
1.3.2 HFrEF  
 
The evidence base for proven pharmacological and device therapies came from 
randomised trials where enrolment was restricted to patients with an LVEF 
below either 35 or 40%.16,17 As a consequence, clinical guidelines have 
historically also employed a similar EF cut off for defining HFrEF 16,17 When 
compared to patients with HFpEF, patients with HFrEF may more frequently 
have an ischaemic aetiology and also other echocardiographic abnormalities such 
as LV dilatation and functional mitral regurgitation. However, the very same 
diastolic abnormalities found in HFpEF patients are also often present in those 
with HFrEF.18 Despite this, both are thought to be separate entities with 
different pathophysiological mechanisms.19 
 
 
1.3.3 HFmrEF  
 
Between the gap of HFrEF and HFpEF trials lies a ‘grey zone’ of patients with an 
LVEF between 40-49%. This intermediate HFmrEF phenotype appears to be 
composed predominantly of male patients, with substantial hypertensive and 
diabetic disease but also more coronary heart disease (CHD) compared to HFpEF 
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equivalents.20 Similar echocardiographic remodelling involving eccentric LV 
hypertrophy has also been described. These likely represent a mixture of 
patients with deteriorating HFpEF and progressive ischaemic coronary disease, 
and recovering HFrEF post-myocarditis or post-myocardial infarction.21 
Randomised trials are still to detail precisely which therapies are of benefit in 
this group. This will remain a challenge as HFmrEF patients comprise less that 
20% of the HF cohort and despite being labelled as having ‘’mild LV systolic 
dysfunction and often have no clinical features of HF. 20 Historically, most 
patients with this intermediate LVEF category have been enrolled into HFpEF 
trials. As such, treatment guidelines are usually extrapolated from HFpEF rather 
than HFrEF studies.1 However, these trials have been re-examined and have 
demonstrated that guideline based therapies (especially agents producing 
neurohormonal and sympathetic blockade) do confer benefit in HFmrEF.22–24 
 
 
1.4 Epidemiology 
 
1.4.1 Incidence  
 
The incidence of HF Is believed to range from around 100 to 900 cases per 
100,000 person-years (though most of these statistics are derived from 
developed nations and are difficult to extrapolate on a global scale).25 
Approximately 915,000 new cases of HF are diagnosed in the United States each 
year and the lifetime risk of HF at age 40 is estimated to be 20%.26 As a 
consequence of improved long term management of hypertension and better 
acute treatments of acute coronary syndromes (ACS), the incidence of HF 
appears to be falling. Data from the Olmsted County studies suggest that 
between 2000 and 2010 the age and sex adjusted incidence rates of HF fell by a 
third from 315.8 to 219.3 per 100,000 residents.27 However, the prevalence of 
HF is continuing to rise, driven by an increasingly aging population. The Multi 
Ethnic Study of Atherosclerosis (MESA) found the highest incident rates of HF 
amongst African-Americans, followed by white and Hispanic Americans and 
lowest amongst Chinese-Americans. Various co-morbidities such as diabetes and 
hypertension may explain some of this variation by ethnicity.28 Older incidence 
rates from the Framingham study amongst others are more difficult to verify due 
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to the lack of objective imaging modalities and biomarkers to confirm the 
presence of absence of HF.  
 
 
1.4.2 Prevalence 
 
The prevalence of HF in developed nations is estimated to be around 1-2% of the 
adult population. 29 Although there are some differences depending on precisely 
which definition which is utilised, around 37.7 million patients are thought to be 
living with a diagnosis of HF.30  
 
Around 5.7 million (2.2%) adults in the United States were believed to have HF 
between 2009-12, and this number is expected to increase by 46% to over 8 
million by 2030.31 Unsurprisingly the prevalence is highest in the elderly, rising 
from under 1% amongst those aged under 40 years to over 10% amongst those 
above 80.32 The prevalence of HFpEF – though this population group remains 
difficult to define and diagnose - is projected to increase and become the 
numerically largest HF subtype. Data from Olmsted Investigators estimate that 
the prevalence of HFpEF has already risen by around a fifth from 38% to 57% 
between 1986 to 2010.33,34 This is also reflected in results from the Get With the 
Guidelines Group which described rising rates of hospitalisation for HFpEF from 
33% in 2005 to 39% in 2010. 35 
 
 
1.4.3 Prognosis    
 
Estimating prognosis for HF patients remains a challenge despite the wealth of 
observational data available. To date, most prognostic models are only 
moderately successful in predicting mortality and much less accurate when 
estimating future morbidity or risk of re-hospitalisation. 36,37 However, it remains 
a condition with major morbidity and with a mortality comparable to that of 
cancer.  
 
Mortality from HF has declined over the last 70 years.27 Between 1950 and 1969, 
the 5-year mortality rate has fallen steadily amongst both men (70 to 59%) and 
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women (57 to 45%).38 An observational study of study of 6,955,461 Medicare 
patients found that between 1993 and 2006 substantial improvement in in-
patient HF related outcomes were observed.  Mean length of stay reduced 
substantially (from 8.8 days to 6.3 days) as did in-patient mortality (from 8.5 to 
4.3%) and 30 day mortality from (12.8 to 10.7%).39 Amongst European patients, 
significant reductions were also seen in 30-day and one-year mortality. Amongst 
patients with HFpEF, in hospital mortality and re-hospitalisation rates are also 
comparable.40  
 
In a Swedish review of 156,919 discharges from 1988 to 2000, 1-year mortality 
fell particularly markedly in younger age groups; by 69% amongst men and 80% 
among women aged 45–54 years. Among those aged 75-84, these improvements 
equated to an annual decrease of 4% and 5% in both men and women 
respectively. Similar improvements were seen a study of HF patients in the 
United Kingdom; one year survival post-hospitalisation rose from 45% in 1993 to 
62% by 2001. In a primary care setting, HF survival rates increased from 2000 to 
2016 whether measured for one year (increased by 6.6%), five years (increased 
by 7.2%) or ten years (increased by 6.4%).41 However, the event of 
hospitalisation continues to confer a poorer prognosis, although the causality of 
influences is not clear.41  
 
The introduction of newer medical therapies (particularly beta blockers and 
angiotensin converting enzyme [ACE] inhibitors), better systems of care, 
declining rates of smoking, and more rigorous management of co-morbidities are 
all thought to have contributed to improving outcomes.42  
 
 
1.4.4 Healthcare and economic costs 
 
1-2% of all worldwide hospitalisations are secondary to decompensated HF.43 
Over half of these currently occur in patients aged over 75, with a mean cost per 
admission of $10,775 under Medicare – a number which is continuing to rise.44 In 
25 years since 1979, HF related admissions tripled in the United States.45 In the 
UK, 5% of all casualty admissions arise due to a complication of HF.46 The 30 day 
re-hospitalisation rate is also substantial – ranging from 17% to 28% - with little 
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change in the last decade.46 The variation between ethnic groups in the United 
States is also distinctly stark; re-admission rates are 50% higher amongst African-
Americans, 20% higher for Hispanic-Americans but 50% lower for Asians-
Americans when compared against a reference Caucasian population.47 
Of the $108 billion spent globally on HF, 86% of this spending was localised to 
higher income nations. This is projected to increase worldwide, particularly as 
economic development continues to accelerate in Asia.42,48 From 2013 to 2030, 
direct medical costs of HF in the United States will more than double from $21 
billion to $53 billion (and when indirect economic costs are also factored, this 
figure rises to over $70 billion).31 Similar increases in Europe are expected. 
Spend on cardiovascular care is projected to increase from €102 billion to €123 
billion from 2012 to 2020. Of critical relevance, 80% of these substantive cost 
increases are expected be incurred from more hospitalisations.  
 
 
1.5 Aetiology 
 
Ischaemic heart disease and hypertension remain the most common causes of 
HF. In the Studies of Left Ventricular Dysfunction (SOLVD) trial, almost 80% with 
left ventricular systolic dysfunction (LVSD) had a history of myocardial 
infarction, 37% had hypertension and 15% concurrent diabetes mellitus49. In the 
Framingham study, hypertensive cardiovascular disease was the most 
predominant condition (37% of males) followed by coronary heart disease 
(14%).50 A subsequent re-analysis of these datasets found that once more 
conventional blood pressure thresholds were applied, hypertension was likely 
present in 90% of patients. It should also be noted that Framingham diagnoses of 
HF were based on clinical criteria alone and so true LV systolic dysfunction may 
not have been present. More contemporary reviews have found a similar 
distribution; 50% of HF cases can be attributed to CHD with fewer due to 
hypertension – likely a reflection of the increasingly better medical management 
of the latter in primary care.51  
 
However, where multiple associated risk factors for HF are present, discerning 
the precise primary aetiology remains problematic. These often remain 
presumed rather than confirmed;  more deliberate strategies to uncover 
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underlying causes (such coronary angiography – with its notable limitations) are 
often not pursued vigorously.52  
 
However, as with other HF studies, most of this research reviews populations in 
only Western Europe and the United States. In Japan, CHD is a less prevalent 
aetiology than in other developed Western countries. In Africa, the average age 
for HF patients is lower (hypertension and dilated cardiomyopathy are the most 
common causes of HF), and in South America almost half of patients have 
concomitant valve disease.53,54   
 
Changing diagnostic criteria and more definitive investigative strategies mean 
that published figures will consistently vary from study to study, however CHD 
and hypertension still continue to appear predominant causes of HF. 
 
 
1.5.1 Taxonomy of aetiologies 
 
No universally accepted or consistently applied system exists for classifying the 
aetiology of HF. Most patients will have a number of different potential 
contributory mechanisms and diagnosis and treatment of all component 
pathologies is required to optimise outcomes. In general, precipitant causes can 
be split into three broad categories relating to either disease of the 
myocardium, abnormal loading conditions or arrhythmias (Table 1-1).1  
 
The term ‘cardiomyopathy’ also has invited much debate. Initially used to 
describe ischaemic, valvular or hypertensive disease, in 2006 the American Heart 
Association (AHA) reserved the term primarily for pathologies of the myocardium 
whilst the European Society of Cardiology (ESC) adopted a more pragmatic 
approach based on phenotypic characterisation.55,56 
 
Within the various aetiologies of cardiomyopathies, there remains a lack of 
consensus regarding the precise construct of definitions; idiopathic dilated 
cardiomyopathy (DCM) and diabetic cardiomyopathy notably continue to be 
difficult to define in an agreed manner.57,58 For example, in diabetic 
cardiomyopathy conflicting research groups have continued to differ as to 
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whether the complete exclusion of potential contributory conditions is required 
or if it is sufficient that the clinician judges that these were not primarily 
attributable factors. Disagreement continues to impair evaluations into the true 
incidence and prevalence of these conditions.  
 
 
Table 1-1. Aetiologies of heart failure. Adapted from Ponikowski et al (2016) 1 
  
Myocardial disease   
Coronary heart disease  Epicardial coronary artery disease, Coronary 
microvascular dysfunction 
Immune / inflammatory 
damage 
Infective Bacteria, viruses (HIV), parasites (Chagas 
disease) 
 Non-infective Myocarditis, auto-immune diseases 
(connective tissue disorders such as systemic 
lupus erythematosus),  
Infiltration Malignancy Direct malignant invasion 
 Not related to 
malignancy 
Amyloidosis, sarcoidosis, hemochromatosis 
(iron), lysosomal storage disease (e.g. Fabry 
disease).  
Metabolic derangement Hormonal  Thyroid disease, pheochromocytoma 
 Nutritional  Thiamine, selenium, iron, calcium deficiency 
Toxic damage Recreational 
substance abuse 
Alcohol, cocaine, amphetamine, anabolic 
steroid use 
 Medications Cytostatic drugs (e.g. anthracyclines) 
 Radiation  
Genetic abnormalities - Hypertrophic cardiomyopathy, dilated 
cardiomyopathy, LV non-compaction 
Abnormal Loading 
conditions 
  
Hypertension   
Valve and myocardial 
defects 
Acquired Mitral, aortic, tricuspid and pulmonary valve 
disease 
 Congenital Atrial and ventricular septal defects 
Pericardial and 
endomyocardial 
pathologies 
Pericardial  Constrictive pericarditis, pericardial effusion 
 Endomyocardial  Hypereosinophilic syndrome, endomyocardial 
fibrosis 
High output states  Renal failure, iatrogenic fluid overload 
Volume overload   
Arrhythmias Tachyarrhythmias Atrial and ventricular arrhythmias  
 Bradyarrhythmias Sinus node dysfunction, conduction block 
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1.6 Diagnostic testing 
 
A probability assessment must initially be performed for each patient based on 
clinical history, physical examination and a 12 lead electrocardiogram 
(ECG)(Figure 1-1).1 Each patient must be assessed clinically based on their signs 
and symptoms before deciding whether HF may be a potential diagnosis and 
what further tests are appropriate. A history can elicit if various risk factors are 
present for HF, such as the presence of CHD, hypertension, or if other a familial 
hereditary pattern may be present (which can point a young patient with 
inherited DCM towards further genetic testing). 
 
Clinical assessment is insufficient on its own and clinical signs are limited by 
inter-observer variability, poor sensitivity and often poor predictive value. 
However they remain key to triage further investigations and to assess if other 
alternative diagnoses are present, such as respiratory pathology.59  
 
 
 
Figure 1-1. Clinical pathway for the diagnosis of heart failure. Adapted from Ponikowski 
et al (2016)1. An integrated diagnostic strategy based on clinical history, physical 
examination and ECG should utilised to guide further testing and the final diagnosis.  
HF: heart failure; JVP: jugular venous pressure; ECG: electrocardiogram; NT-proBNP: N-
terminal-prohormone brain natriuretic peptide; BNP: brain natriuretic peptide. 
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Following this, a standard 12-lead electrocardiogram (ECG) is recommended by 
the ESC as part of each routine evaluation.1 If all assessments are normal then a 
diagnosis of HF is unlikely. However, if one of either clinical history, physical 
examination or the ECG is abnormal then natriuretic peptides should be checked 
(and further HF investigation can be stopped if these are subsequently normal). 
If natriuretic peptides are elevated (or these are not available) then 
echocardiography should be performed.  
 
Once testing confirms HF, more detailed investigations can be employed to 
determine HF aetiology. This may include coronary angiography to look for CHD 
or specific genetic testing to assess for various inherited cardiomyopathies.  
 
 
1.6.1 12-lead ECG 
 
An abnormal resting ECG has a high sensitivity in chronic HF of 89%.60 Risk 
factors that indicate structural and functional cardiac abnormalities may also be 
present. Hypertension may produce changes of LV hypertrophy, a previous 
myocardial infarction can leave residual Q-waves and arrhythmias such as atrial 
fibrillation will be readily apparent on the trace. The specificity of the ECG is 
poorer however -around 56% - so whilst an ECG cannot diagnose left ventricular 
systolic dysfunction (LVSD), the presence of a normal trace is useful for 
excluding H.61 
 
 
1.6.2 Biomarkers 
 
1.6.2.1 Natriuretic peptides 
 
Natriuretic peptides are the most useful diagnostic plasma test to establish a 
diagnosis of HF. They are released by cardiomyocytes as a result of myocardial 
wall stretch - in HF this is secondary to increased end-diastolic pressures arising 
from congestion. The two most commonly measured peptides are brain 
natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP). The normal 
upper limits depend on whether the patient is in a non-acute or acute setting. 
The nominal upper limits for non-acute patients are 35 pg/mL for BNP and 125 
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pg/mL for NTpro-BNP, and in acute patients 100 pg/mL for BNP and 300 pg/mL 
for NT-proBNP.62  
 
The negative predictive values are extremely high (0.94-0.98); a normal 
circulating level of natriuretic peptides suggests HF is not likely and therefore 
further investigations are not required.63 However, false positives are possible. 
Cardiac stressors (atrial fibrillation, myocarditis, acute coronary syndromes) and 
non-cardiac co-morbidities (advanced age, anaemia, renal failure) can all raise 
plasma levels of natriuretic peptides. False negatives are uncommon but arise in 
those already treated with a diuretic and in obese patients. It Is through that the 
reduction in circulating concentrations of natriuretic peptides found in obese 
individuals is the result of adipocyte surface cellular receptors binding 
natriuretic peptides, but this mechanism is not well understood.64  
 
 
1.6.2.2 Cardiac troponin 
 
Cardiac troponin is often raised in HF during acute episodes of congestion, and 
may indicate myocardial injury secondary to congestion.65 Elevated levels 
usually reflect more severe haemodynamic upset and deleterious LV 
remodelling, and are associated with a poorer prognosis.66,67 In acutely 
hospitalised patients, troponin may also be raised by a precipitating ACS, and so 
clinicians should consider whether troponin testing may provide additional 
information in a decompensated HF patient.2  However, whilst troponin can rise 
and fall with congestion and treatment, it cannot be used to diagnose HF or 
direct de-congestive strategies.  
 
 
1.6.2.3 Novel biomarkers 
 
A number of novel biomarkers have shown early potential in the assessment of 
congestion in both acute and chronic HF states. Galectin-3 - a marker of fibrosis 
and inflammation - and has been implicated in HF remodelling. Though elevated 
levels are predictive of death and recurrent HF in AHF patients, interpretation 
of these assays are confounded where concurrent renal fibrosis arises from acute 
kidney injury.68 ST2 is an inflammatory cytokine which mediates fibrosis and 
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vascular remodelling and has also demonstrated prognostic value in HF. 
However, its utility in the diagnosis of stable HF patients is limited.68 
 
In the BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-
CHF), fibroblast growth factor 23 (FGF23) and adrenomedullin (ADM) both 
showed particular promise in this prospective multi-centre European trial of 
2179 patients with new-onset or worsening HF.69 FGF23 has been implicated in 
maintaining sodium homeostasis and in the development LVH. Adrenomedullin 
(ADM) is an known endothelial biomarker which helps maintain the integrity of 
the endothelial barrier. In states of congestion (both pulmonary and systemic), 
capillary leakage has been associated with elevated plasma ADM.70 In BIOSTAT-
CHF, higher levels of FGF23 and ADM were both shown to correlate with more 
severe congestive clinical signs, elevated NPs and residual congestion. Both 
biomarkers could predict subsets of patients at higher risk of poorer clinical 
outcomes (re-hospitalisation, mortality). 
 
However, in the absence of a gold standard, it remains difficult to determine 
how accurately novel and existing biomarkers can track congestion in a manner 
which can inform clinicians on how to modify the therapeutic strategy of an 
individual patient.71 
 
 
1.6.3 Echocardiography 
 
Transthoracic echocardiographic (TTE) remains the preferred first option to 
image the heart and complement clinical assessment in the diagnosis of HF.1 It is 
a readily available, quick and a cost-effective tool, with no associated radiation 
exposure. However, this is tempered the interobserver variation rate of 2-
dimensional LVEF measurement which can be as high as 10%.72–74 
 
Two primary objectives can be achieved with TTE. The first is the quantification 
of the ejection fraction. This allows the clinician to ascertain which category of 
HF is present (HFrEF, HFmrEF or HFpEF). Secondly, other structural and 
functional anomalies which cause HF can be discerned. Doppler tissue velocities 
can examine myocardial wall motion to determine if ventricular stiffness is 
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increased and if diastolic dysfunction could be contributing to a HFpEF 
phenotype.14 Wall motion abnormalities produced by previous infarction or 
inflammation can be seen, as can valvular problems which may either be a cause 
or consequence of HF. 
 
 
1.6.4 Other imaging modalities. 
 
Other imaging modalities may be utilised to confirm the presence of HF, 
evaluate alternative causes or determine the underlying aetiology. Routine 
Chest-x ray (CXR) is not very sensitive or specific and can vary depending on the 
patients congestive state.75 In most cases, the non-specific finding of 
cardiomegaly may be seen.76 However, imaging of the lung fields may be useful 
to determine if concurrent lung pathologies are responsible for the patient’s 
symptoms (such as chronic lung disease, neoplasm or infection). Cardiac 
magnetic resonance imaging (cMRI) is the gold standard for the assessment of 
cardiac pump function and can also evaluate tissue scarring and can help 
distinguish if the underlying aetiology is ischaemic, infiltrative or 
inflammatory.77 However, it is a time and cost intensive investigation and 
limited in patients with irregular and elevated heart rates and in those with 
claustrophobia. Where a history of ischaemic cardiac disease is suspected, non-
invasive cardiac computed tomography (cardiac CT) or invasive coronary 
angiography could be considered. Both carry additional risk from exposure to 
ionising radiation and are not considered first line investigations.1  
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2 Congestion in heart failure 
 
2.1 Neurohormonal axis and congestion 
 
The pathophysiology of HF is characterised by distal tissue hypoperfusion 
secondary to low cardiac output (or an inability to provide adequate output 
while maintaining normal ventricular filling pressures) which triggers 
compensatory sympathetic and neurohormonal reflexes.78 These result in sodium 
and water retention at a renal level which causes expansion in the intravascular 
and interstitial compartments.7 Over time, these compensatory mechanisms 
become deleterious and exert negative effects on the myocardium resulting in 
further decompensation and feeding downward cycles of maladaptive counter-
responses (Figure 2-1). Natriuretic peptides are produced in response to 
congestion to try and ameliorate these haemodynamic changes, but eventually 
pathologic mechanisms pre-dominate and the patient develops the well-
recognised clinical phenotypes of congestion. Myocardial hypertrophy and 
dilation serve to remodel the heart in response to increased wall stress, but 
these changes eventually compromise cardiac function further and compound 
the mileu of dysfunction.79  
 
 
Figure 2-1: Maladaptive neurohormonal responses in heart failure. Progressive 
neurohormonal activation and further direct cardiotoxicity triggers a cycle of progressive 
haemodynamic decline in chronic heart failure. 
RAAS: renin angiotensin aldosterone system; SNS: sympathetic nervous system 
Reduced 
cardiac
output
Activation of RAAS and SNS
Direct Cardiotoxicity
Myocardial Damage
Vasoconstriction
Sodium and fluid 
retention
Increased preload 
and afterload
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2.1.1 Sympathetic activation 
 
Arterial baroreceptors are triggered in response to low arterial perfusion and 
produce reflex sympathetic vasoconstriction and increased sympathetic 
outflow.80 In normal circumstances, this increases venous return and pre-load 
which subsequently increases stroke volume via the Frank-Starling mechanism. 
As myocyte fibres stretch, the strength of each following ventricular contraction 
is potentiated.81 However, an optimal zone of contractility exists and once this 
sarcomere-length reserve is depleted, cardiac output begins to become 
impaired. In HF, chronic wall stress increases myocardial wall hypertrophy and 
reduces wall distensibility, depressing the curve downwards and further 
impairing the mechanism from remaining effective in response to increasing pre-
load (Figure 2-2).  
 
 
 
Figure 2-2. Frank-Starling curves in heart failure. The normal length-tension relationship 
of striated muscle is depressed downwards in heart failure; further increases in pre-load 
arising from congestion instead can act to compromise stroke volume. 
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Ventricular hypertrophy further increases tissue oxygen demand and can 
precipitate ischaemia. Eventually, chronically raised plasma noradrenaline 
concentrations trigger direct toxic effects on cardiac myocytes. Beta-receptor 
downregulation at the level of the myocardium also ensues, blunting the 
effectiveness of this cycle and triggering greater sympathetic activation.  
 
2.1.2 Renin-angiotensin-aldosterone system  
 
At the renal level, the renin-angiotensin-aldosterone system (RAAS) is 
concurrently activated and drives fluid retention and increases in intravascular 
plasma volume (Figure 2-3).82 Renin is released in response to hypoperfusion and 
mediates the conversion of liver angiotensinogen to angiotensin I. This is then 
converted by ACE – mostly found in pulmonary vascular endothelial cells – into 
angiotensin II (AT2). AT2 exerts a number of direct effects. It is a potent 
vasoconstrictor of the systemic arterial circulation, directly enhances 
sympathetic activity and promotes aldosterone release.80 Aldosterone directly 
acts on cells within the renal collecting duct to promote sodium and water 
retention.83  
 
 
Figure 2-3: Renin-angiotensin-aldosterone system in heart failure. Adapted from 
Jackson et al (2000).80 Increased renal renin production catalyses a hormonal cascade 
which eventually triggers further maladaptive haemodynamic and renal effects which all 
worsen congestion. 
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2.1.3 Natriuretic peptides 
 
The natriuretic peptide (NP) family consists of three recognised classes of 
peptides with comparable molecular structure and hormonal effects: atrial 
natriuretic peptides (ANP), brain natriuretic peptides (BNP) and C-type 
natriuretic peptide (CNP).84 ANP and BNP are released by the myocardial wall in 
response to elevated intra-cardiac pressures and wall stretch.85,86 CNP is 
produced by endothelial cells in response to vascular volume overload.  
 
All three act as counter-mechanisms at the levels of the renal, cardiac and 
central nervous systems to the pathological responses which have been initiated 
from an impaired cardiac output.84 Natriuretic peptides can inhibit cardiac 
remodelling, suppress the renal-aldosterone axis and induce vasodilation to help 
reduce the preload and afterload on the heart.84,87 Within the renal system, NP’s 
provoke natriuresis by increasing glomerular filtration via induction of 
vasodilation of the afferent arterioles and supress sodium retention by 
inactivating exchange pumps in the proximal renal tubules.88 However, over the 
course of time the potency of natriuretic peptides on the reno-cardiovascular 
system becomes blunted in HF.89 
 
 
2.2 Haemodynamic mechanism of congestion  
 
Congestion is thought to arise through either a process of fluid accumulation or 
fluid redistribution.90 Increased fluid alters the balance of oncotic and 
hydrostatic pressures in capillary networks resulting in systemic and/or 
pulmonary transudation of fluid and subsequent oedema. These two different 
pathophysiological processes can lead to the development of congestion 
requiring hospitalisation. 
 
 
2.2.1 Fluid accumulation 
 
Compensatory cardiovascular mechanisms which attempt to increase plasma 
volume also cause a corresponding expansion of the interstitial space as oncotic 
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and hydrostatic forces ensure that the two compartments are kept in relative 
equilibrium.10 In HF, capillary beds become more permeable, partly due to 
protein and albumin loss (from renal losses and cachexia) which reduces the 
transcapillary oncotic pressure gradient.7 There is net fluid movement from the 
intravascular compartment into the interstitium and this haemodynamic 
congestion is eventually recognised as symptomatic clinical congestion. If this 
occurs centrally in the lungs, alveolar pulmonary oedema develops.7 In the 
peripheral circulation, this can be visually assessed and palpated as peripheral 
limb oedema.7  
 
In HF, the interstitial space is transformed from a low-compliance to a high-
compliance compartment. A study of untreated patients with severe LVSD 
demonstrated that during periods of congestion the interstitium can increase its 
retentive capacity by around one-third in conjunction with increases in the 
intravascular compartment.91 However, reversal of this process is difficult – even 
when volumes in the intravascular space have been normalised, such as 
therapeutically with diuretics. After pulmonary and peripheral congestion has 
clinically resolved, volumes in this space can remain elevated resulting in 
refractory subclinical fluid overload.91   
 
Volume overload itself may produce a continuous pro-oxidant state mediated by 
endothelial signalling and encourage further vasoconstriction during episodes of 
decompensation.92 Direct wall stress may also precipitate subendocardial 
ischaemia and myocardial necrosis.93 Increased venous congestion can also 
worsen renal function, resulting in diuretic resistance and a vicious cycle of 
greater congestion and progressive cardio-renal dysfunction.94  
 
 
2.2.2 Fluid redistribution 
 
Studies have demonstrated that a large proportion of patients with HF have no 
substantive weight gain before hospitalisation, providing an insight into how 
congestion can arise by fluid redistribution.95,96  
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A nested case-control study observing 134 HF patients from the United States 
demonstrated that 54% did not gain more than one kilogram prior to 
hospitalisation.95 One third of patients in the Chronicle Offers Management to 
Patients with Advanced Signs and Symptoms of Heart Failure (COMPASS-HF) 
study had a similar ‘weight-neutral’ prodrome before admission.96 
 
The venous system - like the arterial system - is heavily innervated. However it 
is over 30 times more compliant than the arterial network, holds 70% of the total 
blood volume and is responsible for mediating rapid fluid shifts.97 In normal 
states it can buffer changes in volume to prevent sudden fluctuations in cardiac 
preload. More dense adrenergic innervation of the media also means that these 
vessels are able to respond more markedly to sympathetic stimuli, such as to 
counter drops in blood pressure during orthostatic changes.98  
 
In certain instances, fluid can move suddenly from the peripheral venous system 
into the main circulatory volume in response to peripheral insults. Splanchnic 
venoconstriction can induce a rapid redistribution of fluid from the latent 
abdominal reservoir resulting in a marked increase in the circulating 
intravascular compartment.98 Venous pressures subsequently increase rapidly, as 
do central filling pressures. As a consequence, fluid quickly transudates into the 
alveolar space producing pulmonary oedema. 
 
In these scenarios, the rapidity of increases in pressures would cause pulmonary 
oedema to develop before worsening of peripheral oedema. This is thought to 
explain part of the mechanism behind the acute presentations of hypertensive 
HF.99 Vasodilators are preferred over diuretics in this scenario, as the 
pathological process is primarily load-mediated rather than volume mediated.1 
 
 
2.3 Clinical course of decompensation  
 
2.3.1 Time course 
 
The time course of presentation from congestion to hospitalisation has not been 
charted extensively but remains variable and dependent on multiple factors 
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including: the precipitants, the balance between fluid accumulation or fluid 
distribution as the pathological driver of deterioration, the patient’s pre-morbid 
state and cardiovascular reserve. In a study utilising implantable RV 
haemodynamic monitors in 32 HF patients who ended up with a hospitalisation 
episode, data could demonstrate that congestive changes would start 4 ± 2 days 
beforehand with systolic pressures increasing by 25 ± 4% (p < 0.05) before 
clinical symptoms peaked.100 Another similar study using implantable 
intrathoracic impedance sensors clearly detailed how increases in 
extrapulmonary water can develop 18 days before true clinical dyspnoea is 
apparent.101 Case control studies charting observed weight changes in HF 
patients have shown that increases in body weight can begin around one week 
before admission.95  The greater the weight gain the greater the risk of 
hospitalisation, the probability of which increases at gains of greater than one 
kilogram. However weight gain is non-specific and as some hospitalised patients 
do not experience an increase before admission, fluid accumulation cannot be 
the only mechanism leading to congestion. Symptoms also do not correlate 
exactly with the onset of congestion.  
 
 
2.3.2 Patterns of presentation  
 
A retrospective case review of hospitalised acute heart failure (AHF) patients by 
Shoaib and colleagues confirmed the theory that different mechanisms of 
congestion can produce various phenotypic sub-types of AHF.11 They sub-
categorised patients into those who were ‘short of breath at rest’ (SOBAR) or 
who were ‘comfortable at rest but breathless on slight exertion’ (CARBOSE). This 
review of 311 patients showed that these groups differed both in baseline 
characteristics and prognosis. SOBAR patients had greater central pulmonary 
congestion than those who were CARBOSE (61 vs 41%) but less peripheral oedema 
(42 vs 48%).11 They also had features of increased sympathetic drive reflected in 
statistically higher median heart rates (101 vs 82 bpm) and higher median 
systolic blood pressure (141 vs 122 mmHg). The findings could be confirmation of 
a more vasoconstricted phenotype where rapid fluid redistribution (rather than 
slow fluid accumulation) precipitates pulmonary rather than peripheral 
oedema.102 These were also a subgroup of patients more likely to present with 
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de-novo AHF (33 vs 19%).  Divergent prognoses between the groups was also a 
critical point of note; SOBAR patients did significantly better than CARBOSE 
patients (19 vs 34%, death at 180 days).11   
 
AHF is therefore not a homogenous entity but composed of a spectrum of 
congestion from predominantly central to peripheral, reflecting different 
pathophysiological mechanisms and varying degrees of sympathetic activation, 
fluid retention and fluid re-distribution.102,103 
 
 
2.4 Reliability of clinical assessment of congestion 
 
Clinical assessment is primarily aimed at assessing the presence and severity of 
congestion.1,2 The gold standard of investigation remains invasive right heart 
catheterisation with assessment of right heart pressures and pulmonary capillary 
wedge pressures (PCWP)6. The ESC Scientific Statement on Assessing and Grading 
Congestion demonstrated the variations in statistical strengths of each of the 
most commonly reported clinical features (Table 2-1).6 These analyses are 
comprised from prospective study data from the clinical assessment and right 
heart catheterisation (RHC) findings of patients referred for cardiac 
transplantation. In 50 pre-transplant cardiac patients undergoing invasive 
catheterisation, even where elevated PCWP was present, in 42% of cases no signs 
(such as elevated JVP, pulmonary rales or oedema) could be detected 
clinically.104 However, these findings are from HF patients with severe but stable 
HF. The incidence rate and predictive values of these may vary depending on the 
severity of LV dysfunction, aetiology of LVSD, the precipitant factor and the 
time course of clinical decompensation.  
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Table 2-1. Diagnostic value of clinical features of congestion. Adapted from 
Gheorghiade et al (2010).6 
 
Clinical feature Sensitivity Specificity PPV NPV 
Dyspnoea on 
exertion 
 
66 52 45 27 
Orthopnoea 
 
66 47 61 37 
Peripheral 
oedema 
 
46 73 79 46 
Elevated JVP 
 
70 42 66 44 
Third heart 
sound 
73 42 66 44 
 
JVP: jugular venous pressure; PPV: positive predictive value; NPV: negative predictive value.  
 
 
 
Five of the most commonly utilised clinical features are reviewed: dyspnoea, 
orthopnoea, pulmonary rales, elevated JVP and peripheral oedema are all 
central to assessing congestion. An understanding of the predictive values, 
pathophysiological origins and limitations of each is essential for evaluating the 
methods of AHF studies.  
 
2.4.1 Dyspnoea 
 
Dyspnoea remains a common presenting complaint in AHF patients, either at rest 
or on exertion. However, it is not pathognomonic of HF. It remains a symptom 
with multiple aetiologies and difficult to assess objectively, and doubts remains 
about whether congestion is fully represented by breathlessness.  
 
 
2.4.1.1 Heterogeneric aetiologies of dyspnoea 
 
In patients with HF, there may be multiple underlying causes for breathlessness, 
from both cardiac and non-cardiac origins and this may not reflect pulmonary 
congestion.105 Additionally, the symptoms of dyspnoea and fatigue may be 
reported inter-changeably by patients with HF.106  
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Chronic lung disease is a common co-morbidity and has been described in up to 
30% of patients with AHF.107,108 Bronchospasm and well as pneumonic processes 
may produce respiratory symptoms.  
 
Obesity is a common co-morbidity in HF and can also produce breathlessness on 
exertion.109 These patients may also have restricted lung function and 
breathlessness as a result of body weight. Coronary ischaemia may occasionally 
present as dyspnoea.  
 
 
2.4.1.2 Pathophysiology of dyspnoea 
 
The pathophysiology of dyspnoea is complex construct which arises from an 
interplay of afferent, efferent and higher cognitive inputs processed centrally 
within the respiratory centres of the medulla.110 When pulmonary ventilation is 
not able to meet metabolic demands, the sensation of dyspnoea is experienced.   
 
Central chemoreceptors in medulla and peripheral carotid bodies monitor 
oxygen and carbon dioxide tensions and hydrogen ion concentrations in the 
bloodstream.111 In the lungs, pulmonary C-fibre receptors located within the 
alveolar walls are activated by hypoxia caused by pulmonary oedema. Deviations 
from normal parameters will trigger increased afferent signalling which is 
integrated in the central respiratory centres to increase outputs to the 
ventilatory apparatus of the chest. Both these central inputs and increased firing 
to respiratory muscles are relayed to higher brain centres to give rise to the 
conscious feeling of breathlessness.111 Chest wall mechanoreceptors monitor 
ventilatory status and modify the intensity of dyspnoea if breathing is not 
adequate. 
 
The sensation of dyspnoea in HF patients is also exacerbated by multiple 
physiological factors. Reduced exercise capacity arising from reduced muscle 
mass, malnutrition, chronotropic incompetence (from beta blocker therapy), and 
general physiological deconditioning can all impair muscle functioning and 
produce faster elevations in lactic acid levels, thus triggering dyspnoea more 
readily on exertion.112 Limbs made heavier by fluid retention also require more 
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energy to sustain movement. Higher brain centre experiences (such as anxiety 
and depression – both prevalent in HF) can produce experiences of dyspnoea 
disproportionate to the degree of ventilatory impairment.113  
 
2.4.1.3 Variable reliability of assessments 
 
The two most common tools to assess breathlessness remain the 7-point Likert 
scale and the visual analogue scale (VAS). The Likert scale is often more easy to 
interpret by patients and both Likert and VAS are thought to have a high degree 
of correlation for determining baseline levels of dyspnoea.114 However, subtle 
intermediate changes remain difficult to pinpoint on the more compressed Likert 
tool as patient recall can often be variable.115 In the Preliminary study of 
RELAXin in Acute Heart Failure (Pre-RELAX-AHF) study, VAS was found to detect 
more subtle changes in symptomatology at an earlier timepoint, but these 
findings have not yet shown clinical relevance.116 Other more global assessments 
of well-being can provide indicators of overall improvement, but these 
determinations also risk being confounded by other subjective factors which are 
unrelated to the patient’s cardiac status.117 
 
2.4.1.4 Dyspnoea may not reflect congestion  
 
Data from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome 
Study with Tolvaptan (EVEREST) trial sub-study demonstrated that whilst a 
composite score for congestion (including dyspnoea) may normalise towards the 
end of a hospital admission, natriuretic peptide levels remain elevated well 
above baseline and this is associated with increased mortality.118 Patients who 
had improved symptoms were not left with a benign longer term prognosis. This 
strongly suggests a disconnect exists between clinical congestion and 
haemodynamic congestion, regardless of the improvements that are verbalised 
by the patient, thereby making it unwise to assume that dyspnoea is the 
absolute metric of haemodynamic congestion. 
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2.4.2 Orthopnoea 
 
Orthopnoea is defined as breathlessness when lying recumbent.119 It correlates 
strongly with invasive haemodynamics and has been demonstrated to have 
reasonable predictive value in reaching a correct diagnosis of HF. 
 
2.4.2.1 Physiology of orthopnoea 
 
As a clinical symptom, orthopnoea unmasks congestion when dependent fluid is 
redistributed from the abdominal reservoirs and into the venous circulation 
when lying recumbent.119 Up to 500 millilitres (mL) may load into the already 
congested central venous system further elevating filling pressures.6 This loading 
of the right ventricle, will correspondingly increase left sided and pulmonary 
venous pressures. Reduced pulmonary compliance and pulmonary oedema 
subsequently develop giving rise to the symptoms of breathlessness when lying 
down. In many instances, orthopnoea is also denoted alongside the degree of 
recline (traditionally assessed by asking the patient how many pillows they use 
during sleep) which is required to alleviate the symptom. 
  
2.4.2.2 Haemodynamic correlation 
 
Orthopnoea correlates closely with PCWP measurement. In pre-transplant 
cardiac patients, orthopnoea was found to be a positive predictor of an elevated 
PCWP of ≥ 22mmHg in 91% of patients.104 In a more contemporary study, clinical 
examination was reviewed against the invasive haemodynamic assessments of 
388 patients enrolled in the Evaluation Study of Congestive Heart Failure and 
Pulmonary Artery Catheterization Effectiveness (ESCAPE) study.120 Right atrial 
pressures and PCWP were recorded and assessed against various clinical 
parameters. Only the presence of raised JVP (of ≥ 12 cm) and orthopnoea 
(specifically of ≥ 2 pillows) were found to be associated with a PCWP of  ≥ 30 
mmHg. Importantly, a lower ‘pillow grade’ of orthopnoea was not found to bear 
as close a correlation. It should be noted that this patient group unlike earlier 
studies consisted of hospitalised not stable patients and with severe disease (an 
LVEF ≤30%).120  
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2.4.2.3 Predictive value and confounders 
 
Orthopnoea holds a positive predictive value of 61%, sensitivity of 66 % and 
specificity of 47% for congestive HF against the gold standard of RHC.6 In these 
respects, the predictive values of orthopnoea may be better than that of 
dyspnoea at rest and on exertion (which have been reported and utilised more 
extensively in AHF studies). However, as with dyspnoea, it can arise due to non-
cardiac causes. In most instances, any condition restricting the ability of the 
patient to lie supine - such as spinal disease or gastro-oesophageal reflux disease 
- may impede assessment. Additionally, pulmonary disease (such as chronic 
obstructive pulmonary disease) and obesity can also produce orthopnoea 
unrelated to HF.121  
 
 
2.4.3 Pulmonary rales 
 
As pulmonary congestion develops, fluid initially builds up in dependent areas of 
the alveolar space beginning with the basal lung segments. On auscultation, this 
can be heard in the form of crepitations.8 In the acute setting these findings can 
be clinically valuable. A review of AHF patients presenting with dyspnoea to the 
emergency department found that the presence of pulmonary rales increased 
the likelihood of a correct diagnosis of HF when supplemented with the patient’s 
clinical history (likelihood ratio, 2.6; 95% confidence interval, 2.1-3.3).122 
 
2.4.3.1 Inter-observer variability of pulmonary rales 
 
Substantial variability exists between clinicians reporting chest examination 
findings. Auscultation between examiners may not produce consistent results, 
and clinical seniority is often a mitigating factor against increased interobserver 
variability.123 In a blinded study of respiratory patients involving medical 
students and respiratory physicians, it was noted that there could be a high level 
of consistency in the detection of pulmonary abnormalities (between 74–89% of 
the examinations).123 However, this was only so long as the targets of 
auscultation were dichotomous lung sounds (such as rales or wheeze) (kappa = 
0.30-0.70). In a more recent multicentre study in 2017, a median kappa 
agreement of 0.49 was observed for crackles124, though this contrasts with an 
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older systematic review of chest examination findings which noted that 
examiner variability was indeed much higher (kappa 0.32 – 0.67).125 However, 
studies from these patients involved examiners of varying seniority and the 
patients enrolled possessed a mix of cardio-respiratory illnesses beyond HF. As 
agreement for dichotomous sounds are better than for softer adventitious 
sounds, it also remains to be seen if there is less observer variation for more 
“severe” signs of congestion, such as when rales at the bases extend completely 
to the apices and involve the majority of the lung field.126  
 
 
2.4.4 Jugular venous pressure 
 
Blood flows into the right heart at pressure into the cardiac chambers. This 
pressure is transmitted back through the venous system and produces a 
detectable column of blood visible as distension of the internal jugular vein.127 
Elevation or depression of this venous manometer can provide insights into right 
atrial pressure.  
 
2.4.4.1 Assessment and limitations 
 
To review the JVP, the patient is positioned at 45 degrees with neck rotation to 
allow the window between the clavicle and mandible to become apparent within 
which the internal jugular vein can be visualised. However, there remains 
debate amongst clinicians as to the precise reference point above which the JVP 
should be assessed. Variation remains between the right atrium and sternal 
angle - the more available reference point.127 The actual additional difference 
between these two points – usually quoted as 5 cm - has also been debated and 
is dependent on the angle of recline.128 Hepatojugular reflux, defined as the 
sustained rise of JVP by more than 3 cm for 10 seconds after hepatic pressure, 
may also be of use to visualise the vein.129 
 
In patients with right sided regurgitant valve disease, particularly tricuspid 
regurgitation, the column of blood in the internal venous system will be raised 
and not reflective of the true haemodynamic state of the patient.127 Similarly in 
pulmonary hypertension, there will be continuous venous distention not 
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reflective of congestion. Visualisation of the internal jugular vein may also be 
impeded in patients with increased adiposity or respiratory pathology.127  
 
2.4.4.2 Haemodynamic correlation 
 
In a review assessing the efficacy of clinical examination in identifying abnormal 
haemodynamic findings in pre-transplant patients, JVP distension at rest was 
found to have a high sensitivity, specificity and positive predictive value (81%, 
10% and 81% respectively) of predicting a PCWP of ≥ 18 mmHg.130 Of note, the 
threshold for elevation was placed at greater than 7 cm H20 above standard 
reference plane, furthering the observation that measurement standards can 
vary from study to study. An elevated JVP also appears to be associated with 
increased risk of clinical events. In a retrospective review of SOLVD, elevated 
JVP was associated with increased re-hospitalization (relative risk [RR], 1.32; 95 
percent confidence interval, 1.08 to 1.62; P<0.01) and death from pump failure 
(RR, 1.37; 95 percent confidence interval, 1.07 to 1.75; P<0.05).131 However, 
more recent post-hoc analyses from the Diuretic Optimization Strategies 
Evaluation (DOSE) trial and Cardiorenal Rescue Study in Acute Decompensated 
Heart Failure (CARRESS-HF) trial found neither JVP elevation on admission nor 
discharge could predict adverse outcome.132   
 
However, other studies are also conflicting104, and accuracy may wane in more 
critically ill patients133, thus it may be only at the more extremes of 
measurements that these correlations are evident.120 There is also evidence that 
the external jugular vein may instead be easier to visualise than the internal 
jugular vein, and can safely predict central venous pressures at ends of the 
haemodynamic range.134 As such, JVP assessment continues to be recommended 
by the American Heart Association (AHA) guidelines on the management of HF. 
They suggest its role in assessing LV filling pressure may be more assured in 
advanced HF, perhaps where signs are most prominent 2. 
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2.4.5 Peripheral oedema 
 
Peripheral oedema remains one of primary signs of non-pulmonary congestion.8 
It has been noted to have a sensitivity of 46%, specificity of 73% and positive 
predictive value of 79% in HF.6 However, peripheral congestion can also develop 
from non-cardiac causes. Falls in plasma oncotic pressure or damage to the body 
lymphatic system can also result in fluid transudation to the interstitium in the 
setting of a normal haemodynamic state. Liver cirrhosis, sepsis and malnutrition 
can all contribute to a hypalbuminaemic state and must be considered in the 
assessment of limb swelling.  
 
 
 
2.4.5.1 Inter-observer variability  
 
In formal comparisons, the traditional clinical assessment of peripheral oedema 
has been found to possess poor inter-observer agreement.135 The precise 
location of where the clinician examines for oedema on the leg is often not 
consistently described, leading to the absence of a standardised assessment 
method. It is also notable that clinician assessment does not always correlate 
well to pit depth or pit recovery time on a swollen leg. Other methods such as 
“oedema tester” plates have been developed which consist of a plastic sheet 
with holes of varying size that can be held at pressure and the indentation 
observed.136 There is no consensus on a standard approach to utilising the tool or 
the threshold which should demarcate mild from severe disease.136  
 
2.4.5.2 Alternative assessment methods 
 
Water displacement volumetery remains a reliable method to determine 
sequential changes in leg volume, but requires recurrent measurements and use 
of a foot volumeter – which is impractical in a hospitalised patient.135 Blood 
volume can be measured with radioisotope techniques and correlate with 
invasive haemodynamic cardiac assessments. However, beyond research 
purposes they cannot be readily utilised in a clinical environment.137  
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2.5 Classification of acute HF 
 
HF requiring hospitalisation can be grouped under a wide variety of terms: 
‘acute heart failure’, ‘decompensated heart failure’ and ‘hospitalised heart 
failure’. At present, no single term or classification system has been adopted, 
though ‘acute heart failure’ remains widespread in its use.2 These 
categorisations also do not distinguish between chronic worsening HF and acute 
de-novo presentations and do not indicate the timespan over which symptoms 
may have been progressively deteriorating before hospitalisation. 
 
A variety of different overlapping classifications systems have been proposed for 
the assessment of stable and acute HF. These vary from focusing on quality of 
life determinations to those based on clinical and haemodynamic review, though 
no single codification has been universally adopted for use. Current ESC and AHA 
guidelines on AHF recommend these at the discretion of the clinician and 
provide only general recommendations as to how they should be utilised.1,2  
 
 
2.5.1 ESC classification of acute heart failure  
 
The ESC has produced a classification system for AHF in a number of guideline 
publications. The presentations are grouped based on the underlying aetiology 
and presenting clinical features of the patient:12,138 
 
1. Decompensated HF: patients with a history of congestive HF who develop 
evidence of congestion necessitating admission. 
2. Pulmonary oedema: patients presenting with acute pulmonary congestion 
in the form of tachypnoea, clearly audible pulmonary rales and arterial 
desaturation to <90%. 
3. Hypertensive HF: heart failure precipitated by an acute vasoconstricted 
state leading to hypertension and rapid fluid redistribution into mostly the 
pulmonary interstitium 
4. Cardiogenic shock: HF characterised by acute tissue hypoperfusion (blood 
pressure < 90 mmHg or a drop of mean arterial pressure of > 30 mmHg). 
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5. Isolated right HF: a syndrome of mostly right heart signs such as increased 
JVP and peripheral oedema but little pulmonary congestion 
6. Acute coronary syndrome (ACS) HF: congestion precipitated by ACS 
 
 
There are two major criticisms of this classification. Firstly, definition for each 
sub-group remains imprecise and to some extent still rely on a degree of 
discretion by the individual clinician. Secondly, there is significant overlap 
between the different entities. A single patient with ACS can develop 
cardiogenic shock, and signs of right HF as well as a degree of pulmonary 
oedema thereby making them eligible for multiple classifications. In such an 
instance, as a result of the lack of clear demarcation between each sub-type, 
the same phenotype of patient can be classified into several sub-categories 
leading to dubiety about the validity of results reported under this method.   
 
 
2.5.2 Forrester classification  
 
The Forrester classification system groups patients into four categories based on 
an assessment of their level of congestion and level of perfusion.139 Congested 
patients are classified as being “wet” (congested) or “dry” (non-congested) and 
the level of perfusion is denoted by describing the patient as “warm” (well 
perfused) or “cold” (hypoperfused). This creates the four categories: ‘warm and 
dry’. ‘warm and wet’, ‘cold and dry’ and ‘cold and wet’ (Figure 2-4).  
 
Current ESC guidelines recommend attempting to perform this assessment to 
identify those patients at highest risk of morbidity, and provide a general 
overview of which therapies could be targeted to each subgroup.1 
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Figure 2-4: Forrester classification system. Adapted from Forrester et al (1976) 139 
The Forrester classification system assigns acute heart patients to one of four categories 
based on levels of congestion and perfusion (as determined by invasive haemodynamics). 
 
The original sub-types were developed based on a clinical, radiographic and 
invasive haemodynamic evaluation of 200 patients post acute myocardial 
infarction.139 To date, there has been limited validation of this system in the 
AHF population.  As has also been demonstrated by Forrester, when correlating 
clinical and haemodynamic changes, clinical examination is only accurate in 83% 
of cases. Additionally, when reviewing decongestive changes, clinical assessment 
does not parallel haemodynamic improvements in 30% of patients. A more 
modified assessment (using clinical assessment and not invasive catheterisation) 
has been demonstrated to predict mortality but when validated in an emergency 
department setting, the system has been shown to have limited inter-rater 
agreement and remains poorly predictive of a final HF diagnosis. 140,141  
 
Another substantive criticism of this classification is that the AHF and post-MI 
populations are two distinct entities with very distinct pathophysiological 
disturbances. It remains debatable whether a substantial number of true 
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hospitalised AHF patients are “dry”, or – as is more probable – comprise patients 
with known LVSD presenting with a heterogenous mileu of non-cardiac 
pathologies. 
 
Whilst this system appears to reflect a semi-confluent continuum from the stable 
patient to those in cardiogenic shock, there are further shortcomings in the 
classification of “dry and cold” patients (i.e. poorly perfused but non-congested 
patients). Classically a group with acute RV infarction – not AHF - with judicious 
use of fluids these patients can easily be relocated from “dry and cold” to “dry 
and warm”, theoretically producing sudden change in Forrester class (and a 
significant difference in expected but not actual prognosis). Another 
problematic area is the definition of ‘hypoperfusion’ which is not synonymous 
with hypotension. Whilst RHC can help clarify normotensive hypoperfused states, 
the best clinical approach for doing this is still undetermined and inter-observer 
agreement remains suboptimal.141  
 
Unlike other classification systems, determining Forrester class requires the use 
of an invasive RHC which in some regions limits its application.   There is some 
evidence from hospitalised patients with mixed pathologies in intensive care 
that the routine use of RHC in acutely compromised patients may be deleterious, 
however, this is not immediately extrapolatable to patients presenting with 
AHF.142 As the availability of RHC in many areas is constrained, physicians are 
limited to a more abridged clinical assessment.  
 
 
2.5.3 New York Heart Association classification 
 
The New York Heart Association (NYHA) classification system was originally 
designed in 1928 and later redeveloped into its current format.143 Patients are 
placed into four categories based on a physician assessment of the impact HF on 
daily activities: NYHA class I patients have no symptoms or limitation to ordinary 
physical activity, NYHA class II patients have mild symptoms during ordinary 
activity, NYHA class III patients have marked limitation of even less-than-
ordinary activity, NYHA class IV patients have severe limitations and experience 
symptoms at rest. This classification is primarily applied for chronic stable 
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rather than decompensated AHF patients requiring hospital admission – a group 
for which there is no clear consensus on how or when the grading determination 
should be made. 
 
One shortfall of the NYHA classification system is that it remains highly 
subjective. There is marked inter-observer variability in distinguishing class II 
from class III patients. In a study reviewing these differences, 30 cardiologists 
were asked to determine how they arrived at the marked NYHA score.144 70% 
incorporated the patient’s self-reported walking distance into the determination 
– a factor which is proven to correlate poorly with objective cardio-pulmonary 
testing. In 46% of cases cardiologists were not able to concur when trying to 
differentiate whether patients should fall into classes II or III.144 Specific activity 
scales have been proposed to improve validity and reproducibility, but these 
remain un-adopted.145 Research studies also have failed to provide any 
standardised approach to determining NYHA class. 
 
Despite its limitations as a valid outcome measure, it is an established predictor 
of clinical outcomes and correlates with objective determinations of functional 
status and prognosis.146 Whilst there is no clear correlation with ejection 
fraction, it remains evident that those with mild symptoms (i.e. NYHA class II) 
carry an increased risk of hospitalisation and adverse outcome compared to who 
are NYHA class I. The Canadian Heart Failure Network demonstrated this risk in a 
16,683 patient study of outpatient HF conducted over a twelve year period.147 
Increased hazard ratios were noted for patients who were initially diagnosed as 
NYHA class II (1.78, CI 1.54-2.06) and NYHA class III (3.51, CI 3.05-4.04) 
compared to NYHA class I patients.    
 
 
2.5.4 Killip classification  
 
The Killip classification system was developed in patients post myocardial 
infarction and is of little relevance to those with decompensated HF.148 In this 
method, the severity of clinically determined HF is graded into four classes: 
class I includes patients with no clinical signs of HF, class II patients have basal 
crepitations (or a third heart sound or elevated jugular venous pressure), class III 
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patients are in frank pulmonary oedema and class IV describes those in 
cardiogenic shock. The scoring system provides important prognostic 
information. In a large post-hoc analysis of the 41,021 patient Global Utilization 
of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary 
Arteries (GUSTO-I) study on thrombolysis post-myocardial infarction, Killip class 
was a strong predictor of 30-day mortality.149  
 
However criticism of the scoring system remains. Within class IV, two separate 
sub-categories clearly exist. Patients may have cardiogenic shock with 
pulmonary oedema and also be shocked without. This four part classification 
also does not overlap fully with the Forrester method. For example, within 
Forrester, there is no equivalent Killip class of patients reflective of patients 
who are hypo-perfused but not congested (“cold-warm”). 
 
In ACS practice, the Killip classification score is more widely reported, 
particularly due to its ease of application and its robustness in predicting 
mortality. Risk scores such as the Global Registry of Acute Coronary Events 
(GRACE) incorporate Killip class to determine cardiovascular outcomes.150 In 
registries and trials of AHF, this data does not tend to be reported as the post-
infarct cohort is not representative of the broader presenting AHF population. 
 
 
2.5.5 De-novo, stable and chronic heart failure 
 
The ESC defines a patient with de-novo HF as one with no previous history of HF 
(or of medical contact with related symptoms) presenting to medical services for 
the first time.1 There is no set maximum period between which the patient can 
have transitioned from an asymptomatic to symptomatic state before 
presentation. Current ESC AHF guidelines therefore allow the sub-category to 
include patients who have had an acute severe precipitating insult causing 
haemodynamic deterioration - such as an acute MI over hours – or those who 
have gradually deteriorated over a longer period of time as a result of 
progressive disease – such idiopathic dilated cardiomyopathy lying indolent for 
months or years. In reality, the majority of patents will have had some 
symptoms prior to first hospitalisation.151 
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A stable HF patient is defined as one who has had no changes in clinical 
symptoms over a one month period.1  This period of time is arbitrary and not 
derived from any specific evidence base. A definition of transient HF was 
produced in the 2008 ESC guidelines on HF but not maintained in subsequent 
documents. It drew attention to a class of patients with “symptomatic HF over a 
limited time period, [of whom] long-term treatment might be indicated”.12 It 
was envisaged that this would include patients with myocarditis who can make a 
full recovery with time or patients with acute myocardial infarction who develop 
temporarily impaired LV dysfunction which resolves once coronary 
revascularisation is performed and medical therapy is instituted.  
 
Clinical trials also vary as to what constitutes a de-novo presentation and 
whether such groups should be excluded from enrolment. However, 
hospitalisation is a key event in the trajectory of a HF patient’s progress. Once 
this has occurred, being cognisant of this distinction is prognostically relevant as 
the mortality rate for these cohorts can rise by a factor of three (though the 
precise reasons for this are multi-factorial).152 
 
 
2.6 Objective assessment of pulmonary congestion 
 
Objective and quantitative assessment of pulmonary congestion continues to be 
problematic. A CXR is recommended in the initial assessment process of HF, but 
it remains a modality with limited diagnostic abilities.1 Lung ultrasound (LUS) is 
an emerging modality with new applications.  
 
 
2.6.1 Chest X-ray 
 
On a chest X-ray, cardiomegaly, interstitial oedema and pleural effusions may 
indicate HF. However, these changes arise in non-sequential manner, and in 
some cases can pre-date signs of clinical HF.153 The findings of upper pulmonary 
venous congestion may occur first at lower pulmonary capillary wedge pressures 
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(PCWP) of 13-18 mmHg, whilst alveolar oedema may become evident at higher 
PCWP above 25 mmHg.75,154 
 
2.6.1.1 Haemodynamic correlation  
 
The CXR does not always correlate with haemodynamic congestion. In a study of 
52 stable patients with severe LVSD who underwent both chest imaging and 
cardiac catheterisation, X-ray changes were absent in almost a third (39% of 
patients) with significantly elevated PCWP of ≥ 30 mm Hg.59 A similar study of 
end stage cardiac patients awaiting transplantation found that in 68% of cases 
minimal or no pulmonary congestive changes were seen despite elevations of 
PCWP.155 It is speculated that in chronic HF, changes in alveolar membrane 
permeability or lymphatic drainage may reduce fluid transudation and 
accumulation in the alveolar space.  
 
 
2.6.1.2 Inter-observer variability 
 
A shortfall of the CXR is its interobserver variability. Problematic inconsistency 
exists depending upon whether the images are reviewed on plain film or digital 
formats, the type and seniority of specialist involved, and if the anomalies 
observed are cardiac or non-cardiogenic pulmonary changes.156,157 In some 
instances, agreement between emergency physicians and radiologists can be 
under 50%.158 A systematic review of diagnostic strategies in AHF also found 
chest films to be only moderately specific (76-83%) with low levels of sensitivity 
(67-68%) to congestion.60 Furthermore, this is also dependent on the specific 
radiographic feature of HF which is being examined on the chest film. The 
sensitivity and specificity of an X-ray for HF can vary if the feature highlighted is 
pulmonary venous congestion (54% and 96% respectively) or pleural effusions 
(26% and 92%). 122  
 
 
2.6.2 Lung ultrasound 
 
2.6.2.1 Principles of LUS 
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Lung ultrasound (LUS) is an emerging semi-quantitative method to detect 
extravascular lung water and pulmonary congestion.159 As increased interstitial 
sub-pleural oedema develops, interlobular septae thicken and at a histological 
level interfaces form between fluid filled and aerated alveoli. When a cardiac or 
vascular transducer is applied, the resultant ultrasonographic reflection at these 
points produces hyperechoic reverberation artefacts which are visualised as 
“comet tails”.160  
 
2.6.2.2 Superiority over CXR 
 
The sensitivity and specificity for LUS is high (94.1% and 92.4%) and much better 
than those reported for most CXR changes of AHF.161 Unlike clinical examination 
and CXR assessment, LUS can be performed with a high level of interobserver 
agreement and with variability consistently below 10%, even between 
experienced and less experienced personnel.162–164 The process of skills 
development and integration into clinical assessment is also easier than most 
other imaging modalities. In a prospective, cross-sectional study of acutely 
dyspnoeic patients who presented to an emergency department (ED), a short 30 
minute training tutorial was adequate enough to develop a basic competency in 
LUS assessment.164  
 
2.6.2.3 Haemodynamic correlation  
 
Changes in “B-line density” refers to the compactness of visualised ‘comet tails’ 
and correlates with changes in pulmonary congestion even within 3 hours of AHF 
treatment.165 In a 100 patient study examining HF patients undergoing both 
catheterisation and LUS, B-line frequency closely matched invasive right atrial 
pressure, pulmonary artery pressure and pulmonary venous resistance.166 These 
findings tie closely with historical data which shows a similar association 
between LUS findings and natriuretic peptide elevations – all of which predict in-
hospital mortality, re-admission and longer term prognosis.167 Of note, when LUS 
and dyspnoea assessments were correlated, it was noted that a quarter of 
patients had no dyspnoea rating on VAS assessments but still possessed evident 
B-lines on LUS. In a similar study of chronic ambulatory out-patients, 81% of 
patients with ≥ 3 B-lines had no audible crackles on auscultation.168 These 
findings provide valuable insight into the subclinical nature of pulmonary 
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congestion and emphasise the potential benefits ultrasound technologies could 
provide in quantifying the congestive characteristics of asymptomatic patients.  
 
2.6.2.4 Clinical utility 
 
LUS is not able to differentiate extravascular lung water arising from pulmonary 
congestion from that secondary to acute respiratory distress syndrome. 169 
Fibrotic lung disease (such as pulmonary fibrosis and systemic sclerosis) can also 
cause “dry” interlobular thickening of the alveolar structures and produce B-
lines on ultrasound.170 Positional changes of the patient can induce fluid shifts 
and alter the number of B-lines detected. Although uncommon, adiposity may 
limit image acquisition and interpretation.160 
 
 
2.7 Objective assessment of peripheral congestion 
 
No established imaging methods are regularly utilised in clinical practice to 
objectively assess peripheral congestion. Research into ultrasound assessment of 
the inferior vena cava (IVC) and jugular vein (JV) are bringing new HF 
applications to existing technologies. Bio-electrical vector analysis (BIVA) is a 
novel technology for assessing total body water content.  
 
The dilemma of identifying subclinical congestion remains. The optimal 
hydration point and tolerances for individual patients are variable and single 
point assessments are inadequate thereby necessitating serial assessments.  
 
 
2.7.1 Inferior vena cava ultrasound 
 
2.7.1.1 Principles of IVC ultrasound 
 
During cardiac decompensation, either through fluid accumulation or fluid re-
distribution, blood enters the venous system and elevates filling pressures as it 
re-enters the right heart. This creates congestion and leads to distension of the 
main conduit venous vessels, particularly the IVC.171 Using ultrasound 
technology, IVC diameter and its variation with respiration can be used to 
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estimate intra-cardiac pressures.171 New generations of pocket devices can 
provide sufficient 2D resolution to allow basic quantitative evaluation of IVC 
changes.172  
 
2.7.1.2 Haemodynamic correlation 
 
Although the evidence base is still nascent in this area, IVC ultrasound has been 
demonstrated to be an effective indicator when compared to invasive intra-
cardiac pressure measurement by RHC. It also tracks changes in congestion in a 
faster and more responsive way than cardiac biomarkers. In ESCAPE, patients 
underwent concurrent echocardiographic and invasive PWCP assessments from 
baseline to discharge as they decongested with diuretic therapy.173 IVC diameter 
and collapsibility corresponded the most to changes in PCWP, with a smaller IVC 
tracking falling wedge pressures. In a similar study of end-stage renal patients, 
it was demonstrated that IVC measurements could follow decongestion during 
fluid removal on dialysis.174 
 
2.7.1.3 Predicting prognosis 
 
During hospitalisation, IVC diameter reduces and collapsibility improves over the 
course of an admission, as would be expected as a result of diuretic therapy. 
However, residual enlargement and lack of collapsibility predicts hospital re-
admission, suggesting that this modality may be able to detect subclinical 
congestion.175 IVC enlargement on admission was also shown to be associated 
with increased 90 day and 36 month mortality, though it is unclear how 
awareness of this might optimally change therapeutic surveillance.176,177 In the 
outpatient setting, similar features of venous engorgement predict the risk of 
hospitalisation though not mortality.178 
 
2.7.1.4 Clinical utility 
 
Acquisition of IVC ultrasound techniques does not require significant additional 
training for those already skilled in basic echocardiography.172 A focused study 
can take as little as 5 minutes.179 In a study of 304 cardiac outpatients,  pocket 
ultrasound was found to increase the diagnostic yield of cardiac abnormalities 
from 38% to 70%. Additionally, IVC visualisation has been demonstrated to 
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reduce time to diagnosis in the emergency department (ED) settings.180 
However, further to clarifying a diagnosis, it is unclear if IVC assessment can be 
used to direct therapy especially if untreated subclinical congestion is suspected 
on discharge. 
 
 
2.7.2 Jugular venous (JV) ultrasound 
 
2.7.2.1 Principles of JV ultrasound 
 
Like the IVC, the jugular vein is a compliant vessel capable of distention in 
response to increased intravascular pressure and volumes. JV distension can be 
detected using the same focused ultrasound principles used to detect IVC 
enlargement.181 
 
2.7.2.2 Haemodynamic correlation 
 
Imaging of changes in the JV cross sectional area has been shown to predict 
increases in invasively assessed central venous pressure (CVP).182 In patients with 
a mean CVP of <10 cm H20, the JV diameter was <7mm whilst for a CVP of >10 
cm H20 this was 12.5 mm.183 Importantly, a high correlation coefficient was 
demonstrated amongst operators (0.92; CI 95%).   
 
2.7.2.3 Determining prognosis 
 
Prognostic information about JV distensibility is still being determined, but 
similar findings have been noted as with those from IVC ultrasound. In a 311 
patient study of HF outpatients, JV distension, echocardiographic filling 
pressures and biomarkers were assessed to determine associations with 
prognosis.  Reduced JV compliance during Valsalva manoeuvres was found to 
correlate positively with cardiac biomarkers (NT-proBNP, r=-0.39, p<0.001) and 
echocardiography (E/e’ filling pressures, r=-0.33, p=<0.001). Lower levels of JV 
distensibility could independently identify patients at increased risk of death 
and HF hospitalisation.184  
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2.7.2.4 JV near infra-red spectroscopy  
 
One shortfall of this imaging method is the lack of a standard set of reference 
values against which static and dynamic measurements should be referenced. 
More advanced technologies using near-infrared spectroscopy (NIRS) of the 
external jugular vein have been utilised to try and provide specific non-invasive 
quantitative values for the clinician. In the Studies Investigating Co-morbidities 
Aggravating Heart Failure (SICA-HF) study, NIRS was performed on 243 stable HF 
patients to non-invasively determine right atrial pressure (RAP).185 Though these 
findings have yet to be validated in broader HF populations, higher RAP values 
were associated with adverse outcomes and matched the prognostic utility of 
NT-proBNP. 
 
 
2.7.3 Bio-electrical vector analysis  
 
2.7.3.1 Principles of BIVA  
 
Peripheral oedema will often not develop until after the interstitial fluid volume 
has expanded to above 30% of normal.186  BIVA can potentially quantify 
intravascular volume expansion in AHF and provide the clinician with early data 
on subclinical congestion.  
 
BIVA functions by utilising the electrical properties of the human body. By 
determining body resistance (a function of intra- and extracellular fluid volume) 
alongside body reactance (a function of the dielectric material of tissue cells), 
the overall total body water of the patient can be calculated and subsequently a 
quantification made of hydration status.187 
 
2.7.3.2 Haemodynamic correlation 
 
Early studies have shown that BIVA can potentially monitor congestion. In study 
of 57 AHF patients, BIVA was used to assess hydration status in conjunction with 
their clinical state.188 BIVA parameter changes matched clinical improvements, 
and those labelled as having “the most significant congestion” by BIVA on 
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admission were found to subsequently experience greater improvements in 
dyspnoea, weight loss and reduction of BNP with diuretic treatment.188   
 
2.7.3.3 Determining prognosis 
 
In a study of 292 patients with AHF, the use of BIVA-determined congestion 
status was combined with BNP to produce a more accurate 90 day predictor of 
cardiovascular mortality (when compared to BNP alone).189 A statistically 
significant improvement in body water status was seen in survivors when 
compared with non-survivors (hydration index [HI] 85 vs 76, p<0.001) and 
discharge BIVA was an independent marker of an increased risk of cardiovascular 
death.189 A follow-up multicentre study by the same research group also 
demonstrated that patients who showed improvements in BIVA parametrics in 
response to diuretic therapy had a lower risk of death and rehospitalisation.190 
 
2.7.3.4 Clinical utility 
 
To date, no large multicentre studies have attempted to trial a BIVA-directed 
approach to decongesting HF patients. One single centre Italian study in 2011 
attempted a limited non-randomised, non-blinded approach, but focused the 
algorithmic decongestion strategy heavily on changes in BNP rather than BIVA 
derived data.191 The role of BIVA in an acute setting remains uncertain but it 
may help identify where residual congestion remains (such as in patients with 
decrementing urine output and persisting mild HF symptoms) and thereby help 
highlight those who require more intensive diuretic strategies. The identification 
of patients with subclinical congestion prior to hospital discharge may also be 
facilitated with the use of BIVA.  
 
 
2.8 Research questions and study aims  
 
The primary research question is to determine the nature of congestion 
reporting in the AHF population and the strategies which are undertaken to 
assess it. 
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2.8.1 Research aims 
 
Through the process of conducting two systematic reviews – on AHF trials and 
AHF registries separately - this study aims to ascertain: i) the assessment 
methods for congestion in AHF trials and in AHF registries, ii) the clinical profiles 
of congestion in both AHF trials and registries iii) how methods of congestion 
assessment are structured into enrolment and end point criteria in AHF trials and 
iv) the congestive profiles of patients with de-novo and acute-on-chronic heart 
failure enrolled into AHF registries.  
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3 Treatment of congestive heart failure 
 
3.1 Acute heart failure 
 
AHF is the exacerbation of the clinical symptoms or signs of HF necessitating 
urgent medical attention. Data from the European Society of Cardiology Heart 
Failure Long-Term (ESC-HF-LT) registry indicate the most common triggers are 
ACS (30%), arrhythmia (30%) and infection (20%).192 A clear precipitant is not 
always identified, though in reality multiple causes often trigger a 
hospitalisation event. As has been described, congestion can arise slowly over 
weeks (due to fluid accumulation) or more rapidly over hours (due to fluid 
redistribution).90  
 
 
3.1.1 Early acute assessment of congestion 
 
The primary aim of an initial assessment is to identify whether congestion is 
present.1 Identification of the Forrester haemodynamic profile of the patient can 
guide therapy – though the majority of patients fall into the “warm and wet” 
category. The ‘ABCDE approach’ is utilised to ensure diagnostic and 
interventional treatments (for HF and precipitants) are performed in parallel.193  
 
 
3.1.2 Clinical and biochemical assessment 
 
No single sign is pathognomonic of AHF, and therefore clinical assessment must 
be reviewed following comprehensive clinical examination alongside 
investigatory findings. It is recommended that all patients receive an initial 
standard CXR to evaluate the presence of pulmonary venous congestion, pleural 
effusions, and alveolar oedema – though in 20% of cases no anomaly will be 
readily detected.59 A standard 12-lead ECG aids the diagnosis of precipitant 
arrhythmias, ischaemia and shows potential evidence of cardiomyopathy. 
Echocardiography is recommended for all de-novo patients within 48 hours of 
presentation and immediately for patients in cardiogenic shock and 
haemodynamic instability – though guidelines acknowledge the availability of 
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clinical expertise to be a limiting factor.1 Assessments can be made of acute 
mechanical complications (valve or septal rupture), obstructive pathology (RV 
strain secondary to pulmonary embolus, cardiac tamponade) and overall left 
ventricular function.  
 
Biochemistry testing will usually be directed by clinical suspicion. Natriuretic 
peptides are elevated in AHF and have a powerful negative predictive value.1,2 
Positive results must be interpreted within the clinical context of each case. 
Cardiac causes (such as ACS, pulmonary emboli, myocarditis) and non-cardiac 
causes (cerebrovascular events, liver disease, severe sepsis) can all elevate BNP 
and NT-proBNP levels. In AHF, the ceiling reference range is higher than that for 
chronic stable HF (BNP 100 pg/mL, NT-proBNP 300 pg/mL). Cardiac troponin is 
not specific for AHF and is often raised secondary to myocardial wall stress or 
myocyte ischaemia due to hypoxia. Troponin assessment should be performed if 
a reasonable suspicion of ACS exists. Raised creatinine and blood urea nitrogen 
can indicate renal venous congestion and should not be taken as indicative of 
pre-renal compromise. Similarly liver function testing may be deranged arising 
either from congestion or a shocked cardiogenic state. Routine use of a 
pulmonary artery catheter is not recommended unless there is significantly 
impaired perfusion and fluid status is indeterminable by clinical means.2  
 
 
3.1.3 Oxygen therapy  
 
Oxygen therapy should be targeted to those who are hypoxic (due to pulmonary 
oedema) with an aim to normalise saturations as appropriate for the patient’s 
target range. A range of 88-92% is appropriate for those at risk of hypercapnic 
respiratory failure (e.g. moderate-severe chronic obstructive respiratory disease 
[COPD], severe spinal or neuromuscular disease, cystic fibrosis).194 Otherwise a 
target of 94-96% should be used.  Severely compromised patients with acute 
pulmonary oedema should initially be treated with oxygen via a reservoir mask 
at 15 l/min. More stable patients can be managed with nasal cannulae (1-4 
l/min) or a simple face mask (7-10 l/min). Those at risk of hypercapnic 
respiratory failure should be managed instead with controlled oxygen delivery 
via a Venturi mask to enable titration as required.194 Care must be taken to 
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avoid hyperoxygenation which can precipitate vasoconstriction and impair 
cardiac output.195  
 
For patients with refractory hypoxia and persisting acidosis, non-invasive 
ventilatory (NIV) methods (continuous positive air pressure [CPAP] and bilevel 
positive pressure ventilation [BiPPV]) can increase alveolar recruitment, reduce 
alveolar oedema and reduce hypoxia.196 Both can reduce venous return (thereby 
reducing preload) and improve cardiac output.197 BiPPV is also more effective at 
clearing hypercapnia and reduce the work of breathing. The 3CPO study 
demonstrated that patients undergoing NIV for cardiogenic pulmonary oedema 
experience faster symptomatic improvement and normalisation of acidosis and 
hypercapnia.198 Whilst no mortality benefit was demonstrated, NIV also reduces 
progression to intubation.196 
 
 
3.1.4 Identification of haemodynamic profile 
 
ESC guidance advises clinicians attempt to identify the haemodynamic profile of 
the patient using the Forrester classification.1,139 However, the method for 
classifying each sub-category remain subjectively determined and the follow on 
treatment strategies are still loosely defined.  
 
For patients who are “warm and wet” (well perfused but congested), clinicians 
must determine whether vasoconstriction or fluid congestion is the predominant 
pathophysiological disturbance.1 This is intended to reflect the differing 
mechanisms of decompensation, namely fluid redistribution and fluid 
accumulation. In both cases diuretic therapy, usually a loop diuretic such as 
furosemide, is required to facilitate decongestion. Where vasoconstriction 
predominates, patients should be treated with a vasodilator and diuretic. Where 
fluid congestion is the primary feature, patients should be initially managed with 
diuretics and consideration given to ultrafiltration if this fails.  
 
Patients who are “warm and dry” (appropriately perfused and not congested) 
should have their oral therapy optimised and no further HF specific interventions 
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are advised.1 “Dry and cold” patients who are hypoperfused and underfilled 
should be considered for cautious fluid challenge followed by inotropic therapy.1  
 
“Wet and cold” patients (those congested and poorly perfused) are treated 
depending on blood pressure.1 Patients with a systolic blood pressure below 90 
mmHg (and in cardiogenic shock) should be given inotropes and diuretic therapy 
if no alternative cause for hypoperfusion exists. Vasopressors may be utilised 
with caution with recourse to mechanical support. “Wet and cold” patients with 
a systolic blood pressure above 90 mmHg (in a non-shocked but poorly perfusing 
congested state) should be given vasodilators and diuretics with inotropic 
therapy added in if perfusion does not improve with decongestion.  
 
 
3.1.5 Congestion scores 
 
Post-hoc analyses from DOSE, EVEREST and PROTECT have attempted to 
construct congestion scores which revolve around a narrow set of core features 
of congestion (orthopnoea, elevated JVP, peripheral oedema and pulmonary 
rales).118,132,199 Scores which are elevated on admission and fail to improve with 
therapy have all been demarcated as a risk factors for recurrent re-admission 
and mortality. EVEREST also demonstrated that patients with low scores can 
continue to have high levels of circulating NPs – furthering the concern that a 
dissociation often arises between clinical and haemodynamic congestion. 
However, how these tools should applied prospectively has yet to be 
determined. 
 
An integrative assessment has been recommended by Girerd and colleagues 
comprising not just congestion scores but also biomarkers (particularly NP) and 
ultrasound imaging (LUS and IVC ultrasound).71 Pre-discharge targets have also 
been included as suggested strategies. However, these remain problematic. 
Clinical assessment is known to remain subjective and variable. In many cases, 
NYHA or dyspnoea scores will not improve in patients with advanced HF (and 
concurrent respiratory disease) regardless of how much additional diuretic 
therapy is deployed. The evidence for instituting pre-discharge thresholds for 
NPs is also weak - no clear link with lowered readmission rates or mortality has 
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been identified.200 NP values can also lag behind true changes in haemodynamic 
pressures by up to one week.201 Both congestion scores and biomarker data have 
not been prospectively trialled within an algorithmic framework and there 
remains uncertainty of how to approach the “non-responder”. The conundrum of 
subclinical haemodynamic congestion may partially resolved with ultrasound 
imaging and an integrative strategy provides an initial framework to try and 
assess this. Providing a ‘live snapshot’ of the haemodynamic congestive burden 
could indicate whether a more aggressive diuretic based approach may have 
value – though what parameters to target remains subject to the discretion of 
the clinician. A strategy of earlier follow-up for patients with residual congestion 
(as evidenced though imaging) may reduce rebound admissions – but further RCT 
evidence is needed.   
 
 
3.1.6 Pharmacological interventions 
 
In the immediate phase, diuretic, vasodilator and inotropic agents are the 
primary pharmacological measures utilised for managing AHF. Other medications 
specific to the precipitant cause can also be administered concurrently. Cautious 
use of opiates may be considered alongside oxygen therapy to relieve severe 
dyspnoea, anxiety and ease secondary sympathetic overstimulation.202 Where 
pharmacological therapy has failed, ultrafiltration is an option in oliguric 
patients with hyperkalaemia, acidosis and worsening renal biochemistry.1 
 
3.1.6.1 Diuretics 
 
Loop diuretics are the first agent of choice for immediate decongestion, with no 
evidence of any one agent being more efficacious. Frusemide is most commonly 
delivered intravenously and possess venodilatory properties when given as bolus 
injection. DOSE ascertained that no difference exists between bolus and 
continuous infusion.203 A strategy of high dose frusemide boluses (defined as 2.5 
times the previous oral dose) reduced congestion in patients faster with better 
dyspnoea improvement but with transient deterioration in renal function and no 
survival difference. Whilst 80 mg of Frusemide can be delivered rapidly with 
vasodilatory effect, higher doses must be slowed to 4 mg per minute to avoid 
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the risk of ototoxicity.204 In such circumstances, continuous infusions may be 
preferred. Diuretic naïve patients (such as de-novo patients) are more 
responsive to diuretics, and so lower doses (e.g. furosemide 40 mg 
intravenously) are more appropriate.1 During hospital stay, as diuretic resistance 
develops, sequential nephron blockade with additional thiazide agents can 
improve diuresis.204  
 
3.1.6.2 Vasodilators 
 
In hypertensive AHF, vasodilators can reduce venous and arterial tone to 
improve cardiac output and reduce filling pressures. The resultant changes in 
haemodynamics are rapid and alongside diuretic therapy can quickly lead to 
resolution of a substantive degree of pulmonary congestion. Nitroglycrine, 
isosorbide dinitrate, and nitroprusside are the most commonly available agents 
in European nations.1 Slow up-titration is required to avoid precipitous drops in 
systolic blood pressure and they should be avoided in patients with severe 
obstructive valve disease or hypertrophic obstructive cardiomyopathy.  
 
3.1.6.3 Inotropes 
 
Despite increasing cardiac output, inotropes increase myocardial oxygen demand 
and can precipitate arrhythmias and vasodilation.205 No survival advantage has 
been demonstrated in AHF with either adrenergic or non-adrenergic agents.  
However current guidance sanctions the cautious use of inotropes in specific 
scenarios such as where hypoperfusion arises without hypovolaemia, or as a 
bridge to mechanical support devices.1 
 
Dobutamine has direct ß1 and ß 2 adrenergic agonism and produces less 
tachycardia than adrenaline. Vasodilation does occur and tolerance arises after 
72 hours of use.205 Dopamine induces natriuresis at low doses (3-5 
microg/kg/min) and also acts on ß-adrenergic receptors to cause increased 
inotropy. However blood pressure is augmented mostly by vasoconstriction 
through actions on α-adrenergic receptors at higher doses (10 to 20 
microg/kg/min). Data from ROSE-AHF where patients were randomised to 
dopamine, nesiritide or placebo suggested that no benefit was achieved with low 
dose therapy.206 However in this study, dopamine and nesiritide were both 
 67 
initiated within 24 hours of hospitalisation and not selectively to patients with 
worsening renal impairment or diuretic resistance. A trend towards increased 
urine volume production with dopamine was also observed in HFrEF patients.206 
 
Levosimendan and milrinone represent two non-adrenergic agents available in 
clinical practice. Levosimendan is recommended where shock arises from beta-
blockade. In clinical trials, no mortality advantage was demonstrated and 
adverse effects secondary to pro-arrhythmia occurred.207,208 Milrinone - a 
phosphodiesterase inhibitor - produces more pulmonary vasodilation than 
dobutamine, but when assessed in Outcomes of a Prospective Trial of 
Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) 
trial, hypotension and sustained arrhythmias were more frequently reported 
with no survival benefit.209  
 
 
3.1.7 Mechanical circulatory support 
 
Mechanical circulatory support (MCS) devices can stabilise cardiac 
haemodynamics and act as a bridge to transplant, recovery or temporary 
stabilisation until further evaluation can be undertaken.1 MCS devices can be 
short term for days (such as intra-aortic balloon pumps [IABP]) or months-to-
years (such as left ventricular assist devices [LVADs]).  
 
IABP are inserted percutaneously into the aorta below the left subclavian. A 
counter-pulsation mechanism help supports circulatory pressures. During systole 
rapid deflation of the balloon creates a dead space easing blood flow out from 
the LV whilst diastolic balloon inflation maintains coronary perfusion. Whilst 
randomised trials have not shown benefit in cardiogenic shock secondary to MI 
there have been no trials in AHF. IABPs are used as a bridge to recovery (for 
example in acute myocarditis), before coronary revascularisation, or prior to 
repair of mechanical complications (such as acute mitral regurgitation or 
ventricular septal rupture secondary to myocardial infarction [MI]).210 
 
Extracorporeal membrane oxygenation (ECMO) can be veno-venous (VV) or veno-
arterial (VA).211 VV-ECMO is utilised primarily for deficiencies of gas exchanges 
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due to respiratory failure (such as secondary to severe pneumonia or acute adult 
respiratory distress syndrome [ARDS]) and not acute HF.211 VA-ECMO can be used 
for AHF, difficulty weaning of bypass, or severe RV failure secondary to 
pulmonary thrombo-embolism (where pulmonary thrombectomy is to be 
scheduled). ECMO functions as a bridge to LVAD implantation or recovery, but its 
longer window for use is associated with higher rates of complications.  
 
LVADs consist of a battery operated external mechanical pump with two 
cannulae surgically implanted into the LV apex and aorta. These devices are 
used to allow patients to survive until transplantation.212 Eligibility criteria 
include an LVEF < 25% (peak VO2 < 12 mL/kg/min), recurrent hospitalisation and 
inotropic dependence. The absence of severe RV dysfunction is critical to 
optimise outcomes.1 Complications from LVAD implantation include bleeding, 
stroke, pump thrombosis and device infection. 
 
The timing of MCS and specifically LVAD implantation can be guided by 
classification scores (Table 3-1).213  
 
Table 3-1. INTERMACS classification. Adapted from Stevenson et al  (2009).214  
 
INTERMACS 
Profile 
Title Description 
 Level 1 Critical cardiogenic 
shock 
Life threatening hypotension refractory to 
inotropic therapy (“crash and burn”) 
Level 2 Progressive decline Inotrope dependent with worsening end-organ 
function (“sliding fast” on inotropes”) 
Level 3 Inotrope dependent Stable haemodynamics but dependent on 
inotropes for stability 
Level 4 Resting symptoms Daily resting symptoms and requiring high dose 
of oral diuretics 
Level 5 Exertion intolerant Housebound and unable to perform any activities 
above basic activities of daily living 
Level 6 Exertion limited Rapidly fatigues on performing minor activities 
(“walking wounded”) 
Level 7 Advanced NYHA III Symptoms on mild exertion 
 
INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support, NYHA: New York Heart 
Association.  
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The Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) scale provides a grading system for risk stratification to aid 
decision making. Patients are scored from 1 to 7 based on clinical symptoms, 
inotropic dependency and haemodynamic state.  Registry data indicates that 
survival rates remain better for those implanted at INTERMACS 2 and 3 than 
INTERMACS 1.215,216 
3.2 Chronic heart failure: Medical therapy 
 
Medical therapies for chronic HF involve pharmacological antagonism of the 
adverse neuro-hormonal systems which cause fluid retention and deleterious 
cardiac remodelling.1 Oral diuretics are initially utilised to decongest patients. 
Beta-blockers, ACE inhibitors and mineralocorticoid antagonists [MRA]) are then 
added to counter the effects of excess sympathetic stimulation and RAAS 
activation.1  Angiotensin receptor blockers (ARB) remain an alternative for those 
who are intolerant of ACE inhibitors. New angiotensin receptor-neprilysin 
inhibitors (ARNi) have shown positive results in direct comparison against ACE 
inhibition and may supersede these in future guidelines. For patients who remain 
tachycardic, ivabradine has a role through heart rate reduction. Hydralazine-
isosorbide dinitrate (H-ISDN) has been proven to have beneficial vasodilatory 
effects in selected patients, particularly those of African-American descent. 
Although not shown to reduce mortality, digitalis may also provide patients with 
symptomatic benefit. It should be noted that unless specified the therapies 
described apply to HFrEF patients. 1 
 
 
3.2.1 Diuretics 
 
The primary aim of diuretics is to decongest patients. At present, no large 
randomised trials have been conducted to demonstrate any mortality benefit of 
diuretic therapy, though they have been a baseline component of standard care 
for all major HF studies.1 A Cochrane review examining diuretics and outcomes 
concluded that there was some evidence that mortality, worsening HF and 
exercise tolerance may be improved.217 Loop diuretics are the first line agents of 
choice in stable chronic HF and act by inhibiting sodium and potassium 
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reabsorption in the ascending loop of Henle. They produce a more powerful and 
shorter acting diuresis when compared to other classes of diuretics. At present, 
furosemide, torasemide and bumetanide remain the most commonly utilised 
diuretics in European practice.1 
 
Each loop diuretic has a different rate of absorption. During periods of 
congestion, intestinal oedema can develop as the interstitial space expands 
significantly, yielding a slower and less pronounced absorption curve.218 In this 
setting, clinicians may prioritise agents such as bumetanide with a more 
lipophilic and bioavailable profile (80% of bumetanide is bioavailable compared 
to 40% of frusemide). However, the risk of gout remains higher and when 
equivalent doses are compared the overall effectiveness remains similar.219 
 
In cardio-renal syndromes, loop diuretics may not be adequately secreted into 
the tubular lumen to exert their channel blocking effects. In such cases, 
increased doses may be required to produce a similar shift in fluid balance.  
There remains significant variation in maximal doses advised. For furosemide, 
ESC guidelines recommend a limit of 240 mg per day, the British National 
Formulary 1,500 mg, whilst small scale individual studies have shown that 
administrations of up to 4,000 mg day may be possible.220 However, 
hypokalaemia, gout and tinnitus occur with increasing frequency at higher 
doses.221 
 
Over time, diuretic resistance can develop necessitating greater doses of loop 
diuretic or combination therapy with thiazides.222 The precise prevalence 
remains unclear, but a retrospective review of the Prospective Randomized 
Amlodipine Survival Evaluation (PRAISE) trial found this occurred in 35 % of AHF 
patients and was independently associated with increased mortality (HR 1.37, 
p<0.004).223 The mechanism of this “renal brake” involves increased 
epithelisation of the distal convoluted tubule resulting in greater salt 
transporting (and therefore water re-absorbing) capacity. By blocking other 
components of the renal tubule, sequential nephron blockade exerts a 
synergistic effect to yield a higher volume diuresis. However, these 
combinations have to be utilised cautiously as over-diuresis and electrolyte 
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imbalance may occur (specifically hypokalaemia and hyponatraemia). Current 
evidence suggests different thiazides have broadly equivalent potency. 
 
Critically all these strategies must be in concurrence with the appropriate 
dietary advice, particularly a restriction of excess fluid and salt intake. After 
loop diuretic administration, compensatory post-diuretic salt retention can 
occur, and if excess dietary salt is present the overall fluid balance may be 
rendered neutral.    
 
 
3.2.2 Beta-blockers  
 
Beta-blockers act by blocking excess sympathetic activity on the cardiovascular 
system.224 They also achieve benefits by reducing arrhythmic risk and assisting 
with rate control. Current trials have confirmed efficacy in ischaemic and non-
ischaemic cardiomyopathy and they produce improvements in symptoms, 
ejection fraction, hospitalisation rates and mortality. There still remains debate 
about whether these benefits can be extended to patients with atrial fibrillation 
and HFmrEF. 225,226 
 
The transition of beta-blockers from a historically contra-indicated drug to a 
core therapy for HF has been driven by changing perspectives of the disease 
process. HF is viewed less as a pure haemodynamic disturbance and more focus 
has been exerted on correcting the neurohormonal disorder. The Cardiac 
Insufficiency Bisoprolol (CIBIS II) study was a landmark trial demonstrating a 
mortality benefit of bisoprolol in NYHA class III-IV patients with severe LVSD.227 
Improvements were seen in all-cause mortality (RR 34%, p<0.0001) and 
hospitalisation (RR 20%, p<0.0006). The Carvedilol Prospective Randomized 
Cumulative Survival (COPERNICUS) trial demonstrated similar benefits for 
carvedilol against placebo in NYHA IV patients with LVEF < 25% (but with ACE 
inhibitors also comprising standard therapy).228 Following this, the Metoprolol 
CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT- HF) 
showed that sustained release metoprolol in HF patients given to a broader 
NYHA class (II-III) and LVEF < 40% could also produce a survival benefit.229 
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A systematic review and meta-analysis of 21 major beta-blocker trials 
determined that just three beta blockers demonstrated a clear mortality benefit 
in HF: bisoprolol, carvedilol and metoprolol.224 Carvedilol has shown to lower 
cardiac mortality in various metanalyses but not to a degree that is statistically 
significant.224 The mechanisms for this is unclear and may relate to effects on 
endothelial function, its inherent anti-oxidant properties and superiority in 
maintaining glycaemic homeostasis in patients with diabetes. In clinical 
practice, bisoprolol, carvedilol, metoprolol and nebivolol remain the 
recommended beta blockers of choice. The overall relative mortality benefit in 
stable HF has been estimated to be 20-35%. 224  
 
In acute decompensated HF, beta-blockers should only be commenced when 
patients are stable and preferably euvolaemic (i.e. after the patient is no longer 
congested).1 For patients already established on beta-blockers, it should be 
continued unless cardiogenic shock is evident. Meta-analysis evidence and 
registry data from OPTIMIZE-HF suggest that acute beta-blocker withdrawal 
during hospitalisation (where the beta-blocker is not the causative agent of AHF) 
can trigger increased rebound sympathetic drive and precipitate angina, 
dysrhythmia and raise mortality. 230,231  
 
 
3.2.3 Angiotensin-converting enzyme inhibitors 
 
ACE inhibitors are capable of attenuating LV remodelling to improve 
mortality.232 In HF, globular dilatation distorts ventricular shape and 
compromises contraction. The resultant altered wall stress leads to further 
cavity dilation and progressively poorer contractile function.232 In SOLVD, 
sequential echocardiography demonstrated that ventricular volumes were better 
stabilised in patients taking enalapril versus placebo.233 At a cellular level, ACE 
inhibitors can also temper secondary adverse changes in molecular and gene 
expression which occur within pathways not associated with haemodynamic 
overload.234 
 
The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) and 
SOLVD trials were the first to establish the beneficial effects of ACE inhibition in 
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large scale randomised controlled trials (RCTs) using enalapril in symptomatic 
and asymptomatic patients with severe LVSD.235,236 Further randomised studies 
have demonstrated a consistent class effect with other ACE inhibitors.237 A 
review by the Collaborative Group on Ace Inhibitor Trials of 32 RCTs 
demonstrated that patients with the poorest LVEF benefited most, with gains 
seen more prominently within the first 3 months. Mortality and hospitalisation 
were all improved (odds ratio [OR], 0.65; 95% CI, 0.57 to 0.74; P < 0.001).237 
Patients post-MI without and without symptoms have also been shown to benefit 
from ACE inhibition.238,239 
 
 
3.2.4  Mineralocorticoid antagonists 
 
MRAs act on the distal nephron to reduce aldosterone mediated expression of 
proteins and ion channels involved in sodium retention and potassium secretion. 
Although the production of aldosterone can be inhibited in a more upstream 
fashion at the adrenal level by ARBs, hypertension studies have demonstrated 
that these levels can normalise via an ‘aldosterone escape’ phenomenon within 
six months.240 By utilising MRAs to antagonise the action of aldosterone at the 
receptor sites of the kidney, this bypass can be effectively inhibited. 
 
MRAs have significant multi-organ effects outwith the nephron. Antagonism of 
MR receptors in the myocardium can attenuate fibrosis, hypertrophy and 
apoptosis whilst in the vascular endothelium, MR blockade reduces endothelial 
dysfunction and vascular stiffness.241 In hypertensive patients, spironolactone 
has been demonstrated to reverse the development of left ventricular 
hypertrophy (LVH) over and above the effect of ACE inhibitors.242 
 
In the Randomized Aldactone Evaluation Study (RALES), spironolactone 
decreased all-cause mortality by 30% against placebo in NYHA III and IV patients 
with an LVEF < 35%.243 Hospitalisation was also reduced by an equivalent 
amount. The positive results of the Eplerenone in Mild Patients Hospitalization 
and Survival Study in Heart Failure (EMPHASIS-HF) study extended use of MRAs to 
patients with milder NYHA II class symptoms.244 Patients post-MI with LV 
impairment have also been shown to benefit from early addition of 
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eplerenone.245 As such, all symptomatic patients with an LVEF ≤ 35% should be 
initiated on MRA therapy.1  
 
 
3.2.5 Angiotensin-receptor neprilysin inhibitor 
 
Angiotensin-receptor neprilysin inhibitors are a new class of HF agents which can 
deliver both RAAS blockade and enhance natriuretic peptide systems. Neprilysin 
is an endogenous endopeptidase that breaks down vasoactive peptides including 
bradykinin, adrenomedullin, substance P and natriuretic peptides.246 In blocking 
neprilysin, these counter-systems responding to neurohormonal changes in HF 
can be enhanced to restore their protective effects on vasodilation, sodium 
excretion and adverse remodelling. 
 
The provisionally titled agent LCZ696 was efficacious against enalapril in the 
landmark Prospective Comparison of ARNI with ACEI to Determine Impact on 
Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial in patients 
with NYHA II-IV HF and LVEF < 40%.247 This combination drug was composed of 
sacubtril and valsartan. Sacubitril functions as the neprilysin inhibitor and 
valsartan adds ARB functionality to enable RAAS and direct AT2 blockade. 
Valsartan is preferred over an ACE inhibitor in this combination as direct ACE 
blockade can result in an excess build-up of vasodilatory mediators which may 
precipitate life threatening angioedema.248 PARADIGM-HF was stopped 
prematurely as the significant benefits of ARNI over enalapril in reducing 
hospitalisation (22% vs 27%, P < 0.001) and all-cause mortality (HR  0.84; 95% CI, 
0.76 to 0.93; P<0.001) became apparent.247 Hypotension was more prevalent in 
the sacubitril-valsartan arm (14 vs 9%, p<0.001) but less hyperkalaemia and renal 
dysfunction was seen. Sacubitril-valsartan is currently recommended as an ACE 
inhibitor (or ARB) substitute for patients who remain symptomatic after 
combination therapy with ACE inhibitor (or ARB), beta-blocker and MRA has been 
attempted.1  
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3.2.6 Angiotensin II receptor blockers  
 
ARBs may be preferred to ACE inhibitors in a number of instances. ACE inhibitors 
can produce two particular side effects specific to their mechanism of action 
which require discontinuation of therapy. Cough is a chronic persistent symptom 
which has been described in 5 to 35% of patients.249 The precise mechanism 
involves the accumulation of bradykinin –  an agent normally degraded by ACE.250 
This is a class effect and necessitates switching completely to a different 
therapeutic class of drug. Angioedema may also occur in 0.1 to 0.2% of patients. 
The onset is variable (between hours to a weeks of starting therapy) and also 
arises from the vasodilatory effects of bradykinin.249  
 
ARBs function by blocking the action of AT2 at multiple organ system levels. 
They also antagonise the effects of AT2 produced through non-ACE regulated 
pathways.251 ARB therapy can block AT2 mediated-vasoconstriction in the 
vasculature and attenuate sympathetic upregulation, myocyte remodelling and 
renal natriuresis. AT2 mediated aldosterone secretion is also inhibited in the 
adrenal cortex.251 Cough and angioedema are not typically associated with ARB 
use.  
 
The Losartan Heart Failure Survival Study (ELITE II) compared losartan against 
captopril in 3152 patients with symptomatic HF and documented LVEF < 40% to 
assess if ARB agents could supersede ACE therapy.252 Most patients were NYHA 
class II or III and 80% were of an ischaemic aetiology. By trial completion, there 
were no significant differences between the two cohorts with respect to either 
mortality or hospitalisation. It should be noted that lorsartan was much better 
tolerated than captopril (discontinuation rate of 9.7 vs 14.7%, losartan against 
captopril).252 In the Valsartan in Acute Myocardial Infarction (VALIANT) study, 
valsartan and captopril were compared against each other in patients post-MI 
with LVSD and/or HF. Both therapies were proven to be equally efficacious in 
this setting.253 However, combination therapy with an ACE and ARB is not 
synergistically beneficial. In the Candesartan in Heart failure: Assessment of 
Reduction in Mortality and Morbidity (CHARM-Added) trial, candesartan was 
added to patients already on standard therapy (including ACE inhibitors).254 
There were trends towards an improvement in cardiovascular mortality and 
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hospitalisation but significant adverse effects arose with dual RAAS blockade. In 
the candesartan arm, 24% of patients discontinued therapy due to side-effects 
including renal dysfunction (rise in creatinine 7.8%, hyperkalaemia 3.4%) and 
hypotension (4.5%). 
 
As a consequence of the above studies, ARB use is indicated in HFrEF when an 
ACE inhibitor cannot be tolerated.1 Dual combination therapy is not 
recommended unless patients are unable to take an MRA. In such cases closer 
monitoring of blood pressure, potassium and renal function is advised. 
 
 
3.2.7 Ivabradine 
 
Ivabradine functions by reducing the rate of sinus node depolarisation via 
inhibition of the If current in sinus nodal cells (but without effecting other cells 
of the conducting system). Pharmacologically, ivabradine has no neurohormonal 
blocking actions. Where beta-blocker induced respiratory symptoms are 
problematic, ivabradine remains an alternative. Blood pressure is also not 
impaired, as the therapeutic effect is mediated by prolongation of diastolic 
perfusion time thereby improving myocardial perfusion without lowering central 
aortic blood pressure.255  
 
In the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) 
study, 6558 patients with symptomatic HF and impaired LVEF (of ≤ 35%) already 
on baseline medical therapy were randomised to ivabradine or placebo.256 
Patients in both groups were in sinus rhythm and on a beta-blocker if tolerated. 
Whilst no absolute mortality benefit was seen, the primary outcome was positive 
driven principally by a 23.8% relative reduction in HF hospitalisation. Patients 
with greater heart rate reduction also reported better symptomatic benefit.257 In 
a post-hoc analysis of the SHIFT trial, a clearer survival benefit was seen in 
those with heart rates of over 75 bpm (HF death: Hazard ratio [HR] 0.61, 95 % 
confidence interval [CI], 0.46-0.81, P < 0.0006) leading to this rate stipulation in 
the current ESC HF Guidelines.258 
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3.2.8 Hydralazine and isosorbide dinitrate  
 
Hydralazine and isosorbide dinitrate (H-ISDN) are both vasodilators capable of 
lowering ventricular filling pressures and vascular resistance.259 Combination 
therapy against ACE inhibition has been studied in the V-HeFT II trial and showed 
no overall mortality benefit (though H-ISDN was associated with better 
improvement in LVEF and exercise tolerance).260 Results from the African-
American Heart Failure (A-HeFT) trial which specifically focused on the African-
American population suggested that H-ISDN added to optimal medical therapy 
could reduce mortality. It is speculated that African-Americans with HF may 
have less aggressive RAAS activation and instead a poorer endogenous 
vasodilatory response to nitric oxide.261,262 
 
 
3.2.9 Digitalis 
 
Digitalis has been utilised as an inotropic and rate control agent for over 200 
years in cardiac disease.263 It belongs to the cardiac glycoside class of drugs and 
functions by blocking the function of sodium-potassium exchange pumps in 
cardiac myocytes.263 The resultant effect is an increase in intracellular calcium 
producing a decrease in heart rate and increase in overall contractile function. 
Blood pressure is also augmented through increases in stroke volume. Due to its 
narrow therapeutic window and renally mediated method of excretion, caution 
is advised with elderly patients, females and those with renal dysfunction.1  
 
The Digitalis Investigation Group (DIG) trial randomised patients with an LVEF < 
45% in sinus rhythm to either digoxin or placebo in addition to standard medical 
care (diuretics and ACE inhibitors, but not beta blockers). There was no 
mortality benefit to digoxin use but hospitalisation was reduced.264 A meta-
analysis of 621,845 patients examined the impact of digoxin use on clinical 
outcomes and similarly concluded that no deleterious effect on mortality were 
present and hospitalisation was lowered in all trial subtypes.265 Current 
recommendations suggest that digoxin only be considered for ventricular rate 
control when there are no other suitable therapeutic options.1 The optimal 
range for rate control is also a subject of ongoing debate for patients in AF. 
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Evidence from the Rate Control Efficacy in Permanent Atrial Fibrillation (RACE II) 
study suggests targeting a HR of below <100 beats per minute (bpm) will yield 
equivalent outcomes to stricter strategies.266 However the ESC currently still 
advise targeting a ventricular rate of between 70 to 90 bpm with a caveat that 
the evidence base is weak in this area. 
 
  
3.2.10  Contra-indicated drugs  
 
Diltiazem has been shown to increase the risk of worsening HF in patients with 
HFrEF and AHF.267 Unlike beta-blockers, this drug produces negative inotropic 
effects on the heart but without any other protective neurohormonal actions. 
Other non-dihydropyridine calcium channel blockers such as verapamil are also 
contra-indicated. Dihydropyridine calcium channel blockers without negative 
inotropy (amlodipine and felodipine) have a positive safety profile.1 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased 
risk of HF events and MI. The mechanism of harm is secondary to disruption of 
cyclo-oxygenase mediated prostaglandin production in renal cells (leading to salt 
and water retention) and in the endothelium (leading to pro-thromboembolic 
activation of platelets).268,269 Thiazolidinediones have also been demonstrated to 
increase fluid retention and should not be used in HF.270 RCT evidence for 
flecainide has proven an increased frequency of fatal ventricular arrhythmias 
with use in LVSD patients and dronedarone is also associated with increased 
mortality in HF.2,271 Corticosteroids may worsen HF through fluid retention, but 
in select instances the overall risk-benefit ratio may necessitate prescription.  
  
 
3.2.11 Treatment of heart failure with preserved ejection fraction  
 
All major RCTs assessing the efficacy of beta-blockers, ACE inhibitors, ARB and 
MRA therapy in HFpEF patients haven demonstrated no survival benefit.13 The 
PARAGON-HF trial is due to report on the efficacy of neprilysin inhibition with  
sacubitril/valsartan in HFpEF, though preliminary results indicate no major 
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difference will be observed in the rates of cardiovascular death or 
hospitalisation (ClinicalTrials.gov Identifier: NCT01920711).  
 
At present, symptom relief should be attempted via the use of diuretics to 
relieve congestion. Concurrent co-morbidities such as hypertension, atrial 
fibrillation, coronary heart disease and diabetes mellitus must also be managed 
as directed by standard guidelines.1,2 The heterogenous nature of the HFpEF 
population and lack of a single gold standard test to correctly filter trial 
enrolment may be responsible for some of the neutral outcomes of these 
studies. Additionally, many HFpEF patients tend to be very elderly with multiple 
comorbidities making trial recruitment more problematic.13 
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4 Methods 
 
Searches were performed for both AHF trials and AHF registries. PRISMA flow 
diagrams for both the screening process and results are shown with overviews of 
the excluded results following full text review. 
 
 
4.1 Acute heart failure trials and registries 
 
4.1.1 Search strategy 
 
A search strategy was performed on EMBASE and MEDLINE for both AHF trials and 
AHF registries. The following search terms were utilised: “acute heart failure”, 
“decompensated heart failure” and “hospitalized heart failure” (Figure 4-1 and 
Figure 4-2). Each search was limited to consider the above terms in title, subject 
heading, keyword or abstract. Studies were limited to those enrolling humans 
and entries which were reported in the English language.  Trials were only 
considered from Jan 1, 2001 to Dec 31, 2018. Patients were included from trials 
which included either exclusively HFrEF patients or mixed HFrEF and HFpEF 
populations.  
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Figure 4-1: Search strategy for acute heart failure trials 
 
 
 
 
Figure 4-2: Search strategy for acute heart failure registries 
Results identified from 
database using search
(n=896) 
Records for full text review
(n=187)
Records for title/abstract screen
(n= 696)
Records excluded on full text 
review with reasons (n = 166)
Studies included in qualitative analysis 
(n =21 )
Papers excluded after detailed review: Sub-study 
(93), wrong study design (38), trial too small or 
insufficient data (34).
Duplicates removed 
(n = 200)
Records excluded by title or 
abstract (not heart failure or 
not randomized trial)
(n= 509
Results identified from 
database using search
(n=2020) 
Records for full text review
(n=559)
Records for title/abstract screen
(n= 1545)
Records excluded on full text 
review with reasons (n = 541)
Studies included in qualitative analysis 
(n =18 ) Papers excluded after detailed review: Conference abstract 
(300), sub-study (91), registry too small (29), wrong study 
design (17), wrong patient population (2).
Duplicates removed 
(n = 475)
Records excluded by title or 
abstract (not heart failure or 
not randomized trial)
(n= 825)
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4.1.2 Exclusion criteria 
 
Trials were restricted to RCTs which enrolled at least 180 patients. Studies were 
only considered for oral and intravenous therapies or for existing non 
pharmacological interventions which may aid decongestion. Registries were 
restricted to those which were prospective and enrolled a minimum of 2,000 
patients. For entry into the systematic review, registries were only considered if 
they provided some information about the clinical features of the presenting 
cohort.  
 
 
4.1.3 Screening and record selection 
 
All titles and abstracts were independently screened buy two reviewers (FA and 
AM). All identified results then underwent full-text screening followed by data 
extraction. Conflicts were resolved by FA and AM with NNL acting as a third 
arbitrating reviewer. Secondary papers published from the same the same 
original data sets (or primary papers preceding sub-study publications) were also 
reviewed to determine if they contained data pertinent to the search topic.  
 
 
4.1.4 Data extraction and analysis 
 
Search results were extracted to a Word document for further review. For each 
study, data was obtained for the nature of the intervention, duration of 
intervention, enrolment criteria, primary and secondary endpoints (with a focus 
on how these relate to congestion). Basic clinical data was also obtained on 
clinical presentation, NYHA class, radiological assessment, phenotypic 
classification (as per ESC guidelines on AHF), and haemodynamic profile (as per 
the Forrester classification method). Further supplementary clinical information 
was included for demographics, vital signs on presentation, laboratory findings 
(including baseline cardiac biomarkers [BNP, NT-proBNP], haemoglobin, serum 
sodium, potassium and creatinine), co-morbidities, aetiology of HF, presenting 
ECG, precipitating factors for the AHF hospitalisation and therapeutic profile of 
the patients (including oxygenation on admission, intravenous interventions, 
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procedural and surgical interventions, pharmacological treatment on admission 
and discharge). For the registry cohorts, further data on the same were also 
obtained for at patients presenting with de-novo and acute-on-chronic HF.  
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5 Systematic review of AHF trials 
 
 
21 randomised trials were identified comprising a total of 25,841 patients (Table 
5-1). 110,190,195–198,280–306,299  
 
Sixteen of these investigated novel compounds against standard medical 
therapy, thirteen involved an intravenous agent and three assessed novel oral 
therapies. Two studies looked at advanced renal interventions (ultrafiltration) 
compared with pharmacological therapy alone.300 One trial looked at varying 
levels of dose and infusion delivery methods of diuretic therapy. One trial 
investigated the difference between different modalities of oxygen delivery 
(namely continuous positive airways pressure [CPAP] against both non-invasive 
BiPPV and standard oxygen treatment).  
 
For the majority of trials, the therapeutic intervention lasted under 72 hours (in 
15 out of 21 trials). Only two (EVEREST and PIONEER-HF) investigated long term 
continuation of therapy. The time to randomisation was specified in thirteen 
studies. In eleven of these, this was mandated to be within 48 hours of 
admission or administration of the first dose of diuretic therapy. Only two trials – 
CARRESS-HF and PIONEER-HF - recruited patients from a longer period out from 
presentation, namely 10 days. 
 
A mandatory requirement of HFrEF was only present in 7 out of 21 trials 
(OPTIME-CHF, LIDO, ACTIV-in-CHF, EVEREST, SURVIVE, REVIVE-2 and PIONEER-
HF). A mixed combination of either reduced LVEF or another abnormal 
parameter (wall motion index, elevated biomarkers) was required for VERITAS 
and ASCEND-HF. The cut off for defining the necessary LVEF varied from < 30% to 
≤ 40%. Echocardiography was not always the pre-specified modality of 
assessment.  
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Table 5-1: Acute heart failure trial inclusion characteristics  
 
 
Trial Year n Intervention Duration of 
intervention 
Time to dyspnoea 
assessment 
Time to 
randomisation 
LVEF inclusion 
criteria 
Biomarker cut off De-novo 
patients 
permitted 
HFrEF           
OPTIME-CHF 209 (2002) 951 Milrinone  
(vs placebo) (1:1) 
48 hour infusion Baseline, Day 3 Within 48 hrs 
admission 
LVEF <40% within 12 
months 
 
- No 
LIDO 297 (2002) 203 Levosimendan  
(vs placebo) (1:1) 
24 hr infusion Baseline to 24 hrs - LVEF < 35% within 1 
month 
- Yes 
ACTIV-in-CHF 272 (2004) 319 Tolvaptan  
(vs placebo) (3:1) 
Oral agent for up to 60 
days 
Day 1 and discharge - LVEF < 40% in 
previous 12 months 
- Yes 
EVEREST A and B 276 (2007) 4133 Tolvaptan  
(vs placebo) (1:1) 
Oral agent (long term; 
median 9 months) 
24 hrs Within 48 hrs 
admission 
LVEF ≤ 40% in 1 yr - No 
SURVIVE 208 (2007) 1327 Levosimendan  
(vs dobutamine) (1:1) 
24 hr infusion 24 hrs - LVEF < 30% 12 
months 
- Yes 
REVIVE-2 207 (2013) 600 Levosimendan  
(vs placebo) (1:1) 
24 hr infusion 6, 24, 48 hrs and day 
3 and 5. 
N/a LVHEF < 35% at 12 
months 
- - 
PIONEER HF 277 (2018) 881 Angiotensin–Neprilysin 
Inhibition 
(vs enalapril) (1:1) 
Oral agent, long term - 24 hrs to 10 days LVEF < 40% in last 6 
months 
BNP ≥ 400 pg/mL, 
NT-proBNP ≥ 1,600 
pg/mL 
Yes 
HFrEF and HFpEF          
VMAC 278 (2002) 489 Nesiritide  
(vs nitrates vs standard 
care)  
(1:1:1) 
24 hr infusion 3 hrs, 24 hrs. - - - Yes 
RITZ-2 294 (2003) 292 Tezosentan  
(vs placebo) (1:1) 
24 hr infusion 6 hrs, 24 hrs - - - Yes 
UNLOAD 280 (2007) 200 Ultrafiltration  
(vs intravenous diuretics) 
(1:1) 
UF within 48 hours 8 hrs, 48 hrs Within 24 hrs 
admission 
- - Yes 
VERITAS 1 and 2 295 (2007) 1435 Tezosentan  
(vs placebo) 
(1:1) 
24 to 72 hours Baseline, 3 hrs, 6hrs, 
24 hrs. 
Within 24 hours 
admission 
LVEF < 40% in 12 
months (or wall 
motion index ≤ 1.2 
within 12 months) 
Elevated levels more 
than 3x upper limit of 
normal 
Yes 
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Trial Year n Intervention Duration of 
intervention 
Time to dyspnoea 
assessment 
Time to 
randomisation 
LVEF inclusion 
criteria 
Biomarker cut off De-novo 
patients 
permitted 
3CPO 281 (2008) 1069 CPAP  
(vs NIV vs standard O2 
treatment)  
(1:1:1) 
Min 2 hrs (investigator 
discretion) 
1 hr - - - Yes 
Pre-RELAX-AHF 291 (2009) 234 Relaxin – multiple doses (vs 
placebo) 
(8:3) 
48 hr infusion 6 h, 12 h, 24 h, 48 h, 
and days 3, 4, 5, and 
14.  
 
Within 16 hrs 
admission 
- BNP ≥ 350 pg/mL, or 
NT-proBNP ≥ 1400 
pg/mL 
Yes 
PROTECT 283 (2010) 2033 Rolofylline  
(vs placebo) (2:1) 
Up to 72 hrs infusion 24 hrs, daily until 
discharge 
Within 24 hrs of 
presentation 
- - No 
DOSE 203 (2011) 308 Frusemide (continuous 
infusion vs bolus and high 
vs low dose) (1:1:1:1) 
Up to 72 hrs infusion Baseline, 72 hrs. Within 24 hrs of 
presentation 
- BNP  ≥250 pg/mL, 
NT-proBNP  ≥1000 
pg/mL 
(* exclusion 
specified) 
No 
ASCEND-HF 301 (2011) 7141 Nesiritide  
(vs placebo) (1:1) 
24 hrs to 7 days 
infusion 
6 hrs and 24 hrs Within 24 hrs of 
intravenous diuretic 
LVEF < 40% within 12 
months (or 
BNP/congestion 
criteria) 
BNP  ≥400 pg/mL, 
NT-proBNP  ≥ 1000 
pg/mL 
Yes 
CARRESS-HF 288 (2012) 188 Ultrafiltration  
(vs stepped 
pharmacological therapy) 
(1:1) 
96 hrs infusion Baseline, 96 hrs, 7 
days. 
Within 10 days - - Yes 
RELAX-AHF 291 (2013) 1161 Serelaxin  
(vs placebo) (1:1) 
Up to 48 hrs infusion Baseline, Days 1-5. Within 16 hours of 
presentation 
- BNP  ≥350 pg/mL, 
NT-proBNP  ≥ 1400 
pg/mL 
Yes 
ROSE 206 (2013) 360 Nesiritide  
(vs dopamine)(1:1) 
72 hours infusion 24 hrs and 48 hrs Within 24 hours - - No 
 
TRUE AHF 293 (2017) 2157 Ularitide  
(vs placebo) (1:1) 
 
48 hrs infusion - - - BNP >500 pg/mL or 
NT-pro BNP >2000 
pg/mL.  
 
Yes 
ATHENA-HF 299 (2017) 360 Spironolactone 
(High dose vs Placebo) (1:1) 
96 hours of oral agent Baseline, , 48 hrs, 92 
hrs 
Within 24 hours of 
intravenous diuretic 
- BNP ≥250 pg/ml or 
NT-proBNP ≥1,000 
pg/ml  
Yes 
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-  no data available. 
HFrEF: heart failure with reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; LVEF: Left ventricular ejection fraction; BNP: brain natriuretic peptide; NT-
proBNP: N-terminal-prohormone brain natriuretic peptide; HF: heart failure; UF: ultrafiltration. OPTIME-CHF: Outcomes of a Prospective Trial of Intravenous Milrinone for 
Exacerbations of Chronic Heart Failure trial; LIDO: Levosimendan Infusion versus Dobutamine study. ACTIV in CHF: Acute and Chronic Therapeutic Impact of a Vasopressin 2 
Antagonist (Tolvaptan) in Congestive Heart Failure; EVEREST: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan; SURVIVE: Survival Of Patients With 
Acute Heart Failure In Need Of Intravenous Inotropic Support; REVIVE-2: Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy; PIONEER-HF: Comparison of 
Saocubitril/valsartaN Versus Enalapril on Effect on NTpro-BNP in Patients Stabilized From an Acute Heart Failure Episode; VMAC: Vasodilation in the Management of Acute CHF; RITZ: 
Randomized Intravenous Tezosentan study; UNLOAD: Ultrafiltration vs. IV Diuretics for Patients Hospital-ized for Acute Decompensated Heart Failure trial; VERITAS: The Value of 
Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies; 3CPO: Efficacy of non-invasive ventilation in patients with acute cardiogenic pulmonary oedema: Pre-
Relax-AHF: The Preliminary study of RELAXin in Acute Heart Failure; PROTECT: Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline 
for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function; DOSE: Diuretic Optimization 
Strategies Evaluation trial; ASCEND-HF: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial; CARRESS-HF: Cardiorenal rescue study in acute 
decompensated heart failure; RELAX-AHF: Relaxin for the Treatment of Acute Heart Failure; ROSE: Renal Optimization Strategies Evaluation; TRUE-AHF: Trial of Ularitide Efficacy and 
Safety in Acute Heart Failure; ATHENA-HF: Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure trial. 
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Nine studies included biomarker inclusion criterion. However, the threshold of 
BNP or NT-proBNP required to enter the trials were not consistent between 
those RCTs. Only five studies specifically excluded patients with de-novo acute 
heart failure. Four required the diagnosis of HF to have been made for a specific 
duration of time (24 hours prior to hospitalization, such as in ROSE) or the use of 
diuretic for a set period before unscheduled hospitalisation (at least 1 month of 
loop diuretic use in DOSE). 
 
 
5.1 Assessment of congestion in AHF trials 
 
Few trials mandated the presence of measures of congestion (Table 5-2, 
Appendix Table A-1). There was much variability in: the definitions of pulmonary 
congestion, the definitions of peripheral congestion and how imaging modalities 
were used to identify congestion. 
 
 
5.1.1 Dyspnoea assessment 
 
16 out of 21 trials included some form of dyspnoea assessment within their entry 
criteria.  In 43 % (9 out of 21 trials) there was a mandatory requirement that the 
patient be hospitalised with either dyspnoea at rest, or dyspnoea on minimal 
exertion. In all trials the assessment was subjective based on the history of 
patient. Only two included an objective assessment of respiratory rate. In 3CPO, 
patients could be eligible if presenting with a respiratory rate of > 20 breaths 
per minute. In VERITAS, this was ≥ 24 breaths per minute. 
 
 
5.1.2 Pulmonary congestion assessment 
 
In 18 out of 21 trials the presence of pulmonary congestion (either from clinical 
examination or radiographic findings) was part of the composite entry criteria to 
enrol into the study. However, in only four studies was pulmonary congestion a 
mandatory requirement for inclusion (3CPO, Pre-RELAX-AHF, RELAX-AHF and 
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TRUE-AHF). For the remainder, a composite score comprising clinical features of 
congestion had to be met. Clinical examination usually specified rales or 
crepitations (12 trials), but there was usually no distinction made between basal 
crepitations and crepitations extending beyond the lower lung field. Five studies 
required the extent pulmonary rales to be recorded and documented, but only 
VERITAS, PROTECT and ASCEND-HF required rales of more than one-third of the 
lung fields to be present to meet the composite entry threshold.   
 
Twelve studies included the use of an imaging modality to aid selection into the 
study. However, in each case this modality was a CXR. The radiographic features 
accepted included pulmonary oedema, pleural effusions or non-defined CXR 
features which the investigator felt could be in keeping with congestive HF, but 
this was not consistent between each study. No use of either chest or cardiac 
ultrasound was permitted to affect recruitment. No trials utilised a core lab to 
validate or standardise CXR findings.  
 90 
Table 5-2: Summary of congestion requirements for enrolment into acute heart failure 
trials  
 
Enrolment Criteria 
Number of trials 
Mandatory 
Non-mandatory 
(composite score) 
Not included 
Dyspnoea 9 8 4 
Pulmonary Congestion 5 13 3 
Peripheral Congestion 0 11 10 
Objective Imaging 47 9 7 
 
 
 
 
 
 
Table 5-3: Summary of congestion requirements for end points in acute heart failure 
trials  
 
End Point Criteria 
Number of trials 
Primary † Secondary Not included 
Dyspnoea 9 9 3 
Pulmonary Congestion 0 7 1 
Peripheral Congestion 2 8 10 
 
 
† Includes primary and co-primary end points 
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5.1.3 Peripheral congestion assessment 
 
10 out of 21 trials collected clinical confirmation of peripheral congestion as 
part of their composite entry criteria. However, peripheral congestion was not a 
sole mandatory inclusion criterion – patients without peripheral findings could 
still be enrolled if there was sufficient evidence of other features of congestion. 
Peripheral oedema was the most commonly described clinical sign of peripheral 
congestion (9 trials), followed by ascites (2 trials) and increased weight gain 
(only 1 study). As with pulmonary congestion, there was no uniform method to 
determine varying severities of peripheral oedema. Two studies (PROTECT and 
CARRESS) made reference to an oedema score (which was rated from 1 to 4 +) 
but this was not specifically defined within the individual study protocols. 
EVEREST described oedema in terms of being either absent, slight, moderate or 
marked. However, again whether this referred to the extent of oedema 
induration or distribution was not detailed. Only REVIVE-2 made reference to 
oedema involving sequentially progressive lower limb structures (legs, sacral, 
lumbar areas) while in PROTECT, either “≥2+” peripheral oedema or pre-sacral 
oedema could be considered clinical features allowing inclusion into the study.  
 
7 studies included JVP assessment as part of the inclusion criteria. However, 
there was much heterogeneity with regards to the threshold at which the JVP 
should be considered suitably elevated. Variations extended from a 
measurement of > 6 cm above the suprasternal notch to ≥ 10 cm. ACTIV-in-CHF 
and VMAC, both specified “raised JVP” and “JVP distension” but did not lay 
down any set elevation point, allowing the clinician to determine what 
constituted suitable elevation at their own discretion.  
 
Of note, no study incorporated imaging assessments - such as IVC ultrasound - 
into the eligibility assessment of peripheral congestion. 
 
Just two studies – PIONEER-HF and  – left the congestive criteria completely to 
the discretion of the clinician and specified only the presence of “signs and 
symptoms of heart failure” or “fluid overload”. 
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5.2 End points and congestion in AHF trials 
 
18 of 21 clinical trials incorporated dyspnoea into either a primary or secondary 
end point (Table 5-3, Appendix Table A-2). In almost half of these cases (nine 
trials), dyspnoea was either a primary, primary composite or co-primary end 
point. The Likert scale was the most common assessment modality (ten studies), 
followed by a visual assessment scale (VAS) (seven studies) usually with some 
form of quantification of the area under the curve. RELAX-AHF utilised both 
scoring systems for dyspnoea evaluation. Only REVIVE-2 utilised a composite end 
point of “worsening heart failure” as a primary end point which had a dyspnoea 
measurement integrated into this.  
 
By contrast, measures of pulmonary congestion were not part of any primary end 
points. In six studies, a variety of different assessments of pulmonary oedema 
were performed (including orthopnoea and presence of pulmonary rales) and 
were incorporated as either solitary secondary end points (half of studies) or 
composite secondary end points. As before, there was no standardised method 
of recording the degree of congestion on chest examination. 
 
Similarly, a minority of studies incorporated measures of peripheral or non-
pulmonary congestion into the primary or secondary end points (eight studies). 
In the ACTIV-in-CHF, UNLOAD and CARRESS-HF, weight loss was recorded at 24, 
48 and 96 hours post-randomisation respectively and formed the primary 
endpoint. In DOSE and ROSE, weight loss at 72 hours formed the secondary end 
points. The assessment of peripheral congestion remained variable as before. 
EVEREST utilised a scoring system dependent on the extent of pitting to grade 
peripheral congestion, but most other studies merely allowed the investigator to 
record whether there had been any improvement in limb swelling. 
 
Objective biomarkers were not sampled routinely. Only seven studies utilised 
either BNP (SURVIVE, REVIVE-2, UNLOAD) or NT proBNP (CARRESS-HF, ROSE, 
TRUE-AHF and PIONEER HF). With the exception of the Aldosterone Targeted 
Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF) 
and PIONEER-HF trials, these results were not incorporated into the primary end 
point.  
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5.3 Presenting features of congestion in patients in AHF trials 
 
A full summary of the clinical features of presentation was not provided by any 
study (Appendix Table A-3). In eleven of 21 studies, there was no record of 
either the dyspnoea status of the patient, the clinical findings of pulmonary 
congestion or the incidence or extent of peripheral oedema.  
 
5.3.1 Presentation with dyspnoea and pulmonary congestion 
 
In six studies (VMAC, VERITAS, 3CPO, Pre-RELAX AHF, ASCEND HF, RELAX AHF) all 
patients recruited – 100% - presented with dyspnoea at rest. In ACTIV-in-CHF, 
ATHENA-HF and EVEREST this figure was only marginally lower (89 %, 83 % and 70 
% of all patients). Dyspnoea on exertion was not a specifically recorded symptom 
in any of the clinical trials.  
 
The recording of pulmonary congestion was extremely variable. Only eleven 
studies provided data on lung assessment, and only two of twelve (REVIVE, 
PROTECT) detailed any breakdown of the degree of pulmonary rales (i.e. basal, 
more than one-third of lung fields, more than two thirds of lung fields). In 
PIONEER-HF – a study which recruited later from the point of admission – the 
overall incidence of pulmonary oedema was lower than other RCTs (at 
33%).Presentation with peripheral congestion 
 
In only half of the trials was there any recording of peripheral oedema. 
Documentation was inconsistent with no standard grading mechanism. DOSE and 
PROTECT used an induration scale to determine severity, whereas REVIVE 
detailed the extent of peripheral swelling in more detail (classifying oedema of 
the limbs separately from that which extended to the sacral and lumbar 
regions). Other markers of peripheral congestion (weight gain, hepatomegaly, 
abdominal swelling, ascites) were not reported at all.  
 
Elevated JVP – a component of the composite entry criteria for most studies – 
was reported in just under half of studies (ten trials). The cut off again was 
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variable from 6 cm of H20 to > 10 cm of H20. In six of these trials which did 
report data, over 70% of patients presented with a positive elevated JVP.  
 
5.3.2 Presentation by imaging findings and ESC phenotype  
 
CXR findings were only detailed in four cases (VERITAS, 3CPO, Pre-RELAX-AHF, 
RELAX-AHF) and a high incidence of positive findings of radiographic pulmonary 
congestion were noted (83 - 100%).  
 
No AHF trial reported the presenting clinical syndrome in a manner as 
recommended by successive ESC Heart Failure guidelines.1,17 
 
 
5.4 Baseline clinical characteristics of patients in AHF trials  
 
The median age of all trial patients from the table was 66.5 years (range 59-78). 
In only five studies was the mean age greater than 70 years. (Appendix Table A-
4) 
 
The presence of respiratory rate was recorded only in PROTECT and RELAX-AHF. 
Baseline natriuretic peptides were fairly varied. BNP measured in six studies 
ranged from 734 to 7156 pg/ml, NT-proBNP measured in eight studies ranged 
from 3000 to 7439 pg/mL.  
 
In nine of ten trials that reported data on aetiology, the commonest cause was 
ischaemia. However, as the majority of trials tended to exclude patients with an 
ACS, only the 3CPO study reported a significant number of patients presenting 
with this condition (22%). With the exception of VERITAS, VMAC and RITZ-2, the 
precise non-ischaemic aetiologies of each patient were not reported in the 
literature.  
 
The four studies with the highest rates of pulmonary oedema or mandatory 
clinical or radiological congestion criteria also had the highest average systolic 
blood pressure (SBP) (132, 142, 148 and 162 mmHg for the VERITAS, RELAX-AHF, 
Pre-Relax-AHF and 3CPO respectively).   
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From the reported data, it is difficult to ascertain precisely what number of 
patients within each cohort were new presentations of acute de-novo HF. For 
the eight studies that did report data, the percentage of patients with acute-on-
chronic decompensated HF ranged from 42 to 88%. The extent of previous HF 
hospitalisation within 12 months was also extremely variable (ranging from 31 to 
95%, from RELAX-AHF and PROTECT respectively). 
 
The initial treatment modalities on admission were also variably described – 
possibly as most patients received an intravenous intervention very close to the 
point of randomisation. The majority of patients – where data was available – 
received some form of intravenous diuretic. These was also variation in the 
extent of nitrate utilisation in these patient groups. In RELAX-AHF, only 7% of 
patients received an intravenous vasodilator. In the 3CPO trial, this number was 
higher at 88%. However, the other five trials which recorded nitrate use, all 
noted pre-randomization usage rates of 9 to 36%. 
 
RITZ-2 reported a fairly low rate of diuretic use (41 to 56%) but this was only 
reflective of intravenous administration in the last 24 hours and patients were 
not recruited immediately on hospitalisation. 3CPO, VERITAS and RELAX-AHF all 
reported higher rates of diuretic administration (over 89% of patients). Use of 
inotropic agents appeared low (dobutamine 0.5 to 10%, dopamine 2 to 8%) but as 
before many studies did not report any final data on these parameters.  
 
 
5.5 Discussion 
 
In AHF trials, indicators of congestion were incompletely recorded. Few trials 
mandated the presence of peripheral or central congestion. Measures of 
congestion played a minor role as primary end points. No studies incorporated 
imaging modalities other than a CXR and almost used dyspnoea as a key 
surrogate symptom of congestion. Further examination of the literature does 
throw into question whether this approach is robust enough for clinical studies.   
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5.5.1 Limited reporting of congestion 
 
This review of AHF trials demonstrates that there continues to be marked 
variation in the reporting of congestion. The time at which pulmonary and 
peripheral congestion were assessed was also not consistent between studies. 
Whether clinical examination is taken at the point of admission or at the 
decision to hospitalise (often after diuretic therapy) could affect the extent to 
which clinical signs – particularly pulmonary congestion – would continue to be 
present. Symptoms like orthopnoea were reported in a very variable manner 
with no transparent approach to determining the manner of assessment. In 
PROTECT, orthopnoea was classified according to whether 1, 2 or 3 pillows were 
required to alleviate the symptom. In ROSE and DOSE, the prevalence was 
detailed but without any pre-specified definition.  
 
In most cases, indicators of congestion were reported as part of a composite 
score which itself may be biased towards different causes of HF (for example, 
towards right sided heart signs). Additionally, the extent of decongestion after 
therapy was also not consistently recorded in AHF trials. As different congestive 
features correlate differently to risk, failure to record these key parameters 
makes it becomes difficult to assess the varying risk profiles of the cohorts 
within each trial.11,302 
 
 
5.5.2 Under-utilisation of adjunctive imaging modalities  
 
In clinical trials, a CXR was the only imaging modality utilised to assess 
pulmonary oedema. In 3CPO, ASCEND-HF, RELAX-AHF and TRUE-AHF, CXR 
findings of congestion were mandatory elements of the inclusion criteria and in 
seven other studies they were also a component of the composite scores used to 
select patients. In none of these trials was a core-lab utilised to validate the 
diagnosis. Other modalities such as lung and IVC ultrasound were not utilised to 
determine whether decongestion had been achieved. 
 
As several trials did not exclude de-novo AHF admissions and 11 trials did not 
require echo assessment of LVEF  (and 7 further trials did not require echo nor 
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natriuretic peptides to qualify for enrolment), there is a probability patients 
were recruited who did not possess true congestive HF.  
 
The use of better imaging assessments of congestion within inclusion criterion 
could have helped enrol populations with more to gain from investigative 
therapies.  
 
5.5.2.1 Variability of CXR congestion requirements 
 
Between clinical trials there remained a variability in the extent of radiological 
features required to cross the threshold to enter AHF studies. Some trials 
specified “interstitial oedema” (pre-RELAX AHF) and others “pulmonary oedema 
or pleural effusions” (CARRESS-HF). It has been established that these CXR 
changes are not uniform and can occur at different elevations of PCWP.75,154 To 
compound this, no core labs were utilised to standardise or validate CXR 
assessments, which is surprising given the interobserver variability which exists 
in this reporting method - even amongst specialists. 156,157,158 
 
5.5.2.2 Radiological congestion and outcomes 
 
As residual clinical congestion has been associated with adverse outcomes, 
residual radiological congestion could also potentially provide relevant 
information pertaining to the risk profile of patients and uncover any 
uncorrected haemodynamic state.118 However, to date this data remains 
incomplete. Residual radiological congestion was also not a feature of any 
clinical trial end point nor noted within any of the major AHF registries. It has 
been recognised that radiological congestion in the setting of acute MI can be a 
powerful predictor of mortality.303 However, the CXR does not completely 
correlate with haemodynamic congestion, and so more objective imaging such as 
LUS may be more accurate in identifying residual fluid overload. 59,155 
 
 
5.5.3 Imbalanced focus on dyspnoea  
 
This systematic review strongly demonstrates the unbalanced and subjective 
measurement of dyspnoea. The presumption that changes in breathlessness 
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closely track congestion and cardiovascular risk may have been a fundamental 
misconception that has led to persistently neutral outcomes in AHF trials.102 
 
5.5.3.1 Dyspnoea is over-utilised in enrolment and end point criteria 
 
AHF trials have shown marked bias towards ‘dyspnoea at rest’ as the key 
gatekeeper symptom for entry into clinical studies and for assessing efficacy as a 
primary end point. In almost half of clinical trials (9 out of 21), breathlessness 
was incorporated as a mandatory inclusion criterion. In 18 out of 21 it formed a 
component of the end point (and in 9 of these studies it was either a primary or 
co-primary end point). Even pulmonary congestion was not as heavily weighted – 
in only four studies were pulmonary rales mandatory for inclusion and in none 
were the endpoints primary. Furthermore, in no AHF trial was a symptom of 
peripheral congestion mandatory for enrolment nor part of the primary end 
point. In retrospect this may explain neutral trial outcomes as emerging 
evidence suggests that hospital stay and mortality rates are higher in patients 
with more severe peripheral oedema.302 Thus the population characteristics of 
trials and their assessments of the interventions applied may have been mis-
centred around one very limited assessment of congestion.  
 
5.5.3.2 Dyspnoea assessment remains subjective  
 
With the exception of VERITAS and 3CPO, there was no objective measure of 
dyspnoea – such as respiratory rate or demonstrable proof of oxygen 
desaturation on pulse oximetry. In these trials, serial measures of dyspnoea 
comprised subjective patient driven feedback methods, such either Likert scales 
or VAS. 
 
 
5.5.4 Criticisms surrounding dyspnoea assessment  
 
Though not captured in this systematic review, various insights from post-hoc 
analyses and substudies in the literature appear to indicate that dyspnoea 
assessments are not necessarily robust and that changes do not consistently 
completely correlate with clinical outcomes.  
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5.5.4.1 Dyspnoea may resolve rapidly without intervention  
 
The natural progressive history of dyspnoea during an HF admission appears to 
be one of rapid resolution with standard care. The literature indicates that in 
many cases, diuretic administration achieves fairly rapid pulmonary 
decongestion and improvements in overall symptom burden.  
 
In SURIVE, 82% of patients experienced at least a mild improvement in dyspnoea 
in the placebo group.208 In RELAX-AHF, 63% of patients reported at least 
moderate improvement in symptoms as assessed by changes in Likert scores at 
just 24 hours.290 A similar pattern was seen in the placebo groups of PROTECT 
(41% reporting moderate or marked improvement in breathlessness by day 2 and 
3) and ACTIV-in-CHF (50% improvement in dyspnoea by day 1).272, 283 Earlier and 
more rapid changes in symptoms were also observed at an even earlier 
timepoints in VMAC.278,304 50% of patients who did not receive the active 
intervention felt that they had symptomatic benefit from standard therapy 
within just three hours. Though a few studies did report the frequency of 
resistant symptoms these numbers remained relatively low. In REVIVE-2, the rate 
of “persistent or unresponsive” dyspnoea in the standard care arm was less 
remarkable at 18% after just 24 hours.207 
 
5.5.4.2 Dyspnoea scores may be unreliable  
 
There also remains no consensus around a reliable method of assessing dyspnoea 
in AHF trials.305  
 
The reported findings can vary depending on factors such as the degree of 
recumbency of the patient and on the nature of the scoring system used. A 
patient in a fully supine position may experience a degree of orthopnoea or 
obesity induced respiratory restriction resulting in a higher baseline score and 
receive less improvement when compared to one who is sitting upright. As 
assessments remain non-standardised it is not clear if these factors remain 
confounders.  
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Furthermore, in ASCEND-HF, notable geographical differences were observed in 
dyspnoea relief. The greatest improvement was seen in Latin America (57% of 
patients) and lowest In Central Europe (36%).306 It is unclear if the differences 
are the result of an actual phenotypic variation of the presenting cohort by 
region, or treatment strategies, or – more problematically in this instance – 
significant variations in the cultural perceptions of dyspnoea. 
 
In MEASURE-AHF, a multi-centre cohort with hospitalized HF were prospectively 
assessed with both with patient-reported scores and physician clinical 
assessments to review their reliability.117 As expected, dyspnoea improved 
rapidly in the first 24 hours, but tailed off beyond this point. VAS measures of 
dyspnoea were more gradual and persistent throughout the course of the 
hospital stay and correlated better with changes in clinical examination. 
However, it was noted that clinical signs of HF – notably pulmonary and 
peripheral oedema – resolved more completely than clinical symptoms. 72% 
patients were clinically free of oedema by day 7 (or discharge) but only 52% of 
patients reported improved dyspnoea. This lends suspicion to concern that self-
reported breathlessness by patients may be influenced by multi-factorial inputs 
and once initial symptom relief is achieved, patient perspectives become more 
dissociated from actual congestion. A retrospective review of symptoms from 
the ESCAPE trial also speculated that patients may mis-report fatigue as 
difficulty breathing, as both were pre-dominant symptoms and improved 
substantially in either arm of the trial.106  
 
5.5.4.3 Dyspnoea may not be a robust surrogate for clinical outcomes  
 
Whilst dyspnoea remains a symptom which may trigger medical contact for AHF 
and symptom relief remains critical to a patients perception of quality of life, it 
is debatable whether dyspnoea per se is an appropriate therapeutic target.307 
From a pathophysiological standpoint, dyspnoea can induce anxiety and increase 
sympathetic drive, consequently driving further haemodynamic deterioration if 
unchecked. However, there is no current evidence to suggest that targeting this 
consequence of congestion with more than basic diuretic therapy improves 
overall survival. 
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5.5.4.4 Dyspnoea relief does not always predict improved mortality  
 
Further analysis of ASCEND-HF suggested that whilst dyspnoea is an important 
determinant of 30 day mortality, this finding was not sustained at 180 days.301 
This may be a reflection of multiple other serious cardiac and non-cardiac 
processes which result in cardio-respiratory compromise (such as infection or 
ischaemia). These might contribute to refractory symptoms and poorer short 
term outcomes, but are not readily modifiable by investigational HF therapies.  
 
In pre-RELAX-AHF, successful dyspnoea relief at 24 hours did not correlate 
significantly with reduced mortality at 30 or 60 days.116 In PROTECT-pilot, whilst 
a mortality benefit was observed at 30 and 60 days with dyspnoea relief at 72 
hours, there was no clear association with the composite 60-day endpoints of 
mortality and hospitalisation.308 
 
 
5.5.5 Implication for AHF trial outcomes 
 
5.5.5.1 Potential futility of targeting dyspnoea  
 
It remains debatable whether trials should employ such a heavy focus on a 
symptom which rapidly improves with standard therapy. This emerging oversight 
may be a large driver towards the neutrality of many AHF studies. To find a 
beneficial effect of a potential therapy upon a symptom which is already 
resolving will be difficult. Additionally, the overall clinical benefit for such 
minor improvements also are yet to be determined.  Those patients with 
refractory respiratory symptoms against whom these treatments are targeted 
may also be a subgroup that are unlikely to respond to a short infusion of 
therapy, and as such the majority of interventions which cease after 48 hours 
will not begin to modify the pathophysiology of this cohort.  
 
It should be noted that in the most recent and positive PIONEER-HF trial, the 
randomisation period was between 24 hrs to 10 days post-presentation to 
hospital.277 This window that was much wider than most other AHF studies. In 
PIONEER-HF, it is notable that the prevalence of pulmonary oedema was lower 
than all of the other studies (33% at randomisation). The finding of peripheral 
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oedema was higher (62%) and is comparable to other trials. Dyspnoea was also 
less central to enrolment and in the final end point analysis, and may be the 
correct approach for future AHF trials.  
 
 
5.5.6 Conclusion 
 
This systematic review has demonstrated how AHF trials have structured their 
enrolment criteria and end points in an unbalanced fashion to revolve around 
dyspnoea. Evidence from the broader literature indicates that dyspnoea does not 
hold a robust correlation with clinical outcomes. Central and peripheral 
congestive signs should be considered as inclusion criteria to provide greater 
degree of balance. Resolution of congestion may be a more appropriate target of 
clinical trials, though this is yet to be proven definitively. The incorporation of 
adjunctive imaging modalities - such as LUS - into study protocols can provide a 
route to achieve this.  
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6 Systematic review of AHF registries  
 
18 registries were identified which investigated AHF presentations and presented 
data on clinical presentation and patient characteristics (Table 6-1, Appendix 
Table A-5). 104-105,184, 316–342  
 
These registries comprised a multi-continent set of 238,651 patients from North 
America, Europe and Asia. 12 registries were international and only six focused 
on populations within a single nation state (Beijing AHF – China; Kor-AHF – 
Korea; IN-HF – Italy; RO-AHFS – Romania; RICA – Spain; KCHF – Korea). 
 
 
6.1 Assessment of congestion in AHF registries 
 
In every study, the assessment of clinical signs for both pulmonary and non-
pulmonary congestion was left to the discretion of the clinician. In particular, 
clinical signs such as ‘raised JVP’ did not have a pre-specified definition or 
method for assessment. 7 registries (EAHFE, AHEAD, ADHERE, HEARTS, RO-AHFS, 
EHFS-II and RICA) did not report any data on signs or symptoms. 
 
 
6.1.1 Dyspnoea in AHF registries 
 
With the exception of Gulf CARE (98% of patients) the incidence of dyspnoea at 
rest varied from as low as 34 to 44% in the larger OPTIMIZE-HF and ADHERE-AP 
registries, to 73% in ALARM-HF. Most patients also had a degree of accompanying 
pulmonary oedema, but this was variable (61% to 92%). Dyspnoea on exertion 
appeared to be more common – though was only recorded in four registries. In 
OPTIMIZE-HF, 61% of patients presented as such, but in KCHF and the much 
larger ADHERE and ADHERE-AP studies, this was much higher at 95%. Only 
ADHERE, OPTIMIZE-HF and ADHERE-AP reported on dyspnoea at rest and 
dyspnoea on exertion. In all 3, the rate of exertional breathlessness was greater 
than breathlessness at rest (95% vs 34%, 61% vs 44%, 95% vs 40% for ADHERE, 
OPTIMIZE-HF and ADHERE-AP respectively).  
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6.1.2 Pulmonary and peripheral congestion in AHF registries 
 
No study specified any set method for assessing pulmonary rales or peripheral 
oedema. Unlike AHF trials, no differentiation was made for patients with only 
basal crepitations versus those with congested lung fields extending up to the 
apices.  
 
Similarly, for peripheral oedema, swelling that was clinically present only at the 
ankles or collecting more extensively towards the upper thighs were both 
recorded as a binary “yes” or “no”. The severity of congestion and oedema were 
not otherwise documented with any further descriptive detail.  
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Table 6-1: Summary of clinical presentations of patients in acute heart failure registries  
 
 Summary of Registries Registries reporting data 
Year 2001-16 - 
Patients 185,886 - 
Clinical Congestion 
(pulmonary) 
 - 
SOB at rest  34 - 98 6 
Pulmonary rales 61 - 92 12 
Orthopnoea 27 - 80 6 
PND 15 – 71 5 
Clinical Congestion 
(Peripheral) 
  
Peripheral oedema 43 - 82 10 
Weight gain 25 - 26 2 
Hepatomegaly 25 - 27 2 
Ascites 12 - 14 3 
Raised JVP 17 - 78 7 
Clinical Congestion (Other)   
SOBOE 61 - 95 4 
Fatigue 32 - 57 3 
Third heart sound 31 - 37 3 
Cold extremities 11 - 56 5 
Hypoperfusion 9 - 18 3 
NYHA Class   
I 2 – 24 3 
II 2 - 63 7 
III 23 - 44 6 
IV 32 - 63 9 
Radiological Assessment   
Pulmonary congestion on CXR 9 - 85  5 
Pleural effusion on CXR 19 - 46 3 
Cardiomegaly on CXR 82 - 89 3 
 
 
Categorical values are expressed as percentage 
† = combined for NYHA class I and II. § = combined for NYHA class III and IV.  - = no data available 
SOB: shortness of breath; PND: paroxysmal nocturnal dyspnoea; SOBOE: shortness of breath on 
exertion; JVP: jugular venous pressure; CXR: chest X-ray.  
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6.1.3 Variability of congestion reporting 
 
 
The key congestive signs of both pulmonary and peripheral congestion were 
reported with variable completeness between registries. 
 
6.1.3.1 Pulmonary congestion 
 
Data for “pulmonary rales”, the main clinical sign of pulmonary congestion, was 
published in only ten registries. There was marked variation in incidence 
between the registries in which this was recorded (61 to 92%).  
 
Other well recognised and common symptoms of pulmonary congestion were 
variably described, with little standardisation of data collection. Central 
pulmonary symptoms of congestion had a wide range of incidence between 
registries (orthopnoea 27 to 80%; PND 15 to 71%). Registries with the lowest 
rates of orthopnoea unsurprisingly also had lower reported rates of PND (e.g. 
OPTIMIZE-HF reported that orthopnoea was present in 15% and PND in 27% of 
patients, KCHF reported orthopnoea in 80% and PND in 71% of patients).  
 
6.1.3.2 Peripheral congestion 
 
Data for peripheral oedema, the main clinical sign of peripheral congestion, was 
provided in only 10 registries. The reported rates varied from 43% to 82%. In 
ALARM-HF and Gulf CARE, 43% and 54% of patients were reported to have 
presented with peripheral oedema though only 25% and 26% were described as 
having experienced weight gain. This emphasises the point that hospitalisation 
arising from pulmonary congestion can occur due to fluid redistribution as well 
as fluid accumulation.  
 
Other signs of peripheral congestion were not prominently reported either. 
“Weight gain” was recorded in 3 studies (ALARM-HF, Gulf CARE and a substudy of 
RO-AHFS) but was not a very common symptom (25% to 26% of patients). It was 
not clear how much weight gain was required for it to be substantial and 
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recorded, nor how this was assessed (i.e. patient reported or from objective 
evidence). In a RO-AHFS sub-study which exclusively looked at patients who 
presented with pulmonary oedema, only 45% presented with peripheral oedema. 
This was much lower rate when compared to 6 of the other 7 registries. The 
presence of hepatomegaly and ascites were also only recorded by three 
registries.  
 
JVP elevation was recorded in just 7 studies. A positive finding of JVP distention 
varied greatly between each cohort ranging from 17 to 78%.   
 
 
6.2 Presenting clinical characteristics of patients in AHF Registries 
 
6.2.1 NYHA and Killip class based classification 
 
The use of NYHA functional classification was also not consistently recorded. It is 
difficult to identify any specific trends across the AHF registries. In 6 of 9 studies 
(ATTEND, Beijing AHF, Gulf CARE, Kor-AHF, ADHERE, KCHF), the majority of 
patients presented with NYHA class III-IV symptoms. In 3 studies, (EAHFE, RICA, 
KCHF) the majority of patients were NYHA class I-II (63-76% of patients). 
 
It should be noted that registries did not provide data categorising patients with 
AHF according to the Killip classification system.  
 
 
6.2.2 Clinical phenotype based classification 
 
Registries utilised two different methods in attempts to classify AHF patients 
into more discernible groups:  phenotypic classification based on either 
pathophysiology or based on haemodynamic profile (Table 6-2, Appendix Table 
A-5).  
 
The first type is based on clinical syndromes as defined by the 2008 ESC Task 
Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure.12 
These divided patients into 7 sub-categories based on presenting phenotype: 
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decompensated congestive HF, pulmonary oedema, cardiogenic shock, 
hypertensive HF, RHF, high output HF and ACS induced HF. The guidelines for 
each category are laid out in the original reference documents and are discussed 
previously.12 The registries did not elaborate further on how this classification 
may be applied. In each case – as with interpretation of clinical signs – it was left 
to the discretion of the investigator to decide which phenotypic category each 
patient should be assigned to.  
 
Eight of 18 registries reported data on phenotypic classification based on ESC 
recommendations (ALARM-HF, AHEAD, EAHFE, ESC-HF-LT, ESC-HF Pilot, EHFS-II, 
IN-HF and RO-AHFS). In each study, “decompensated congestive HF” was the 
most common presentation (ranging from 39 to 77% of cases). “Pulmonary 
oedema” was the second most common (13% to 37%). However data was not 
always reported for each sub-type.  
 
6.2.3 Haemodynamic classification 
 
Where haemodynamic profiles were recorded, the Forrester method of 
classification was used.139 Within this, patients were placed into four recognised 
sub-types “warm and dry”, “warm and wet”, “cold and dry” and “cold and 
wet”, all based on the quality of distal perfusion and the extent of congestion. 
However, only four registries out of 18 reported data for their cohorts in this 
manner. The most common presentation was “warm and wet” (70 to 82 % of 
patients), followed by “cold and wet” (11 to 17%), “warm and dry” (6 to 15%) 
and “cold and dry” (1 to 3 %). As with the ESC classification system, investigator 
discretion determined how the patient was classified. No adjunctive invasive 
methods were utilised to assist this process.  
 
6.2.4 Imaging guided classification 
 
Four registries reported the use of CXR findings from their patient cohorts 
(Beijing AHF, EAHFE, RO-AHFS and RICA). While most patients appeared to 
present with cardiomegaly (75% in EAHFE and 89% in RICA) the prevalence of 
actual pulmonary congestion was very variable (9% in RICA and 85% in Beijing 
AHF). Of note, no studies incorporated any other imaging modalities – such as 
lung ultrasound – when trying to determine the nature of congestion.  
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Table 6-2: Summary of baseline clinical profiles of patients in acute heart failure 
registries  
 
 
 Summary of Registries 
 
Clinical Syndromes  
Decompensated congestive HF 44 - 77 
Pulmonary oedema 13 - 37 
Cardiogenic shock 2 - 14 
Hypertensive HF 2 – 18 
Right HF 3 – 9 
High output HF 1 -3 
ACS-HF 2 – 14 
Haemodynamic profile  
Warm and dry 6 – 15 
Warm and wet 70 – 82 
Cold and dry 1 – 3 
Cold and wet 11 - 17 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are expressed 
as percentage 
HF: heart failure; ACS: acute coronary syndrome.  
 110 
 
6.3 Outcome reporting for patients in AHF registries 
 
Outcome reporting was variable between registries (Table 6-3). The rates of 
worsening HF were recorded in only two studies, in-patient mortality in 16 
studies, re-admission rates in 5 and 1-year all-cause mortality in just eight. It 
should be noted that the time windows for capturing the rates of re-admission 
and mortality were also not uniform.  
 
‘Worsening HF’ was also variably defined between studies and not always clearly 
consistent with changes in congestion. In KCHF this was described as “additional 
intravenous drug treatment for HF, haemodialysis, or mechanical circulatory or 
respiratory support, occurring >24 h after therapy initiation”. In OPTIMIZE-HF, 
the changes in congestive symptoms were instead recorded (as either: “worse”, 
“unchanged”, “better, symptomatic” or “better, asymptomatic”). 
 
The in-patient mortality rate was found to vary from 5% to 13%, whilst the 
median length of stay varied from 5 to 21 days.  
 
 
6.3.1 Outcome by clinical phenotype 
 
Only seven studies published outcomes by presenting clinical syndrome (AHEAD , 
ESC-HF-LT, ESC-HF Pilot, EHFS-2, IN-HF and RO-AHFS). A comparison between 
patients presenting with central and peripheral congestion was not possible 
because the ESC classification method does not contain a separate sub-category 
for ‘peripheral oedema’ as it does for ‘pulmonary oedema’.  
 
However, a comparison was attempted using data in AHEAD and ESC-HF-LT. 
Patients presenting with “pulmonary oedema” were classified as such and their 
outcomes were directly examined. For patients presenting with peripheral 
oedema, the classification of “right heart failure” was utilised instead (as this 
most closely matched a predominantly peripherally congested patient). The 
shortcomings of this should be noted; right heart failure is a classification for 
congestion arising from isolated RV dysfunction and the overlap with 
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peripherally congested patients with LV systolic dysfunction is likely to be 
limited.  
 
In ESC-HF-LT, the rates of adverse outcomes were higher in all categories for 
patients with peripheral over central pulmonary congestion, including in-hospital 
mortality (10% vs 6%), re-admission with HF (31% vs 21%) and all cause one year 
mortality (34% vs 28%). A similar pattern was seen in the AHEAD (in-patient 
mortality 17% vs 7%).  
 
 
Table 6-3: Summary of clinical outcomes for patients in acute heart failure 
registries  
 
 
 Summary of Registries 
In-hospital mortality 4 - 13 
Rate with pulmonary oedema 6 – 7 
Rate with peripheral oedema 6 – 17 
Re-admission rate (1 year) 40 – 47 
Rate with pulmonary oedema 21 
Rate with peripheral oedema 31 
All cause Mortality (1 year) 17 – 32 
Rate with pulmonary oedema 28 
Rate with peripheral oedema 34 
Length of stay (days) 5 – 21 
Rate with pulmonary oedema - 
Rate with peripheral oedema - 
 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are expressed 
as percentage  
- no data available 
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6.4 Baseline clinical characteristics of patients in AHF registries 
 
6.4.1 Age, ejection fraction, previous AHF history 
 
The median age of all the registry patients from the table was 71.5 years (range 
59-80) (Appendix table A-3). For almost three quarters (11 out of 16) of 
registries for whom published data was available, the mean or median average 
for the patient cohort was ≥ 70 years of age. 
 
In the registry population, the average ejection fraction reported in the studies 
ranged from 35 to 51 %. Half of all registries (eight) reported an average (mean 
or median) heart rate ≥ 90 beats per minute. By contrast, only 1 AHF trial 
reported such an elevated level of tachycardia from its enrolled patient cohort. 
 
Only two registries noted the numbers of patients presenting with a previous 
AHF hospitalisation. In ATTEND and KCHF, these were both at 36%. 9 studies did 
report the number of patients presenting with a known HF diagnosis, but did not 
distinguish if this syndrome was HFpEF, HFmrEF or HFrEF. In these cases, the 
prevalence of previous HF diagnosis varied from 36% to 88%.   
 
 
6.4.2 Aetiology and precipitating factors  
 
The underlying aetiology of HF was reported in 12 out of 18 studies. However, 
there was no unifying methodology for arriving at this. In each case, the 
assessment was left to the discretion of the clinical teams. There was also no 
published consensus around how the aetiology of each was defined (e.g. 
idiopathic dilated cardiomyopathy). Ischaemia was the most common cause of 
HF (27 to 61% of cases). The next most prevalent were hypertension (4 to 44% of 
cases), cardiomyopathy (15 to 25%) and valvular heart disease (9 to 36 %).  
 
The precipitating factor for AHF was infrequently reported; only nine registries 
reported any substantive data. ACS appeared to the be most recurrently 
common cause for hospitalisation. In KOR-AHF, GULF CARE, Beijing AHF, ESC HF 
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LT, EHFS-2, ALARM HF, HEARTS and IN-HF all reported the incidence of ACS 
precipitating AHF from 26 to 42%. Other common precipitants included 
arrhythmia (6 – 30%), infection (16 – 35%), uncontrolled hypertension (3 – 20%) 
and poor medication adherence (6 – 22%).  
 
Given the heterogeneity of precipitating factors, therapeutic interventions 
targeting congestion in AHF patients will require a personalised approach 
incorporating an appreciation of the specific clinical circumstances of each 
patient. Whilst current approaches dictate broad interventions in terms of 
oxygen therapy, diuretics and vasodilators, it is clear that trial evidence must 
help answer the question of how particular causative aetiologies should be 
managed. 
 
6.5 Acute therapeutic interventions in AHF registries 
 
The most common approach to alleviating congestion in the registry population 
remains through the use of diuretics and vasodilators, with ultrafiltration, MCS 
and percutaneous interventional procedures being reserved for a minority of 
cases. With the exception of KCHF, AHF registries did not provide substantive 
data on changes in congestive symptoms in response to medical therapy. 
 
Intravenous diuretics were used in the majority of acute admissions for patients 
with acute decompensated HF (13 registries reported data; administration rate 
between 70 to 98%). Intravenous vasodilators were also frequently used but 
variably so (15 studies reported data; administration rate between 14 to 78%) 
(Appendix Table A-6). Inotropic agents also formed part of the treatment regime 
for some patients but were less commonly selected (2 to 33%). Of these, 
dobutamine, dopamine and adrenaline were the most widely utilised. 
 
Invasive respiratory measures such as CPAP or IPPV were not as common. The 
use of CPAP was noted in a minority of cases (2 to 23%), whilst intubation was 
performed less frequently (1 to 16% of patients). 
 
Renal replacement or renal supportive measures such as haemodialysis and 
ultrafiltration were noted in seven studies (1 to 8%). Use of supportive bridging 
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interventions such as intra-aortic balloon pumps (IABP) were infrequent (0.2 to 
5%). LVAD implantation was performed in only a very small minority of patients 
(0.1 to 0.4 %), but data were only available from 2 registries.  
 
More invasive cardiology procedures were performed in a minority of AHF 
admissions. Percutaneous coronary intervention was required in 0.1 to 13% of 
AHF admissions (although the angiography rate without intervention was not 
accessible). Device implantation (either permanent pacemaker, implantable 
defibrillator or cardiac resynchronisation therapy) was infrequent, and ranged 
from 0.01 to 10%. Acute valvular surgery was required in only 0.3 to 4% of 
patients. However, in common with all the above described interventions, most 
registries did not supply data. 
 
  
6.6 Comparing patients with de-novo acute heart failure and acute-on-
chronic decompensated heart failure in acute heart failure registries 
 
Six AHF registries provided data comparing patients who presented with de-novo 
acute heart failure (DN-AHF) against those with a known history of chronic HF 
who were hospitalised with decompensation (i.e. an acute-on-chronic 
decompensated heart failure [AC-DHF] cohort)(Table 6-4). These registries were: 
EHFS-2, ALARM-HF, AHEAD, IN-HF, Gulf CARE and RICA. This comprised a total of 
23,096 patients involving hospitalisations from 2006 to 2016.  Of these, 9,759 
(42%) were new DN-AHF presentations and 13,337 (58 %) were AC-DHF 
presentations. The precise definition of “de-novo” was taken as per the ESC 
Guidelines on Acute Heart Failure, namely the episode was required to have 
been the first presenting event of HF.1 
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Table 6-4: Summary of clinical features of de-novo versus acute-on-chronic 
decompensated heart failure patients  
 
   
Subgroup DN-AHF AC-DHF 
n 9759 13,337 
Age (years) 57 - 71 70 
Male  48 – 63 46 - 64 
SBP (mmHg) 130 - 142 129 – 137 
HR (beats per minute) 93 - 95 82 – 95 
Clinical Presentation 
(Pulmonary) 
  
SOB 97 99 
Orthopnoea  74 83 
PND 56 71 
Signs of pleural effusion 16 21 
Pulmonary crepitations 81 - 92 76 – 91 
Clinical Presentation 
(Peripheral) 
  
Peripheral congestion 49 61 
Abdo/limb swelling 32 55 
Tender liver 22 31 
Ascites 7 21 
Weight gain 19 32 
Clinical Presentation (Other)   
Raised JVP 46 56 
Third heard sound 39 36 
Cold extremities 10 - 29 11 – 24 
Peripheral hypoperfusion 11 12 
HF Classification    
Cardiogenic shock 7 - 19 2 – 11 
Pulmonary oedema 26 - 40 10 – 35 
Hypertensive HF 6 - 11 3 - 11 
Right Heart Failure 3 3 
NYHA Class   
I 3 3 
II 20 20 
III 40 46 
IV 20 20 
 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are expressed as 
percentage 
† median,  ‡ combined values for NYHA class I and II,   § combined values for NYHA class III and IV, -  no data 
available DN-AHF: de-novo acute heart failure; AC-DHF: acute-on-chronic decompensated heart failure; 
SBP: systolic blood pressure; HR: heart rate; SOB: shortness of breath; PND: paroxysmal nocturnal 
dyspnoea; JVP: jugular venous pressure; HF: heart failure; NYHA: New York Heart Association. 
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6.7 Clinical profiles of DN-AHF and AC-DHF patients 
 
6.7.1 Haemodynamic profiles 
 
Patients with DN-AHF and AC-DHF had different clinical profiles, though limited 
data was published in this area. In Gulf CARE, IN-HF and RICA, the admission 
blood pressure was higher in each of the registries for DN-AHF compared against 
AC-DHF. These patients also exhibited higher degrees of tachycardia on 
presentation in Gulf CARE (98 vs 95 bpm; p<0.001), IN-HF (95 vs 82 bpm; 
p<0.0001) and RICA (93 vs 85 bpm; p<0.001).  
 
Those with DN-AHF were also more likely to present with a better LVEF. This was 
observed in ALARM-HF (mean LVEF: 40 vs 37%; p<0.0001) Gulf CARE (median 
LVEF: 38 vs 34% ;p<0.001), IN-HF (mean LVEF: 39 vs 37%; p<0.001) and RICA 
(LVEF > 50%: 65 vs 60%; p<0.007) 
 
 
6.7.2 Profiles based on clinical features  
 
Only IN-HF and Gulf CARE provided substantive data on admission 
characteristics. In IN-HF, DN-AHF patients appeared to present more with 
symptoms of central congestion, whereas AC-DHF patients presented with more 
peripheral symptoms. 81% of de-novo patients were noted to have central 
pulmonary crepitations compared against 76% of patients with chronic HF from 
IN-HF. However, AC-DHF patients more commonly presented with peripheral 
congestion such as ankle oedema (61% vs 49%).  
 
Similar data could be observed from Gulf CARE. AC-DHF patients were more 
likely than their DN-AHF counterparts to present with peripheral congestive 
symptoms of abdominal or limb swelling (55 vs 32%; p<0.001), weight gain (32 vs 
19%; p<0.001) and other abdominal symptoms of fluid overload such as ascites 
(21 vs 7%; p<0.001). 
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6.7.3 Profiles based on NYHA class and clinical phenotypes  
 
In RICA there was a more pronounced difference in NYHA symptom classification 
between the two groups. DN-AHF were often hospitalised with a less severe 
background of symptoms (75% presenting as NYHA class I-II) when compared to 
the AC-DHF cohort (57% presenting as NYHA class I-II) (p<0.001).   
 
When reviewing HF classification by ESC clinical phenotype, DN-AHF patients 
from the ALARM study tended to present more often with symptoms of 
cardiogenic shock (19% vs 8%) and pulmonary oedema (40 vs 35%). A similar 
pattern was also observed in EHFS-II (cardiogenic shock, 7 vs 2%; pulmonary 
oedema, 26 vs 10%; p<0.0001). 
 
 
6.7.4 Profiles based on biomarker and laboratory data 
 
Examination of the two presenting HF groups did not reveal any consistent 
patterns in relation to natriuretic peptide levels (either BNP or NT-
proBNP)(Table 6-5). However there were prominent differences in other 
laboratory findings. In Gulf CARE, IN-HF and RICA patients with AC-DHF were 
more likely to be anaemic. Comparing ACD-AHF against DN-AHF patients, the 
average reported haemoglobin results were 122 vs 130 mg/dL (p<0.001) in Gulf-
CARE, 123 vs 129 mg/dL (p<0.0001) in IN-HF and 119 vs 125 mg/dL (p<0.001) in 
RICA. These patients were also more likely to have advanced renal impairment 
on presentation: average creatinine 1.6 vs 1.4 mg/dL (p<0.001) in Gulf CARE, 1.3 
vs 1.2 mg/dL (p<0.0001) in IN-HF and 1.5 vs 1.2 mg/dL (p=0.045) in RICA. 
 
 
6.8 Clinical background of DN-AHF and AC-DHF patients in AHF registries 
 
Patients with AC-DHF presented with a greater number of pre-existing co-
morbidities that those with a new first presentation of DN-AHF (Table 6-6).   
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6.8.1 Underlying cardiac co-morbidities and congestion 
 
Information detailing differences in co-morbidities and their relationship to 
congestion remains limited from the registry population. However, notable 
differences in the rates of co-morbidities were seen between AC-DHF and DN-
AHF populations.  
 
In Gulf CARE, almost twice as many patients with AC-DHF presented with 
underlying CHD than those with DN-AHF (60 vs 30%; p<0.001). In the EHFS-2 
registry a similar difference was found (62 vs 39%; p<0.001). Marked differences 
were also seen with respect to the prevalence of other cardiovascular diseases. 
In Gulf CARE and EHFS-2, the differences in the rate of atrial fibrillation were 
very pronounced (17 vs 6 %, 47 vs 25% respectively). Similar patterns were also 
seen in published data from IN-HF (43 vs 30%; p<0.0001) and RICA (56 vs 52 %; 
p<0.001). Although only two registries compared underlying valvular heart 
disease between the AC-DHF and DN-AHF cohorts, in both of these (Gulf CARE 
and EHFS-2) the prevalence was higher in the hospitalised population with a 
known background of HF (18 vs 8% in Gulf CARE; 44 vs 19% in EHFS-2).   
 
In all three registries where data on precipitant causes were reported (Gulf 
CARE, EHFS-2 and RICA), ACS was the first or second most common cause. 
Furthermore, it was more prevalent in new DN-AHF patients (39 vs 17%, p<0.001; 
42 vs 23%, p<0.001; 8 vs 6%, p=0.49). The Gulf CARE registry which supplied data 
of subsequent follow up interventions noted that the rate of PCI was also higher 
in the DN-AHF group (10 vs 3%, p<0.001). Data on the use of diuretic and 
vasodilator therapy was limited and did not appear to show any clear trend. 
 
Though data on underlying aetiologies is mixed between the registries, 
hypertensive HF was more common in patients with DN-AHF in Gulf CARE (18 vs 
14%, p<0.001) and RICA (42 vs 37%, p=0.006). By contrast, cases of dilated 
(idiopathic) cardiomyopathy were more likely to be found in chronic patients 
compared to first presentation HF cases in Gulf CARE (20 vs 16%, p<0.001) and 
EHFS-II (25 vs 10%, p<0.001). 
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Table 6-5: Echocardiographic and laboratory characteristics of congested de-novo versus acute-on-chronic  
decompensated heart failure patients   
 
 
Registry ALARM-HF 310 IN-HF 336 Gulf CARE 337 RICA 338  
 
 DN-AHF AC-DHF DN-AHF AC-DHF DN-AHF AC-DHF DN-AHF AC-DHF 
Echo parameters         
Ejection fraction 
(%) 
40 37 39 37 38 † 34 † - - 
LVEF < 40% - - - - - - 21 24 
Laboratory findings         
BNP (pg/mL) 908 † 1040 † 925 †  1200 †  1605 † 1154 † - - 
NT-pro BNP 
(pg/mL) 
- - 5964   4496 †  3236  3127  5678  6706 
Elevated Troponin - - - - - - 17 16 
Haemoglobin 
(mg/dL) 
- - 129 123 130 † 122 † 125 119 
Na (mmol/) - - - - 138 138 139 139 
K+ (mmol/l) - -   4.2 4.2 4.4 4.4 
Creatinine (mg/dL) - - 1.1 † 1.3 † 1.4 1.6 1.2 1.5 
 
 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are expressed as percentage 
† median, -  no data available 
DN-AHF: de-novo acute heart failure; AC-DHF: acute-on-chronic decompensated heart failure; LVEF: left ventricular ejection fraction; BNP; brain natriuretic peptide; ; NT-pro BNP: N-
terminal-prohormone brain natriuretic peptide  
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Table 6-6: Co-morbidities and aetiology of congested de-novo versus acute-on-chronic acute heart failure patients  
 
 EHFS-II  335 IN-HF 336 Gulf CARE 337 RICA 338 
 DN-AHF AC-DHF DN-AHF AC-DHF DN-AHF AC-DHF DN-AHF AC-DHF 
Co-morbidities         
Chronic lung disease 16 22 27 33 - - 20 27 
Coronary heart disease 39 62 - -  30 60 - - 
Hypertension 59 64 61 56 54 67 82 88 
Hypercholesterolaemia - -   27 43 - - 
Diabetes Mellitus 30 34 37 43 44 54 49 59 
Chronic kidney disease 11 20 24 39 9 19 - - 
Peripheral vascular 
disease 
- - 17 22 4 5 - - 
Cerebrovascular disease 11 15 5 5 6 10 - - 
Atrial fibrillation 25 47 30 43 6 17 52 56 
Haemodialysis - - - - - - - - 
Anaemia 11 17 - - - - - - 
Intra-cardiac device 4.3 12 - - - - - - 
ICD - - 2 15 - - - - 
CRT - - 1 9 - - - - 
BMI (kg/m2) - - 28 28 27 † 27 † 29 29 
Smoking  - - - - 30 16 - - 
Valvular heart disease 19 44 - - 8 18 - - 
Aetiology of LVSD         
Ischaemic - - 38 45 55 52 24 29 
Hypertensive - - - - 18 14 42 37 
Cardiomyopathy  10 25 - - 16 20   
Valvular heart disease - - - - 7 11 12 20 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are expressed as percentage 
† median, -  no data available DN-AHF: de-novo acute heart failure; AC-DHF: acute-on-chronic decompensated heart failure; ICD: implantable cardiac defibrillator; CRT: cardiac 
resynchronisation therapy; BMI: body mass index; LVSD; left ventricular systolic dysfunction.  
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6.8.2 Non-cardiac co-morbidities 
 
Diabetes mellitus was more prevalent in AC-DHF patients across the registries: 
Gulf CARE (54 vs 44%, p<0.001), IN-HF (43 vs 37%,p=0.008), EHFS-II (34 vs 
30%,p<0.01) and RICA (59 vs 49%, p<0.001). Similarly, the incidence of chronic 
kidney disease was higher for AC-DHF patients in Gulf CARE (19 vs 9%, p<0.001) 
IN-HF (39 vs 24%,p<0.0001) and EHFS-II (20 vs 11%, p<0.001). 
 
 
6.9 Outcomes between DN-AHF and AC-DHF patients  
 
Length of stay outcomes and in-hospital mortality did not show a consistent 
trend between all of the registries when DN-AHF and AC-DHF patients are 
compared (Table 6-7). However, this was not the case with longer term one year 
data. Re-hospitalisation at one year was much higher in the AC-DHF population 
in Gulf CARE 44 vs 34%, p<0.001) and RICA (45 vs 33%, p<0.01). One year 
mortality was similarly much higher in patients with a known history of 
decompensated congestive cardiac disease (Gulf CARE: 23 vs 17%, p<0.001; RICA: 
27 vs 15%, p<0.01). This may be viewed as unexpected, given that the rates of 
cardiogenic shock were higher for DN-AHF patients in all registries which 
reported data, indicating that blood pressure alone does not indicate congestive 
severity.  
 
 
6.10 Discussion 
 
This systematic review of AHF registries shines light on two areas: the variations 
which exist in the reporting of key features of congestion, and the marked 
differences in patient characteristics between congested patients with de-novo 
and acute-on-chronic decompensated HF.  
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6.10.1 Congestion reporting remains limited 
 
Data on congestion in HF registries with respect to clinical presentation, clinical 
and haemodynamic phenotypes and outcomes are variably (and under-) 
reported. Collaboration is required between expert groups to agree upon 
classifications that are reliable, reproducible and relevant. Radiological 
information regarding congestion remains limited across the registries.  As newer 
technologies – particularly lung and IVC ultrasound are more widely utilised –
objective and semi-quantitative assessments should become available for 
incorporation into registry datasets. 
 
6.10.1.1 Limitations of reporting of presenting clinical features 
 
A retrospective, single-centre review of 311 patients with AHF by Shoaib and 
colleagues reported how there may be markedly different phenotypic groups of 
patients with AHF, which can be classified depending on the presenting 
complaint: dyspnoea at rest, dyspnoea on exertion or predominant ankle 
oedema.302,339 Peripheral and central pulmonary decongestion may be associated 
with different future risks of clinical events. However, only 4 of 18 registries 
provided complete data on these three key symptoms. Whilst other 
haemodynamic variables such as blood pressure, heart rate and laboratory data 
may be well recorded, the presenting clinical features may provide a better 
indication of the actual nature of the haemodynamic disturbances.  
 
As such, valuable information about prevalence, prognosis, the clinical 
composition of congestive phenotypes, and how to best structure AHF trials are 
all limited by the lack of available data. These revealing insights from less 
selected registry populations have shone light on potential errors within AHF 
trial recruitment.102 Current trial inclusion and exclusion criteria result in a 
population of patients who are predominantly breathless at rest and the 
proportion of patients with predominant peripheral congestion is limited. This 
latter group is more prevalent in the ‘real world’ and have a worse prognosis 
than their AHF counterparts with predominant ‘central/pulmonary congestion’. 
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Table 6-7: Summary outcomes of de-novo versus acute-on-chronic decompensated 
heart failure patients  
 
 
   
 DN-AHF AC-DHF 
Outcomes   
Length of Stay (days) 6 - 9 7 – 11 
In hospital mortality  7 - 14 6 – 14 
Re-hospitalisation at 1 yr 33 – 34 44 – 45 
Mortality at 1 yr  15 - 17 23 - 27 
 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are 
expressed as percentage 
DN-AHF: de-novo acute heart failure; AC-DHF: acute-on-chronic decompensated heart failure; 
 
 
 
6.10.1.2 Limitations of clinical and haemodynamic classification systems 
 
While the 2008 ESC Guidelines for the Diagnosis and Treatment of Acute and 
Chronic HF suggested a range of clinical phenotypes for categorising AHF 
patients, just 7 of 18 registries provided data based on this classification.12  A 
criticism of these phenotypes remains the significant overlap between 
categories.   
 
In ESC-HF-LT, the prevalence of each clinical profile exhibited marked 
geographic variation.192 Rates of pulmonary oedema varied from 9.9% in Eastern 
European countries to 35.9% in Western Europe. There may be genuine 
epidemiological variables driving these differences. However, the distinction 
between each AHF sub-type remains highly subjective and different cultural 
perceptions may exist of how these patients were classified. Revealingly, when 
patients in the registry were stratified by presenting blood pressure, the 
differences across the European regions were minimal.192  However whilst there 
are significant differences in prognosis in each group, there is no defined 
treatment strategy based on classification, rendering the clinical import of the 
classification process academic.  Therefore it may be unsurprising that in more 
recent AHF guideline updates, incorporating this system into daily clinical 
assessment has not been greatly emphasised.1 
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The Killip classification system was not utilised by any registry. Given it is a 
post-MI assessment score centred mostly around pulmonary congestion and does 
not direct treatment options, its relevance in an AHF setting is questionable.148 
The Forrester classification also has similar limitations139 and only four registries 
noted complete data on patients in this regard. The original gradations were 
designed for grouping HF in a post-MI setting and involved RHC to determine 
cardiac index and PCWP.139 In practice, the assessment of congestion and 
perfusion is clinical and subjective. In a further assessment of this method, 200 
patients post-infarct were evaluated using clinical assessment and 
haemodynamic tools (primarily right heart catheterisation). Clinical examination 
was only able to accurately predict the type haemodynamic disturbance in 83% 
of cases.  
 
A prospective analysis of 452 advanced HF patients from the Brigham and 
Women’s Hospital was performed to group patients into these categories and 
was able to verify that these clinical profiles predict outcomes.140 As expected, 
”wet cold” had the poorest prognosis (HR 1.83, p=0.02) but the classification 
methodology only utilised clinical judgement when assigning patients to each 
group. However, it has already been proven in this patient group that the 
presence of normal clinical signs do not indicate the absence of true 
congestion.59  
 
Data from the 7865 patient ESC-EORP-HFA Heart Failure Long Term registry has 
confirmed that “cold and wet” patients have the poorest outcome.340 A large 
proportion of patients (30.9%) were also discharged with ‘residual congestion’, 
but this categorisation was entirely clinical. It raised further questions about 
interpretations of congestion – particularly ongoing subclinical disturbance - and 
ascertaining objectively when adequate decongestion has been achieved. 
Another limitation is the heterogenous nature of the “warm and wet” cohort 
which comprises around 70% of AHF patients across the registries.192, 341,342 ESC-
EORP-HFA noted that the clinical course for each was diverse – within this group 
could be found the greatest improvement in natriuretic peptides, the high 
proportion of in-hospital worsening renal function but also a residual congestion 
rate of 39%.340 This suggests the Forrester method - whilst providing prognostic 
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information - groups too many diverse AHF phenotypes into the broad “warm-
wet” category and lacks the discriminatory ability to distinguish the specific 
haemodynamic interactions and therapeutic requirements of patients in this 
subgroup.  
 
 
6.10.2  De-novo and chronic acute heart failure are different entities 
 
This systematic review has collected data from multiple registries (AHEAD, 
ALARM-HF, EHFS-II, Gulf CARE, IN-HF and RICA) which strongly indicate that 
patients with de-novo and chronic AHF do not share uniform profiles. The 
congestive profile of DN-AHF patients tended to be more central and pulmonary 
rather than peripheral in nature. Haemodynamically, DN-AHF patients present 
with higher blood pressure, less tachycardia, have more preserved LV systolic 
function and less concurrent renal dysfunction – all features which are 
associated with a more favourable prognosis.109,343  Longer term registry data 
also confirms the expected findings; reduced hospitalisation and improved 
survival, which would be expected in a cohort with less advanced disease. 
 
6.10.2.1 Implications for clinical trial design  
 
The current findings are of relevance when considering the inherent 
heterogeneity of the recruited AHF trial population and persistently neutral 
results. With the exception of OPTIME-CHF, no recent study from the systematic 
review of AHF trials excluded de-novo patients. It could be argued this has 
allowed unintended recruitment of patients without true HF but other co-
morbidities – such chronic lung disease – which have been misclassified as HF. 
Additionally, in the younger de-novo cohort where the aetiology was deemed 
idiopathic, myocarditis is a typical probable cause.344 This condition often 
presents with mild LVSD and recovery is spontaneous within weeks or months. 
Similar findings have been noted with idiopathic dilated cardiomyopathy.345 
Acute hypertensive episodes, tachyarrhythmias and toxin induced 
cardiomyopathy (especially alcohol) can produce a rapid recovery of LV function 
once the precipitant is treated. Contamination of a study population with these 
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relatively benign subgroups with a different pathological mechanism of HF would 
influence outcomes.  
 
By focusing trial recruitment on populations with more chronic disease, 
investigators can ensure that therapies are targeted against a pathophysiological 
construct which is defined and well established. However the definition of 
“chronic” and “new” HF and the minimum time window from diagnosis (or 
diuretic commencement) to hospitalisation remains unclear. A post-hoc analysis 
from the ATTEND study demonstrated that patients with a diagnosis of up to 1 
month duration shared similar characteristics as described.346 The congestive 
profile was also more distinct. De-novo patients had more pulmonary rales and 
less peripheral oedema than those with more chronic disease. Prognosis was 
equally more favourable; 30 day mortality and hospitalisation was lower (5.9 vs 
9.7%, HF duration < 12 months against others) as was the 180 all-cause mortality 
rate (8.1 vs 12.3%, HF duration < 12 months against others). Thus by enrolling a 
more consistent phenotype of patient with already poorer outcomes, an 
evidence of therapeutic benefit may be more easily seen. 
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7 Conclusions and General Discussion 
 
 
From these systematic reviews it can be seen that congestion as assessed by 
dyspnoea does not manifest in an identical manner between AHF trials and AHF 
registries. There is a varying prevalence of patients recruited based whether 
breathlessness is sub-categorised as being as either ‘at rest’ or ‘on exertion’. 
AHF trial design has also been shown to be narrowly focused on dyspnoea over 
other broader non-pulmonary manifestations of congestion when enrolling 
patients and for triggering end points.  
 
This systematic review also has shown how the assessment of congestion is 
inconsistently performed from study to study, both in terms of the lack of 
formulation of any pre-defined ‘core features’ or in the determination of 
severity. The use of adjunctive imaging technologies has also not been 
incorporated into trials or registries with any regularity.  
 
It should be stated that broader conclusions of the complex nature of congestion 
cannot be drawn from the raw data extracted from these two systematic reviews 
– which are primarily restricted to detailing the methods and balance of 
congestion assessments. However, there is a large reservoir of literature derived 
from substudy analyses and other clinical studies which discuss further the 
multifaceted nature of congestion. Numerous key aspects of this include: 
accepting that dyspnoea cannot be considered a uniform entity, congestion does 
not manifest as a homogenous phenotype, the extensiveness of congestion can 
be used to predict risk, and that adjunctive imaging may be essential to detect 
residual subclinical congestion – a feature in itself associated with prognostic 
hazard. 103  
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7.1 Limitations of the systematic reviews 
 
As with any systematic review, a risk remains that the studies included are of 
significant variability in quality. To attempt to minimise this clinical trials were 
required to be randomised and registries required to be prospective. The search 
criteria were broad to ensure a representative population was caught. Eligible 
RCTs had a low recruitment threshold of 180 patients, and registries a similarly 
low ceiling of 2000 patients. The cut offs employed had a degree of 
arbitrariness, but the number of studies enrolled in each group (21 RCTs and 18 
registries) suggest that reasonable capture was achieved. Most major reported 
and recognised studies were included in the literature review. This systematic 
review did not assess the variability of congestion assessment methods or clinical 
features by the geographical jurisdiction of each study. This could be a valid 
shortcoming as regional variations are known to occur.306,347 However, data 
availability restricted the ability to review this.  
 
The comparisons made between data from each set of trials and registries was 
also limited. Access to full data sets may have enabled more statistically 
rigorous comparisons of clinical profiles to be performed. It could be argued that 
trials selection should have been based on a requirement for an adequate 
sample size based on the study questions postulated for each trial. Selecting 
based on statistical power would have been appropriate for a systematic review 
examining the efficacy of a common intervention across a cohort of studies, but 
as this was a general assessment of methods, such a strategy may not have 
provided much further validity. It remains possible that smaller RCTs may have 
incorporated more novel or holistic assessment methods for congestion. 
Publication bias may also have meant that such studies were also not reported. 
Additionally had the review not excluded RCTs that examined imaging 
interventions, a different picture may have emerged of more sophisticated 
assessment methods. However, the broader aim of this review was to be capable 
critiquing AHF trial design in the context of repeated negative outcome studies 
in the field of AHF. Therefore the review would have had to primarily 
incorporate studies from this group.  
 
 129 
As has been detailed, these systematic reviews were limited to a focused set of 
questions and broader discussions on the nature of congestion and adjunctive 
imaging modalities are obtained from a more general examination of the 
literature.  
 
7.2 Dyspnoea is not uniform 
 
7.2.1 Marked difference of dyspnoea prevalence between AHF trials and 
registries 
 
The stringent use of dyspnoea as the main surrogate marker for congestion has 
resulted in the recruitment of an AHF population into clinical trials which is 
markedly distinct from the registry and possibly real world populations.   Overly 
tight enrolment criteria permitting only those with dyspnoea to participate has 
produced a selected cohort which is unrepresentative.  
 
In VERITAS, 3CPO, Pre-RELAX-AHF, ASCEND-AHF and RELAX-AHF, 100% of the 
enrolled subjects had dyspnoea at rest. Even in ACTIV-in-CHF, ATHENA-HF and 
EVEREST - which had less rigorous criteria - the proportion of patients with 
dyspnoea at rest was relatively high at 70% to 89%. The registry group is 
markedly dis-similar. In ADHERE, ADHERE-AP, ALARM-HF and OPTIMIZE-HF and 
rate of dyspnoea at rest ranged from 44 to 73% (Figure 7-1). These are 
substantial registries comprising large numbers of recruits (over 170,000 
patients) from multiple continents (North America, Europe and the Asia-Pacific 
region), lending significant weight to the generalisability of this finding. 
Furthermore, the rate of dyspnoea on exertion was much higher than dyspnoea 
at rest: 65% in OPTIMIZE-HF, 95% in ADHERE, 95% in ADHERE AP and 95% in KCHF. 
In keeping with the analyses from a retrospective review which subdivided 
patients into SOBAR and CARBOSE categories based on presenting symptoms, it 
supports the proposition that dyspnoea on exertion is the predominant 
presenting phenotype of AHF and is under-represented in randomised trials.11 
 
 
 
 130 
 
 
Figure 7-1: Comparison of enrolled patients with dyspnoea  at rest in acute heart failure 
registries and trials. Dyspnoea at rest is present in a far higher proportion of patients 
enrolled in AHF trials compared to AHF registries suggesting that both are not recruiting 
patients with the same baseline congestive profile. AHF: acute heart failure. 
 
 
 
7.2.2 Implications for AHF trial design 
 
HF induced fluid retention can potentially begin up to 30 days before 
presentation and congestion accelerates in the week preceding admission.95 This 
may explain why registry data has shown dyspnoea at rest is not the primary 
presenting complaint. The pathological process most likely involves gradual fluid 
accumulation. By contrast, patients breathless at rest (or minimal exertion) may 
have sudden fluid redistribution leading to rapid pulmonary oedema. As would 
be expected, dyspnoea in this latter cohort will improve rapidly and the longer 
term outcomes should be more favourable.11 Considering this, peripheral 
congestion may represent a more appropriate pathophysiological target against 
which AHF therapies must be trialled.  
 
Another issue that requires consideration is whether congestive processes 
beginning weeks before presentation can be undone by a short therapeutic 
intervention lasting just a few days. Of all AHF trials, 15 out of 21 therapeutic 
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interventions lasted under 72 hours. These intravenous peptides were vasoactive 
or inotropic compounds with no longer term effects on neurohormonal function. 
Additionally, randomisation was performed early – usually within 48 hours of 
medical contact or diuretic administration. A more delayed intervention may 
instead pick up more diuretic-resistant patients with poorer baseline outcomes 
against which smaller incremental benefits are seen.  
 
 
7.2.3 Orthopnoea and risk 
 
The outcome of patients with orthopnoea in clinical trials has not been 
extensively documented and remains an area for more research. In a pooled 
analysis of 496 patients enrolled into DOSE and CARRESS-HF, patients with 
orthopnoea at baseline had a much higher event rate (of a combined endpoint of 
death and re-hospitalisation) than those who were orthopnoea free (62 vs 
41%).132 This effect was sustained for patients with residual orthopnoea at 
discharge (70 vs 57%). Critically it should be noted that this finding was specific 
for ≥2 pillow orthopnoea. In the out-patient setting, orthopnoea post-discharge 
also remains an adverse prognostic clinical symptom. In a study of 146 patients 
post-hospital admission with NYHA class IV symptoms of HF, the ongoing 
presence of orthopnoea at 4 to 6 weeks after hospital discharge predicted a drop 
in 2-year survival from 77 to 38%.348 Whilst the study did not determine whether 
this increased hazard was a result of left-sided central congestion or potential 
secondary respiratory effects arising from compromised ventilation, the 
prognostic change was still evident.   
 
 
7.3 Pulmonary congestion  
 
7.3.1 Extensiveness of pulmonary rales predicts risk  
 
Only REVIVE and PROTECT sought to provide any detailed clinical information on 
the extent of pulmonary congestion.207,283 A post hoc analysis of PROTECT 
demonstrated that not all pulmonary congestion is alike. The study 
characterised congestion as being either “none”, or noted the different involved 
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proportions of the lung field (“<1/3”, “1/3 to 2/3” or “>2/3”). Multivariable 
analysis of the cohort demonstrated that when comparing “>2/3 vs none”, this 
increase in pulmonary congestion was a major predictor of all-cause mortality at 
180 days (HR 1.650 [95% CI 1.07-2.54].  However this was not included in the 
final predictive model due to concerns about potential high levels of 
interobserver variability. 
 
 
7.3.2 Pulmonary decongestion does not negate ongoing risk 
 
EVEREST demonstrated that patients with the highest composite congestion 
scores had paradoxically lower levels of pulmonary rales (76 vs 85% for highest 
against lowest scores).118 This may be evidence of bias within the scoring system 
but also suggests that congestive features may not develop in tandem and that 
pulmonary oedema may not be a precise marker of fluid status. Most of the 
cohort with higher scores had more severe peripheral oedema, and this was 
associated with poorer long term outcomes. Importantly, worse than expected 
outcomes were seen in recovering patients with virtually no pulmonary oedema 
and a low composite score.118 This lends credence to the idea that risk does not 
completely normalise with clinical improvement and a degree of prognostically 
relevant subclinical haemodynamic disturbance may lie untreated. 
Unsurprisingly, a clear correlation was also seen between incomplete 
decongestion and poorer outcomes. Thus the persistence of pulmonary rales on 
discharge clearly remains a feature which must be reported carefully in AHF 
studies.  
 
 
 
7.4 Peripheral congestion  
 
As with quantifying pulmonary rales, a more nuanced methodology to 
approaching peripheral oedema is required as peripheral congestion is not a 
binary entity.  
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7.4.1 Severe peripheral oedema and risk in AHF trials 
 
In a subgroup analysis of RELAX-AHF, patients graded with moderate or severe 
(2+ or 3+) peripheral oedema had poorer outcomes than those graded as having 
no or mild oedema (1+).349 Similarly. a review of PROTECT found that whilst 
dyspnoea relief may yield short term benefits, more severe peripheral 
congestion was associated with longer inpatient stays and higher inpatient 
mortality.350 A post-hoc analysis of DOSE and CARRESS-HF found similar 
confirmatory findings. Persistent refractory peripheral oedema resulted in a 
higher frequency of adverse post-discharge outcomes when compared with those 
without oedema (71 vs 51%, rate of death or recurrent hospital contact).132 
 
 
7.4.2 Severe peripheral oedema and risk in registry studies 
 
In the previously described analysis examining presenting HF phenotypes, 
patients with marked peripheral oedema were dyspnoeic on exertion (possibly 
due to the exertion of moving their heavier congested limbs).11 In these 
‘CARBOSE’ groups, the presence of peripheral oedema itself was a remarkable 
independent risk factor for mortality (52 vs 33%, for patients with peripheral 
oedema against those without).  
 
To more robustly assess the effect of peripheral oedema on AHF outcomes, 
Shoaib and colleagues reviewed 121,214 patients from the National Heart Failure 
Audit for England & Wales.302 Peripheral oedema was classified as “none”, 
“mild”, “moderate” and “severe” in the database. Compared to patients with no 
leg congestion, more severe oedema was markedly associated with increased 
length of stay (12 vs 6 days, p<0.001), in-patient mortality (16 vs 7%, p<0.0001) 
and mortality at around one year (59 vs 39%).302 Patients with more severe 
oedema were also more likely to be older, female, have hypertension, more 
renal dysfunction and less HFrEF. 
 
A subset of these patients may have concurrent RV dysfunction or increased 
pulmonary hypertension – both of which are associated with a poorer prognosis. 
Peripheral congestion may have more deleterious renal affects, produce greater 
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diuretic resistance or disruption of nutritional absorption as a consequence of an 
oedematous gut. In the AHF population these patients represent the ‘less 
dramatic’ presentations with more indolently deteriorating symptoms, but 
clearer objective assessment of this group remains critical. 
 
 
7.5 Future directions 
 
7.5.1 Standardisation of congestion assessment 
 
It is clear that congestive symptoms must be classified and reported in a more 
objective and complete manner. The severity of both pulmonary and peripheral 
congestion correlate with various adverse outcomes during and after 
hospitalisation. Key haemodynamic variables and co-morbidities are routinely 
documented with a high level of rigour and completeness, and the same must be 
done with congestion. Achieving standardisation will enable the structuring of 
more appropriate trial enrolment criteria, allow better comparison across study 
populations, and aid in the assessment of confounders on outcomes.  
 
7.5.1.1 Objective methods to assess dyspnoea 
 
The methodology of assessing dyspnoea currently remains the subject of ongoing 
investigation. As has been demonstrated, it becomes clear that dyspnoea at rest 
and dyspnoea on exertion must be considered as reflective of two different 
congestive entities with divergent prognoses.339 Dyspnoea with provocation 
manoeuvres may be a more effective method to elicit subtle changes in global 
congestion. The Renal Optimization Strategies Evaluation in Acute Heart Failure 
and Reliable Evaluation of Dyspnea in the Heart Failure Network (RED-ROSE) 
study will further investigate provocative dyspnoea assessment against VAS to 
determine whether it may be a more sensitive tool.351 
 
In ASCEND-HF study, peak expiratory flow rate (PEFR) assessment was performed 
on patients at time points during the first 24 hours of intervention. Increases in 
PEFR correlated with moderated or marked dyspnoea improvement scores on the 
Likert scale. Further validation studies with other patient-reported tools may 
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help researchers arrive at more objective and reproducible methods for 
documenting the symptom of breathlessness and integrating these into future 
clinical studies.  
 
7.5.1.2 Orthopnoea 
 
When categorising the presence of orthopnoea, it should be noted that invasive 
assessment from ESCAPE showed that it was only ≥ 2 pillow orthopnoea that 
indicated a PCWP of pressure ≥ 30 mmHg (odds ratio, 3.6; P<0.05).120 
Additionally, post-hoc analysis from the DOSE and CARRESS-HF cohorts suggested 
it was ≥ 2 pillow orthopnoea at baseline that was associated with a greater 
event rate.132 Whilst these are based on limited patient numbers, they may form 
a basis on which to standardise the threshold at which orthopnoea is defined. 
 
7.5.1.3 Systematic quantification of pulmonary congestion  
 
Given then heterogeneity of outcomes dependent on the degree of pulmonary 
congestion, developing a structured method of grading pulmonary oedema can 
provide additional value. Platz and colleagues recommended a reporting schema 
along the following framework by dividing the lung field into thirds:352  
 
• No crackles or rales 
• Crackles/rales ≤1/3 from bases  
• Crackles/rales 1/3 to 2/3 from bases  
• Crackles/rales >2/3 from bases  
 
In this manner, the patient can be assessed as having one of four categories of 
pulmonary rales: no crepitations, crepitations at less than one-third of the lung 
field, crepitations from one-third to two-thirds of the lung field and crepitations 
beyond two thirds of the lung field. This may direct AHF inclusion criteria for 
clinical studies to enable enrichment of trial populations with patients of 
appropriate risk.  
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7.5.1.4 Systematic quantification of peripheral congestion 
 
An outcome with significant prognostic import like peripheral oedema must be 
reported in a meaningful manner. From this review of trials, oedema was not 
reported consistently (if it all). In REVIVE, the degree of limb oedema was 
recorded based on how extensive it was (“no oedema”, “leg oedema” or “sacral 
oedema”). In PROTECT and DOSE, a more historical scoring system was utilised 
based on the extent of pit depth and recovery. In ROSE, oedema was only noted 
to be present if it met a “≥2+ “ threshold. Six studies gave absolute numbers 
presenting with peripheral limb swelling but no breakdown of severity. Similarly 
registries allowed the clinician to note whether oedema was present but only in 
a binary fashion. Whilst trials did not always expressly state their grading 
methodology, it was assumed that it is based on the universally recognised 4-
point scale (Table 7-1).353  
 
 
Grade Physical Characteristics 
1+ 
Slight pitting, no visible change in the shape of the extremity; depth of indentation 0-
1/4” (<6 mm); disappears rapidly. 
2+ 
No marked change in the shape of the extremity; depth of indentation 1/4 -1/2” (6- 12 
mm); disappears in 10 to 15 seconds. 
3+ 
Noticeably deep pitting, swollen extremity; depth of pitting1/2-1” (1-2.5 cm); duration 1 
to 2 minutes. 
4+ 
Very swollen, distorted extremity; depth of pitting > 1” (>2.5 cm); duration 2 to 5 
minutes. 
 
Table 7-1: Standard grading scale for ankle oedema. Adapted from Bates et al (1992) 353 
 
 
In the absence of a true gold standard for assessing oedema, no substitute 
technique or technology is validly apparent. However, it would seem reasonable 
to consider whether a score of 1-4 may be better represented by quantifying the 
extent of limb swelling (which be of closer resemblance to the severity of fluid 
accumulation, and by proxy congestion). Such a method would also be easier to 
apply in a consistent fashion (Table 7-2). 
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Grade Physical Characteristics  
1+ Pitting oedema at the ankle position 
2+ Pitting oedema at the mid-skin  
3+ Pitting oedema over the mid-thigh 
4+ Sacral oedema  
 
 Table 7-2: Proposed alternative grading scale for ankle oedema 
 
 
7.5.2 Use of adjunctive imaging modalities 
 
The nature of congestion and the perennial dilemma of subclinical congestion 
suggests that profiling on clinical grounds alone is not adequate and other 
imaging modalities must be employed to help assess two critical areas: to 
quantify if congestion is present and to quantify if decongestion has been 
achieved. New technological modalities may aid to prevent misjudgements of 
fluid status and better unmask the true treatment effects of therapies 
investigated.  
 
7.5.2.1 Assessing subclinical congestion. 
 
Clinical assessment has been demonstrated to be variable and not always in 
synchrony with invasive measurements.120 ESCAPE has shown that even when 
congestion appears to have resolved clinically, there may be a detachment from 
ongoing haemodynamic parameters which have not normalised and still confer 
risk.118 This is in keeping with data from the ESC-EORP-HFA HF-LT registry and 
PROTECT which demonstrate that resistant congestion during therapy or residual 
congestion on discharge risk both increase mortality. 340,199  
 
The key questions of congestion remain difficult to assess. Determining the 
baseline level of congestion and ascertaining what constitutes adequate de-
congestion remain unanswered in an objective or quantitative manner. It also 
invites speculation as to whether patients in AHF trials may have been 
discharged prematurely. In ESC-HF-LT, 5% of patients were noted to have an 
increase in body weight on discharge.192,354 One may query if excess residual 
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congestion had remained uncleared (or re-accumulated) thus putting the patient 
at risk of early re-admission and adverse outcome. 
 
Achieving a return to true euvolaemia remains difficult in practice. Hesitation 
remains amongst clinicians treating AHF that worsening renal failure may be 
incurred by prolonged diuresis strategies – though the evidence suggests that this 
does not necessarily result in permanent damage or adverse outcomes.355,356 
Conversely, excess diuresis may induce orthostatic effects such as syncope which 
will limit re-institution of ACE inhibitors and other critical HF medications. 
Cultural variations in clinical assessment may also drive early discharge before 
haemodynamic normalisation has been achieved.  
 
New imaging techniques suggest that ancillary information may potentially be 
provided to help to tailor patient specific therapies to haemodynamic profiles. 
However, the application of these during a complete patient journey - from AHF 
diagnosis, to monitoring de-congestion, tailoring diuretic therapy, and deciding 
on hospital discharge - is still subject of ongoing evaluation. 
 
7.5.2.2 Pulmonary congestion 
 
LUS is the most developed technology to assist in the quantification of 
congestion, though it remains unused in AHF trials and registries. In some 
respects it still remains an emerging technology; a consensus statement on the 
role of lung ultrasound was only recently published in 2017 by the Acute Heart 
Failure Study Group of ESC Acute Cardiovascular Care Association.357 Operator 
familiarity may also have been another consideration precluding its inclusion in 
clinical trials. However as LUS represents a closer approximation to a semi-
quantitative gold standard for evaluating central pulmonary congestion it should 
progressively be adopted in a more standardised manner in both AHF trials and 
AHF registries.  
 
LUS-implemented approaches allow better diagnostic determination of true 
cardiac congestion and enable a quantification of congestion, determination of 
subclinical congestion and assessment of risk. In a multi-centre Italian study of 
1,005 patients presenting to the emergency department, LUS augmented the 
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diagnostic process to help more accurately differentiate cardiac from non-
cardiogenic dyspnoea, resulting in re-classification of 19% of cases.358 In clinical 
trials, such an approach could enrich trial populations by filtering through only 
truly congested candidates. B-line quantification has been shown to correctly 
risk stratify patients at higher risk of rehospitalisation and death in both AHF and 
ambulatory CHF states, and correlates with elevated levels of natriuretic 
peptides.159,168,359 Critically when trying to identify subclinical congestion, B-line 
scores are elevated even when pulmonary auscultation is clear, underlining its 
value in uncovering residual haemodynamic disturbances.168 
 
Integrating LUS into AHF trials is potentially more straightforward than other 
echocardiographic techniques. A basic degree of proficiency can be delivered 
with just 30 minutes of training and a focused study requires only 5 
minutes.164,357 A standard curvilinear scanning probe is also sufficient for this 
purpose. Unlike in the critical care setting, LUS protocols have yet to be 
developed for congestion assessment in AHF, though Platz and colleagues have 
suggested a concise method based on scanning pre-specified lung zones.159 The 
accelerated incorporation of LUS into clinical studies will provide necessary the 
impetus for a uniform standard.  
 
7.5.2.3 Peripheral congestion 
 
At present, no imaging modality is yet capable of acting as a gold standard for 
the evaluation of peripheral congestion. IVC ultrasound has yielded promising 
data: there is fairly robust haemodynamic correlation between imaging and 
invasive assessments, it can indicate prognosis, remains easy to perform with 
low variability and can integrate readily into a clinical assessment.174–177 
However, unlike LUS it does not provide semi-quantitative information about the 
extent of congestion. Some patients will always have IVC dilation (either due to 
persistently poor ventricular function or co-morbid cardio-respiratory disease), 
though a collapsed IVC may steer the clinician away from a misjudged 
intensification of diuretic therapy. It remains able to track congestion so serial 
assessments are of value relative to changes in a patient’s condition.  
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BIVA remains a technology that could provide an absolute metric of hydration 
status, but most studies are still exploratory and single centre.187 It also is not 
clear how diuretic strategies would be tailored to BIVA assessments as trials 
have not been robust in this examining this area.  
 
JV ultrasound - like IVC ultrasound - can track congestion and predict prognosis, 
but an agreed standard method of assessment and data evaluation remains 
elusive.183,184 Near-infrared spectroscopy of the jugular vein may provide more 
concrete numerical assessments of estimated venous and right pressures to 
guide therapy and assess therapeutic effectiveness, but trials are ongoing.185  
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8 Future directions 
 
 
AHF trials of the future have to be more representative of the real world 
hospitalised population. Whilst dyspnoea at rest is a common symptom, it is not 
present in all patients admitted with AHF and should not be a sole mandatory 
requirement for enrolment. As dyspnoea tends to improve rapidly with standard 
medical therapy, so less focus should be given to this measure as a sole primary 
end point. Instead, trials must reflect the more balanced picture of patients 
attending with more chronically accumulated peripheral oedema rather than 
more acute pulmonary signs.  
 
Congestion also needs to be more clearly defined in a standardised manner. 
Clinical assessment should be modified to assess and document the severity of 
central pulmonary and peripheral congestion - as it is clear the degree of both 
correlate with prognosis. However, as clinical examination is not completely 
robust in this regard, more objective measurements are also required. 
Ultrasound technology provides techniques to rapidly assess both pulmonary and 
peripheral congestion in a semi-quantitative manner. These adjunctive imaging 
measures should be incorporated into clinical trials to help enrich trial 
populations by ensuring recruited patients have genuine decompensated AHF.  
 
More robust end points using objective imaging methods can provide a reliable 
indicator of whether - and to what extent - decongestion has actually been 
achieved by trial therapies. These tools can also address the dilemma of 
identifying patients with subclinical congestion – a subgroup at high risk of 
rehospitalisation and adverse outcome – and ensure adequate strategies are 
employed to bring patients to a euvolaemic state prior to discharge into the 
community.  
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9 Appendix A: Supplementary Tables 
 
Table A-1: Congestion requirements for enrolment into acute heart failure trials  
 
 Inclusion Criteria (Dyspnoea) Inclusion Criteria (Pulmonary 
congestion) 
Inclusion Criteria (Peripheral 
congestion features) 
Inclusion Criteria (Other non-
specific) 
Inclusion Criteria (Use of objective 
imaging) 
Trial Mandatory? Description Mandatory? Description 
 
Mandatory? Description Mandatory? Description Mandatory? Description 
HF-REF            
OPTIME-
CHF 209 
No 
(Part of 
composite ‘HF 
score’) 
 
Dyspnoea 
(exertional , 
nocturnal, 
orthpnoea or at 
rest) 
No 
(Part of 
composite ‘HF 
score’) 
 
 
Rales (bases only, or 
> bases) 
No 
(Part of 
composite ‘HF 
score’) 
“JVP > 6 cm with 
oedema or 
hepatomegaly” 
No  
(Part of 
composite ‘HF 
score’) 
“JVP > 6 cm” - - 
LIDO 297 - - - - - - - -  - 
ACTIV-in-
CHF 272 
-  No Rales 
CXR signs of 
pulmonary 
congestion 
No Pedel oedema 
Increased abdominal 
girth, 
Weight gain of > 10 
pounds above 
baseline 
 
No Raised JVP 
 
No CXR (signs of 
pulmonary 
congestion) 
EVEREST A 
and B 276 
No 
 
Dyspnoea at rest 
(or minimal 
exertion) 
No 
 
SOB (none, seldom, 
frequent, 
continuous. 
Orthopnoea (none, 
seldom, frequent, 
continuous) 
 
No 
 
Pitting oedema 
(Absent, slight, 
moderate, marked) 
 
No 
 
JVP (≤ 6 cm, 6-9 
cm, 10-15 cm, ≥ 
15 cm) 
Fatigue (none, 
seldom, 
frequent, 
continuous) 
 
- - 
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 Inclusion Criteria (Dyspnoea) Inclusion Criteria (Pulmonary 
congestion) 
Inclusion Criteria (Peripheral 
congestion features) 
Inclusion Criteria (Other non-
specific) 
Inclusion Criteria (Use of objective 
imaging) 
Trial Mandatory? Description Mandatory? Description 
 
Mandatory? Description Mandatory? Description Mandatory? Description 
SURVIVE 208 No  Dyspnoea at rest No - No - - - - - 
REVIVE-2 
207 
Yes Dyspnoea at rest No Pulmonary rales  
(basal, >1/3 lungs, > 
2/3 lung fields) 
No Peripheral oedema 
(legs, sacral and/or 
lumbar) 
- - - - 
PIONEER 
HF 277 
No “Signs and 
symptoms of 
fluid overload” 
No “signs and 
symptoms of heart 
failure” 
No “signs and 
symptoms of heart 
failure” 
No “signs and 
symptoms of 
heart failure” 
- - 
HF-REF and 
HF-PEF 
          
VMAC 278 Yes Dyspnoea at rest No PND 
Orthopnoea (2 
pillow) 
CXR consistent with 
heart failure 
No Abdominal 
discomfort due to 
mesenteric 
congestion 
No JVP distension No CXR (features 
consistent with 
decompensated 
heart failure) 
RITZ-2 294 - - - - - - - - - - 
UNLOAD 
280 
- - No PND 
Orthopnoea. 
Pulmonary rales 
CXR (pulmonary 
oedema or pleural 
effusion) 
 
- - No JVP ≥ 7 cm  
 
No CXR (pulmonary 
oedema or pleural 
effusion) 
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 Inclusion Criteria (Dyspnoea) Inclusion Criteria (Pulmonary 
congestion) 
Inclusion Criteria (Peripheral 
congestion features) 
Inclusion Criteria (Other non-
specific) 
Inclusion Criteria (Use of objective 
imaging) 
Trial Mandatory? Description Mandatory? Description 
 
Mandatory? Description Mandatory? Description Mandatory? Description 
VERITAS 1 
and 2 295 
Yes Dyspnoea at rest 
(with RR ≥ 24 
breaths per 
minute)  
No Pulmonary oedema 
(rales >1/3 chest),  
CXR (pulmonary 
congestion or 
oedema) 
- - - - No CXR (pulmonary 
congestion or 
oedema) 
3CPO 281 Yes  Dyspnoea at rest 
(with RR > 20 
breaths per 
minute) 
Yes 
 
Bilateral crackles 
CXR (showing 
interstitial oedema) 
- - - - Yes CXR (showing 
interstitial oedema) 
Pre-RELAX-
AHF 291 
Yes Dyspnoea at rest 
(or min exertion) 
Yes  
 
CXR showing 
pulmonary 
congestion 
- - - - No CXR (showing 
pulmonary 
congestion) 
PROTECT 
283 
 Yes Dyspnoea at rest 
(or min exertion) 
No Pulmonary rales ≥ 
1/3 not clearing 
with cough 
No ≥2+ peripheral 
oedema or pre-
sacral oedema) 
No JVP >8 
 
- - 
DOSE 203 No Dyspnoea at rest No Pulmonary rales 
 
No Peripheral oedema  
Ascites 
- - No CXR (pulmonary 
vascular congestion) 
ASCEND-HF 
301 
Yes Dyspnoea at rest 
(or min exertion) 
Yes  
 
Tachypnoea (RR  ≥ 
20) or pulmonary 
congestion (rales 
≥1/3 of chest)  
CXR features of 
“congestion or 
oedema”  
- -   Yes CXR( features of 
“congestion or 
oedema”) 
CARRESS-
HF 288 
No - No CXR signs 
(pulmonary edema, 
pleural effusions) 
No  ≥2+ peripheral 
oedema 
 
No JVP ≥10 cm No CXR (pulmonary 
edema, pleural 
effusions) 
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 Inclusion Criteria (Dyspnoea) Inclusion Criteria (Pulmonary 
congestion) 
Inclusion Criteria (Peripheral 
congestion features) 
Inclusion Criteria (Other non-
specific) 
Inclusion Criteria (Use of objective 
imaging) 
Trial Mandatory? Description Mandatory? Description 
 
Mandatory? Description Mandatory? Description Mandatory? Description 
RELAX-AHF 
291 
Yes Dyspnoea at rest 
(or min exertion) 
Yes  
 
Pulmonary 
congestion on CXR  
- - - - Yes CXR “pulmonary 
congestion” 
(mandatory) 
ROSE 206 No Dyspnoea at rest No Orthopnoea  
Pulmonary rales 
Pulmonary vascular 
congestion on CXR 
No Oedema 
Ascites 
 
 
- - No CXR “pulmonary 
vascular congestion” 
TRUE AHF 
293 
Yes Dyspnoea at rest Yes CXR (radiological 
evidence of heart 
failure) 
No - - - Yes CXR (radiological 
evidence of heart 
failure) 
ATHENA-
HF 299 
No Dyspnoea 
(unspecified) 
No Orthopnoea 
Pulmonary rales 
No Peripheral oedema 
Ascites 
- - No CXR “pulmonary 
vascular congestion” 
 
- no data available 
HFrEF: heart failure with reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; CXR: chest X-ray; RR: respiratory rate; JVP: jugular venous pressure; PND; 
paroxysmal nocturnal dyspnoea. 
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Table A-2: End points and congestion assessment in acute heart failure trials  
 
  ENDPOINT: Dyspnoea ENDPOINT: Pulmonary Congestion ENDPOINT: Peripheral congestion 
Trial Primary Endpoint Primary or 
Secondary? 
(Description) Primary or 
Secondary ? 
(Description) Primary or 
Secondary? 
(Description) 
HF-REF         
OPTIME-CHF 
209 
Days of hospitalization for CV 
events within 60 days  
 
Secondary 
(composite) 
Composite HF score Secondary 
(composite) 
Pulmonary rales (bases, > 
bases) – part of composite 
HF score 
Secondary 
(composite) 
“JVP > 6 cm”, “JVP > 6 cm 
with oedema or 
hepatomegaly”  – part of 
composite HF score 
LIDO 297 Proportion of patients achieving 
haemodynamic improvement at 
24 h 
- - - - - - 
ACTIV-in-
CHF 272 
2 Co-primary: change in body 
weight at 24 h; worsening HF at 
7 weeks (unscheduled 
hospitalization or visit for HF, 
death)  
 
Secondary  VAS Secondary Rales Primary and  
Secondary 
Change in body weight in 
24 hrs (primary) 
Oedema, hepatomegaly, 
Jugular venous distension 
 (secondary) 
EVEREST A 
and B 276 
2 Co-primary: time to all-cause 
mortality; time to CV mortality 
or HF hospitalization  
 
Secondary  7-point Likert scale Secondary Rales (4 point-scale: none, 
base, to <50% base, > 50% 
base) 
Secondary Change baseline body 
weight day 1, oedema 
score  (4 point scale: trace, 
slight, moderate, marked) 
SURVIVE 208 All-cause mortality (180 days) Secondary  7-point Likert scale - - - - 
REVIVE-2 207 Composite: patient-reported 
clinical improvement, death or 
worsening clinical status (day 5) 
Primary  
(composite) 
VAS (quantified by AUC) – 
as part of “worsening 
clinical status” composite 
- - - - 
PIONEER HF 
277 
Time averaged proportional 
change in NT-proBNP from 
baseline 
- - - - - - 
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  ENDPOINT: Dyspnoea ENDPOINT: Pulmonary Congestion ENDPOINT: Peripheral congestion 
Trial Primary Endpoint Primary or 
Secondary? 
(Description) Primary or 
Secondary ? 
(Description) Primary or 
Secondary? 
(Description) 
HF-REF and 
HF-PEF 
-    - -  
VMAC 278 Co-primary: change in PCWP; 
self-reported dyspnoea  
Primary   7 point Likert scare  - - - - 
RITZ-2 294 Mean change in cardiac index 
from baseline to 6 h  
Secondary 7 point Likert scale  - - - - 
UNLOAD 280 Weight loss and patient-
reported dyspnoea 
Primary 7 point Likert scale   - Primary  Weight loss (48 hrs post 
randomization) 
VERITAS 1 
and 2 295 
2 co-primary end-points: death 
or worsening heart failure (7 
days): dyspnoea 
Co-Primary  VAS (quantified by AUC) - 
 
- -  - 
3CPO 281 7 day mortality (and intubation)  Secondary VAS - - - - 
Pre-RELAX-
AHF 291 
Nil (dose finding study) - - - - - - 
PROTECT 283 Composite: dyspnoea, death/HF 
readmission day 7, worsening 
HF signs and symptoms  
 
Primary  7-point Likert scale  - - - - 
DOSE 203 2 Co-primary: patient-assessed 
symptom improvement (72 h); 
change in serum creatinine (72 
h)  
 
Co-Primary  VAS (quantified by AUC) Secondary 
(composite) 
No orthopnoea; as part of 
“patients free of 
congestion” composite 
end-point at 
Secondary   Weight change (at 72 
hours) 
“JVP < 8cm” and “trace 
peripheral oedema or less”; 
as part of “patients free of 
congestion” composite end 
point 
ASCEND-HF 
301 
2 Co-primary: change in self-
reported dyspnoea (6 and 24 h); 
composite: HF rehospitalization 
or death (30 days)  
Co-primary  7-point Likert scale  - - - - 
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  ENDPOINT: Dyspnoea ENDPOINT: Pulmonary Congestion ENDPOINT: Peripheral congestion 
Trial Primary Endpoint Primary or 
Secondary? 
(Description) Primary or 
Secondary ? 
(Description) Primary or 
Secondary? 
(Description) 
CARRESS-HF 
288 
Bivariate end-point (change in 
serum creatinine and weight) 
assessed at 96 hours 
Secondary  VAS (quantified by AUC) Secondary Clinical decongestion 
(including absence of 
orthopnoea) at 96 hrs, 7 
days, 30 and 60 days, 
Bivariate and 
Secondary 
Weight change at 96 hours 
(Bivariate primary end 
point). 
Clinical decongestion 
(including no more trace 
peripheral oedema, JVP < 8 
cm) at 96 hrs, 7 days, 30 
and 60 days 
Weight loss ≥ 3 kg. 
 
RELAX-AHF 
291 
2 Co-primary: change in self-
reported dyspnoea (day 5); 
dyspnoea improvement from 
baseline  
 
Primary  VAS (quantified by AUC), 7 
point Likert scale 
- - - - 
ROSE 206 2 co-primary end-points: 72 hr 
cumulative urine volume; 
change in cystatin C  
Secondary VAS (quantified by AUC) - - Secondary  Change in weight after 72 
hours 
TRUE AHF 293 All-cause mortality and 
cardiovascular rehospitalization 
at 30 days  (co-primary 
endpoint) 
Primary 
(hierarchical 
composite) 
Clinical composite including 
7-point Likert scale of 
global self-assessment  
Secondary 
(hierarchical 
composite) 
“Worsening 
signs/symptoms of heart 
failure” 
Secondary 
(hierarchical 
composite) 
“Worsening 
signs/symptoms of heart 
failure” 
ATHENA-HF 
299 
Proportional change in NT-pro-
BNP from randomization to 96 h 
Secondary VAS (quantified by AUC), 
Likert scale 
Secondary Congestion score (including 
orthopnoea)  
Secondary Congestion score (including 
pedel oedema, weight 
change) 
 
HFrEF: heart failure with reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; CV: cardiovascular; PCWP: pulmonary capillary wedge pressure; VAS: visual 
analogue scale; AUC: area under curve; RR: respiratory rate; JVP: jugular venous pressure; PND; paroxysmal nocturnal dyspnoea; BNP: brain natriuretic peptide; NT-proBNP: N-
terminal-prohormone brain natriuretic peptide. 
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Table A-3: Presenting features of congestion in acute heart failure trials 110,190,195–198,280–306 
 
 OPTIME-
CHF  
LIDO  ACTIV in 
CHF  
EVEREST  SURVIVE REVIVE PIONEER 
HF 
VMAC RITZ-2 UNLOAD VERITAS 3CPO Pre-
RELAX-
AHF 
PROTECT DOSE ASCEND-
HF 
CARRESS 
HF 
RELAX-
AHF 
ROSE TRUE-AHF ATHENA-
HF 
Clinical Presentation 
(Pulmonary) 
                     
SOB at rest - - 70 89 - - - 100 † -   100 † 100 † 100 † - - 100 † - 100 † - - 83 
Pulmonary rales 81 - 77 80 - 76 33  73 - 59 90  100 - 90  - - - - 60 - 62 
Orthopnoea - - - 52 - - - - - - - - - 96 90 - - - 89 - 85 
Clinical Presentation 
(Peripheral) 
                     
Peripheral oedema - - 45 78 - 68 62  73  - 81 - - - 86 79  - 89 - 69 - 77 
Weight gain - - - - - - - - - - - - -  - - - - - - - 
Clinical Presentation 
(Other) 
                     
SOBOE - - - - - - - - - - - - - - - - - - - - - 
Third heart sound 59 - - - - - - - - 44 - - - - - - - - - - - 
Raised JVP 73   80 26 - - - 89  - 68 - - - 89 92 - 97  - 99 - - 
NYHA Class                      
I - - - - - - 1 - - - - - 3 - - - - 3 - 5 - 
II 8 - - - - - 23 6 - - - - 26 - - - - 38 - 33 - 
III 56 - 72 58 - - 64 44 - 52 - - 38 48 - - - 44 - 49 - 
IV 58 - 55 39 86 - 9 42 - 45 - - 20 30 - - - 14 - 14 - 
Radiological Assessment                      
Pulmonary congestion on 
CXR  
- - - - - - - - - - 83  100 † 100 † - - - - 100 † - - - 
 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are expressed as percentage 
† = mandatory inclusion criteria 
- = not recorded    
SOB: shortness of breath; PND: paroxysmal nocturnal dyspnoea; SOBOE: shortness of breath on exertion; CXR: chest X-ray; HF: heart failure; ACS: acute coronary syndrome; JVP: jugular venous pressure; 
PND; paroxysmal nocturnal dyspnoea. 
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Table A-4: Baseline clinical characteristics of patients in acute heart failure trials 110,190,195–198,280–306  
 
 OPTIME-
CHF 
LIDO ACTIV in 
CHF 
EVEREST SURVIVE REVIVE PIONEER 
HF 
VMAC RITZ-2 UNLOAD VERITAS 3CPO Pre-RELAX-
AHF 
PROTECT DOSE ASCEND-HF CARRESS RELAX-AHF ROSE TRUE-AHF ATHENA-HF 
Baseline features (& vital 
signs) 
                     
Age 65 59 62 66 67 64 61 † 62 62 62 70 78 69 70 66 67 69 † 72 71 69 65 
Male 71 88 79 74 74 73 74 73 82 70 60 43 66 67.3 73 67 78  69 66 64 
Ejection fraction (%) 24 20 24 28 24 23 24 † 27 24 - 29 - - 32 35 - 30 † - 35 - 34 
SBP (mmHg) 120 115 119 120 116 116 118 † 121 - 126 132 162 148 124 121 123 † - 142 114 † 134 120 † 
Heart rate (Beats/min) 85 82 84 80 84 81 81 † - - 81 81 113 82 80 80 82 † - 79  86 78 † 
RR (breaths/min) - - - - - - - - - - - 32 - 21 - - - 22 - - - 
Co-morbidities                      
Hypertension 67.6 - 84 70 61  87 70 54 74 79 55 82 80  72 85  85 80 - 87 
Myocardial infarction 48.2 - 53 50 68 55 6 47 64 - 52 - - 51 - - - - - - 28 
Atrial fibrillation 31.8 - 52 43 49 - 33 37 24 - 35  - 43 54 51 37 57 51 64 - 50 
Chronic lung disease 23.1 - 17 10 - -  - - 27 - 15  20    16  - 21 
Diabetes Mellitus 44 - 59 38 31 - 18 43 38 50 45 30 49 45 51  65 48 58 38 40 
Hypercholesterolaemia 43 - 56 49   36     33 - - - - - 52 - - - 
Chronic renal disease - - - 27 - - 30 - 33 - 39  - - - - - - - - 24 
Valvular heart disease - - - 32 - - - - - - - 11 - - - - - - - - - 
Coronary heart disease - - - 70 47 - - 66 - 56 23 64 67 71  60  51 - 51 - 
Peripheral Vascular disease - - - 21 - - - - - - - 11 - - - - - 13 - - - 
Cerebrovascular disease - - - 11 - - 10 - - - 17 17 - - - - - 13 - - 16 
Permanent pacemaker - - - 15 - - - 27 § _ _ _ _ _ - -   11  - - - 
ICD - - - - - - 18 - - - - - - 16 37 _ _ 14 43 - - 
CRT - - - - - - 10 - - - - - - 11 - - - 10 - - - 
Smoker / Ex-smoker 63 - 75.8 - - - 21 - - - - 19  - - - - - 12 - - 17 
Laboratory findings                      
Serum Na (mmol/L) 138 - - - - - - - - 139 139 - 141 140 † 138 139 † - - - - 140 † 
Serum K+ (mmolL) 4.2 - - - - - 4.2 † - - 4.0 - - - 4.2 †  - - - - - 3.9 † 
Serum Creatinine (mg/dL) 1.4 - 1.9 1.4 - - 1.3  † - 1.4 1.5 1.4 - 1.4 1.4 † 1.5 - 1.9 † - 1.6 † 1.2 1.2 † 
Haemoglobin (mg/dL) - - - - - - - - -  130 - 131 126 † - - - - - 131 † - 
BNP (pg/mL) - - - 734 1581 - - - - 1256 - - - 1290 † - 994  † - - - 7156 † 1131 † 
NT Pto-BNP (pg/mL) - - - 4857 - - 4821 † - - - - - - 3000 † 7439  4508 † 5013 † 5125 † 5760 †  4028 † 
Aetiology of LVSD - - -                   
Ischaemic  51 47  65 76   53 68  73    56   70 60  60 
Idiopathic - - - - - - - 24 20  12 - - - - - - - - - - 
Hypertensive - - - - - - - 9   26 - - - - - - - - - - 
Valvular - - - - - - -    4 - - - - - - - - - - 
Precipitating factors                      
ACS - - - - - - - - - - - 22 - - - - - - - - - 
Treatment performed                      
NIV - - - - - - - - - - - - - - - - - - - - - 
IPPV 2.5 - - - - - - - - - - - - - - - - - - - - 
Inotropes - - 16 4 - 10 - 29 - - - - - - - - - - - - - 
Dobutamine 10 - - - - - - 16 - - 2  - - - - - - - - 0.5 - 
Dopamine - - - - 8 - - 7 - - 2 * - - - - - - - - - - 
Nitrates - - - - 36 13 - - - - 15 * 88 - - - 16 - 7 - 9 - 
Cardiac Catheterisation 7 - - - - - - - - - - - - - - - - - - - - 
Right heart catheter 6 - - - - - - - - - - - - - - - - - - - - 
DC Cardioversion 2 - - - - - - - - - - - - - - - - - - - - 
IV diuretics - - - - 79 - - - 41 - 99 89 - - - - - 99 - - - 
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 OPTIME-
CHF 
LIDO ACTIV in 
CHF 
EVEREST SURVIVE REVIVE PIONEER 
HF 
VMAC RITZ-2 UNLOAD VERITAS 3CPO Pre-
RELAX-
AHF 
PROTECT DOSE ASCEND-
HF 
CARRESS RELAX-
AHF 
ROSE TRUE-
AHF 
ATHENA-
HF 
Medication use (pre-
admission) 
                     
ACEi or ARB - - - 42 70 76 47  88 - 63 - 69 76 61 60 55  43  58 
 ACE inhibitor 70 89 83 - - - - 63 - 49 - - - - - - - 54 - - - 
Angiotensin receptor 
blocker 13 
- - - - - - 9 - 14 - - - - - - - 15 - - - 
Beta-blocker 22 38 42 70 51 68 60 35 57 65 47  - 59 77 81 57 79 67 80 - 74 
Diuretic 90 93 98 97 -  60 87 97 72 33 - - - - 95 91 - - - 97 
Digoxin 73 75 68 44 - 82 10 60 63  21 - 18 27 - 27 - 21 21 - 8 
Calcium channel blocker 14 4 9 11 - - - 15 - 8 16 - 11 - - - - - - - 20 
Aspirin 46 - - - - - - 46 - - 64 - - - - - - - - - - 
Amiodarone / anti-
arrhythmic  16 
- - - - - - - 22 - 12 - - - - - - - - - - 
Nitrates - 41 - 28 - - 10 37 69 - - - 23 27 - 24 -  27 - 19 
Anticoagulants - 43 - - - - - 34 - - - - - - - - - - - - - 
Anti-platelets - 1 - - - - - - - - - - - - - - - - - - - 
Mineralocorticoid 
antagonist 
- - 40 54 51 37 11 - 33 21 19 - 34 45 28 28 22 33 28 - 11 
Lipid lowering - - -    - 26 - - 46 - - - - - - - - - 57 
 
 
 
All continuous variables are given as the mean unless stated otherwise.  Categorical values are expressed as percentage 
§ = ICD and PPM,    † = median,     - = no data available 
 
SBP: systolic blood pressure; RR: respiratory rate; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; ICD: implantable cardiac defibrillator; CRT: cardiac resynchronisation 
therapy; BNP: brain natriuretic peptide; NT-proBNP: N-terminal-prohormone brain natriuretic peptide; LVSD: left ventricular systolic dysfunction; ACS: acute coronary syndrome; NIV: non-invasive 
ventilation; IPPV: invasive-positive pressure ventilation; ACEi: angiotensin-converting enzyme inhibitor; ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker.  
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Table A-5: Baseline characteristics of patients in acute heart failure registries 105,184, 316–342 
 
 
 ADHERE OPTIMIZE-HF EHFS-II ALARM HF ADHERE-AP AHEAD IN-HF RO-AHFS ESC-HF Pilot HEARTS ATTEND Beijing AHF GULF-CARE Kor-AHF ESC HF LT RICA EAHFE KCHF 
Age (yrs) 72 73 70 - 66  74  † 72 69 70 61 73 71 59 69 - 79 80  80 † 
Male sex  - 48 61 62 57 58 64 56 63 71 58 53 63 53 63 47 45 55 
Ejection fraction (%) 34 39 38 - - 37 † 38 38  38 - - 44 † 35 † 38 39  51 - 
LVEF < 40% - 49 - - - - - - - 73  53 - - - 53 23 22 - 
Vital Signs                   
RR - - - - - - - - - -  - - - - - 23  - 
Pulse oximetery - - - - - - - - - - 93 - - - - - 92 - 
Systolic blood pressure 144 143 135 † 130 - 134 † 134 143 133 128 146 130 137 131 130 † 139 131 147 
SBP >140 mmHg - - - - - - - - - - 50 43 - - - - - 54 
SBP 100-140 mmHg - - - - - - - - - - 43 
 
53 † - - - - - 39 
 
SBP < 100 mmHg mmHg - - - 21 - 16 
 
- - - - 8 
 
- - - - - - 7 
 
DBP (mmHg) - - - - - 80 †  - - 74 83 80 † 81 79 - - - - 
HR (bpm) - 87 95 † - - 90 † 93 99 88 88 99 - 97 
 
93 88 † 88  89 96 
Laboratory findings                   
BNP 840 † 1273 - - - 767 † 1112 † - 870	† - 707 † 1280 1300 † 1335 765 † - 658 721 † 
NT-pro BNP - - - - - 5,294 † 5168 † - 4007	† 5738 † - 4920  3209 † 9240 3825 † 6382  3892 5,830 † 
Haemoglobin (mg/dL) - 121 - - - 132 † 125 131 - 124 120 126 † 126 † 124  127 † 121 120 115 
Na (mean, mmol/) - 137 - - - 139 † - 138 - 135.1 139 138 † 138 138 139 † 139 138 139 
K+ (mean, mmol/l) - - - - - 4.1 † - 4.4  - - - 4.2 † 4  4.4  4.4 - 
Glucose (mg/dL) - - - - - 144 - 147 110 † 149 † - - - 155 -  - - 
Creatinine (mg/dL) 1.8  1.8 - - - 1.2 † 1.5 1.3 - - 1.4 1.0 † 1.5 1.5 1.2 † 1.4 1.3 1.1 
Co-morbidities                   
Chronic lung disease - - 19 - - 16 30 - 15 19 10 15 - 11 19 25 24 8 
Myocardial infarction 31 -  - - 32 - 17 - - - - -  54   22 
Coronary heart disease 57 - 54 31 50 65 - - - 53 31 - 47 43 20  30 33 
Hypertension 73 71 63 70 64 73 58 67 62 71 70 42 61 62 - 86 84 72 
Hypercholesterolaemia - - - -  - - 40 - 36 37 - 36 - - - 43 38 
Diabetes Mellitus 44 42 33 45 45 43 40 33 35 64 34 30 50 40 40 56 42 37 
Chronic kidney disease 30 - 17 21 22 - 33 - 26 30 - 17 15 14 26 - 26 45 
Peripheral vascular 
disease 
- - - - - - 20 - 10 4 - - 5 - 14 - 9 - 
Cerebro-vascular 
disease 
31 - 13 - 13 17 5 - 10 10 14 20 8 15 - - 13 16 
Atrial fibrillation - 31 39 24 24 27 38 44 44 16 40 28 12 29 - 55 49 41 
Haemodialysis - - - - - - - - -  2 - - - - - - - 
Anaemia - - 15 14 - 35 - - 42 21 - - - - 16 - - 67 
Pacemaker (PPM, CRT, 
ICD) 
- - 9 6 - 12 - - - - - - - - 6 - 9 6 
 
ICD - - - - - - 10 - 6 9 3 - - - - - - 2 
CRT - - - -  - 6 - 3 3 - - - - - - - 2 
BMI (kg/m2) - - 27 † - - - 28 
 
27 - 29 - 24 † 27 † 23 - 29 28  22 
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 ADHERE OPTIMIZE-
HF 
EHFS-II ALARM 
HF 
ADHERE-
AP 
AHEAD IN-HF RO-AHFS ESC-HF 
Pilot 
HEARTS ATTEND Beijing 
AHF 
GULF-
CARE 
Kor-AHF ESC HF LT RICA EAHFE KCHF 
Smoking  - - - - 47 - - 25 - 33  43 22 22 - - - - 12 
Prev HF hospitalization  - - - - - - - - -  36 -  - - - - 36 
Prev HF diagnosis 75 88 63 36 - 42 57 81 - 64 - 50 - 48 71 - - - 
Valvular heart disease - - 34 - - - - - - - - - 13 - - - 26 - 
Aetiology of LVSD                   
Ischaemic - 46 - - - - - 61 51 - 31 43 53 38 57 27 - 33 
Hypertensive - 23 - - - - - 44 - - 18 17 16 4 8 39 - 24 
Cardiomyopathy  - - 19 - - - - 25 - - 13 10 18 21 14  - 15 
Valvular heart disease - - - - - - - 36 - - 19 10 9 14 12 18 - 20 
ECG                   
Atrial Fibrillation - - - - - - 32 44 35 17 - - 14 - 43 - 49 36 
LVH - - - - - - - 25 16 - - - 30 -  - 4 - 
LBBB - - 22 - - - - 17 - 12 - - 13 5 15 - 9 - 
Paced rhythm - - - - - - - 4 - - - - 2 - - - 9 - 
QRS (> 120 ms) - - - - - - - 4 - 15 - - 21 - - - - - 
Precipitating Factors                   
ACS - - 30 37 - 36 42 11 - 38 - 30 27 26 30 7 2 - 
HTN  - - - - - - - - - 20 - - 8 3 17 7 6 - 
Arrhythmia  - - 32 27 - - - - - 11 - 19 6 20 30 23 15 - 
Infection  - - 18 16 - - - - - 21 - 26 15 20 20 31 35 - 
Medication adherence - - 22 13 - - - - - 21 - - 19 8 6 - - - 
Anaemia - - - - - - - - - - - - 3 3 16 - 7 - 
Valvular cause - - 27 - - - - - - - - - - - - - - - 
 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are expressed as percentage 
† = median 
LVEF: left ventricular ejection fraction; RR: respiratory rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; BNP: brain natriuretic peptide; NT-proBNP: N-terminal-
prohormone brain natriuretic peptide; PPM: permanent pacemaker; ICD: implantable cardiac defibrillator; CRT: cardiac resynchronisation therapy; BMI: body mass index; HF: heart failure; LVH: left 
ventricular hypertrophy; LBBB: left bundle branch block; ACS: acute coronary syndrome; HTN: hypertension. 
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Table A-6: Therapeutic profiles of patients in acute heart failure registries 105,184, 316–342 
 
 ADHERE OPTIMIZE-HF EHFS-II ALARM HF ADHERE-AP AHEAD IN-HF RO-AHFS ESC-HF Pilot HEARTS ATTEND Beijing AHF GULF-CARE Kor-AHF ESC HF LT RICA EAHFE KCHF 
CPAP - - 14 10 - 9 - - - - 15 2 10 - - - 3 23 
IPPV 5 - 5 16 9 14 - 4 - 11 8 2 9 - - - 1 4 
Intravenous Therapy                   
IV Diuretic 92  84 90 85 - 98 80 85 - 76 79 91 75 82 - 87 84 
IV Vasodilator 9 14 38 41 14 - 30 33 19 - 78 75 21 41 21 - 16 68 
IV Inotrope 15 7 30  15 - 19 18 11 - 19 33 16 31 12 - 2 16 
• Adrenaline - - 2 4 - 9 - 4 - - - - - - - - - - 
• Dobutamine - - 10 22 - 10 8 10 - - 11 0.2 - 23 - - 1 12 
• Dopamine - - 11 13 - 9 14 12 - - 9 14 - 18 - - 1 2 
• Levosimendan - - 4 6 - 3 4 2 - - - 0.1 - - - - 0.4 - 
• Noradrenaline - - 3 4 - 19 - - - - 5 0.1 -  - - 0.3 3 
Oral Therapy                   
Beta blocker - - 10 38 - - - - - - - 31 - 58 - - - - 
ACE inhibitor or ARB - - -  - - - - - - - 26 - 76 - -  - 
Mineralocorticoid antagonist - -  28 - - - - - - - 34 - 56 - -  - 
Amiodarone/anti-arrhythmic - - 18 3 - - - - - - - - - - - -  - 
Digoxin - -  - - - - 26 - - - 25 - - - - 15 2 
Heparin - - 19 2 - - - - - - - - - - - - - 27 
LMW Heparin - - 41 1 - - - - - - - 13 - - - - - - 
Oral anti-coagulant - -  - - - - - - - - 5 - - - - - - 
Anti-platelet - -  - - - - - - - - 35 - - - - - - 
Nitrate  - -  - - - - - - - - 26 - - - - - - 
Calcium channel blocker - -  - - - - - - - - 10 - - - - - - 
Statin  - -  - - - - - - - - 19 - - - - - - 
Procedural / Surgical 
Interventions 
                  
PCI 8 - 8 13 - - - 2 - - -  0.1 6 11 10 * - - 9 
Coronary Artery Bypass Graft - - 2 3 - - - 0.4 - - -  0.03 1 2  - - 1 
Intra-aortic balloon pump - - 2 5 - - - 0.2 - 3 3  0.3 2 4 1 - - 3 
Permanent pacemaker  - - 3 3 - - - 2 - - 4  0.03    - - 2 
ICD 6 2 1 2 - - - 0.3 - 6 3 -  0.01 1 10 - -  0.3 
CRT 3 - - - - - - - - 3 2 -  0.01 1 9 - - 1 
Valvular Surgery - - - 4 - - - - - - 3  0.3 2 3 - - - 1 
LVAD - - - - - - - - - - 0.4 -  0.1 - - -  
Haemodialysis / Ultrafiltration 5 - - - - - - 1 - 5 - 1 3 8 - - - 5 
Cardioversion 1 - - 8 - - - - - - - - -  - - - - 
Pharmacological treatment 
(admission) 
                  
ACE inhibitor or ARB  - - - - - 59 - - 68 - - - 38 - - 57 46 
ACE inhibitor 41 40 63 - 36 48 - 45 60 _ - - 43 11 - - - 12 
ARB 12 12 -  - 12 - 8 - - 25 _ 13 28 -  _ 35 
Beta-blocker   48 53 43 - 37 51 41 45 62 79 - - 44 28 - - 40 38 
Mineralocorticoid antagonist - 7 28 - 21 23 - 34 53 29 - - 17 18.8 - - - 18 
Diuretic  70 61 71 - 57 55 64 69 68 53 - - 58 - - - 76 49 
Digoxin  28 23 27 - 26 17 16 35 21 - - - 17 - - - 16 7 
Amiodarone (or other anti-
arrhythmic) 
11 10 13 -  12 - 9 - - - - 3 - - - 6 4 
Oral anti-coagulant - - 24 - 14 18 - - - 16 - - 12 - - - 41 31 
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 ADHERE OPTIMIZE-
HF 
EHFS-II ALARM 
HF 
ADHERE-
AP 
AHEAD IN-HF RO-AHFS ESC-HF 
Pilot 
HEARTS ATTEND Beijing 
AHF 
GULF-
CARE 
Kor-AHF ESC HF LT RICA EAHFE KCHF 
Anti-platelet  - 40 43 - 42 45 
 
- 41 - 64 - - 62 - - - - 33 
 
Nitrate  26 22 28 - 32 19 - - - 22 - - 26 - - - 18 13 
Calcium channel blocker  - 8 18 -  23 - - - - - - - - - - 26 37 
Statin  - 39 28 - 40 32 - 21  55 - - 51 - - - 42 - 
Pharmacological treatment 
(discharge) 
                  
ACE inhibitor  or ARB - - - - 64 - - - - 75 - 29 - - - 7 - 57 
ACE inhibitor - - 80 - 50 69 - 55 - 75 - - 61 66 - 71 - 25 
AT2 blocker - - - - - 10 - 11 - - 46 - 17  -  - 33 
Beta-blocker - - 61 - 41 77 - 56 - 84 67 40 71 50 - 60 - 66 
Mineralocorticoid antagonist - - 48 - 31 57 - 54 - 38 - 33 43 45 - 30 - 45 
Diuretic  - - 90 - 81 84 - 81 - 83 - 49 94 71 - = - 81 
Digoxin  - - 31 - 34 20 - 40 - - - 25 25 8 - 21 - 6 
Amiodarone or anti-arrhythmic - - 18 - - 17 - 10 - - - 25 5 8 - - - 7 
Oral anticoagulant - - 33 - 18 29 - 10 - 19 - 9 19 28 - 50 - - 
Anti-platelet - - 49 - 51 67 - 59 - 76 - 38 81 54 - 36 - - 
Nitrate - - 33 - 41 13 - - - 34 - 36 38 22 - - - - 
Calcium channel blocker  - - 15 -  18 - - - - - 15 - - - - - 34 
Anti-lipid agent  - - 42 - 47 58 - 31 - 70 - 24 72 41 - 45 - - 
 
 
* value for PCI and CABG  
Categorical values are expressed as percentage 
CPAP: continuous positive airways pressure; IPPV: invasive positive pressure ventilation: ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; LMW: low 
molecular weight; PCI: percutaneous coronary intervention; ICD: implantable cardiac defibrillator; CRT: cardiac re-synchronisation therapy; LVAD: left ventricular assist device. 
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Table A-7: Summary of precipitating factors and underlying ECG of de-novo versus acute-on-chronic decompensated heart 
failure patients  
 
 EHFS-II 334 IN-HF 336 Gulf CARE 337 RICA 338 
 DN-AHF AC-DHF DN-AHF AC-DHF DN-AHF AC-DHF DN-AHF AC-DHF 
Precipitating Factors         
ACS 42 23 - - 39 17 8 6 
HTN - - - - 10 7 6 7 
Arrhythmia  32 33 - - 5 7 31 19 
Infection  15 19 - - 11 18 26 33 
Medication 
adherence 
7 32 - - 9 28 - - 
Anaemia - - - - 3 3 - - 
Valvular cause 21 30 - - - - - - 
ECG         
Atrial fibrillation - - - - 10 16 - - 
LVH - - - - 29 32 - - 
LBBB - - 7 11 9 16 - - 
Paced rhythm - - - - - - - - 
QRS duration > 120 
ms 
- - - - 15 25 - - 
 
 
All continuous values are given in mean unless stated otherwise. Categorical values are expressed as percentage 
† median, -  no data available 
DN-AHF: de-novo acute heart failure; AC-DHF: acute-on-chronic decompensated heart failure; ACS: acute coronary syndrome; HTN: hypertension; LVH: left ventricular hypertrophy; 
LBBB: left bundle branch block.  
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Table A-8: Summary of therapeutic interventions of de-novo versus acute-on-chronic decompensated heart failure patients  
 
 IN-HF 336 Gulf CARE 337 
 DN-AHF AC-DHF DN-AHF AC-DHF 
Oxygen Therapy     
CPAP - - 11 9 
IPPV - - 9 8 
Intravenous Therapy     
IV Diuretic 98 98 90 92 
IV Vasodilator 26 35 24 17 
IV Inotrope 21 17 16 16 
Adrenaline - - - - 
Dobutamine 10 5 - - 
Dopamine 15 13 - - 
Levosimendan 4 4 - - 
Procedural / Surgical 
Interventions 
    
PCI - - 10 3 
CABG - - 2 1 
IABP - - 2 1 
ICD - - 0.5  1.5 
CRT - - 0.1 1 
Valvular Surgery - - 2 2 
HD / UF - - 2 3 
 
All continuous values are given as the mean unless stated otherwise. Categorical values are expressed as percentage 
-  no data available 
DN-AHF: de-novo acute heart failure; AC-DHF: acute-on-chronic decompensated heart failure; CPAP: continuous positive airways pressure; IPPV: invasive positive pressure 
ventilation; PCI; percutaneous coronary intervention; CABG: coronary artery bypass graft; IABP: intra-aortic balloon pump; PPM: permanent pacemaker; ICD: implantable cardiac 
defibrillator; CRT: cardiac-resynchronisation therapy; LVAD: left ventricular assist device; HD: haemodialysis; UF: ultra-filtration. 
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